US20070110720A1 - Vectors, mutant viruses and methods for generating mutant viruses - Google Patents

Vectors, mutant viruses and methods for generating mutant viruses Download PDF

Info

Publication number
US20070110720A1
US20070110720A1 US10/579,607 US57960704A US2007110720A1 US 20070110720 A1 US20070110720 A1 US 20070110720A1 US 57960704 A US57960704 A US 57960704A US 2007110720 A1 US2007110720 A1 US 2007110720A1
Authority
US
United States
Prior art keywords
nucleotide sequence
herpes simplex
simplex virus
vector
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/579,607
Inventor
Susanne Brown
Joe Conner
Paul Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crusade Laboratories Ltd
Original Assignee
Crusade Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crusade Laboratories Ltd filed Critical Crusade Laboratories Ltd
Assigned to CRUSADE LABORATORIES LIMITED reassignment CRUSADE LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BROWN, SUSANNE MOIRA
Assigned to CRUSADE LABORATORIES LIMITED reassignment CRUSADE LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUNN, PAUL
Assigned to CRUSADE LABORATORIES LIMITED reassignment CRUSADE LABORATORIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CONNER, JOE
Publication of US20070110720A1 publication Critical patent/US20070110720A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Definitions

  • the present invention relates to nucleic acid vectors for delivery of a nucleic acid cassette to an insertion site in a selected viral genome, to methods of generating mutant virus using said vectors and to the mutant viruses generated, and particularly, although not exclusively, to mutant herpes simplex viruses and nucleic acid vectors for use in generating mutant herpes simplex viruses.
  • HSV herpes simplex virus
  • Shuttle vectors have been used to generate recombinant adenoviral vectors, e.g. the pAdEasyTM system of vectors (Stratagene), for use in overexpressing recombinant proteins in mammalian cells.
  • these vectors require the cloning of the gene of interest into a first shuttle vector which is then co-transformed into a specially constructed cell line to generate a recombinant adenoviral plasmid which is transfected into a separate specially constructed mammalian cell line in which the recombinant adenoviral plasmid is directly packaged into virus particles.
  • the HSV genome comprises two covalently linked segments, designated long (L) and short (S). Each segment contains a unique sequence flanked by a pair of inverted terminal repeat sequences.
  • the long repeat (RL or R L ) and the short repeat (RS or R S ) are distinct.
  • the HSV ICP34.5 (also ⁇ 34.5) gene which has been extensively studied 1,6,7,8 , has been sequenced in HSV-1 strains F 9 and syn17+ 3 and in HSV-2 strain HG52 4 .
  • One copy of the ICP34.5 gene is located within each of the RL repeat regions.
  • Mutants inactivating both copies of the ICP34.5 gene i.e. null mutants
  • HSV-1 strain 17 mutant 1716 2 (HSV1716) or the mutants R3616 or R4009 in strain F 5 are known to lack neurovirulence, i.e. be avirulent, and have utility as both gene delivery vectors or in the treatment of tumours by oncolysis.
  • HSV1716 has a 759 bp deletion in each copy of the ICP34.5 gene located within the BamHI s restriction fragment of each RL repeat.
  • ICP34.5 null mutants such as HSV1716 are, in effect, first-generation oncolytic viruses. Most tumours exhibit individual characteristics and the ability of a broad spectrum first generation oncolytic virus to replicate in or provide an effective treatment for all tumour types is not guaranteed.
  • the prior art provides technically challenging, procedurally slow and inefficient materials and methods for generating recombinant HSV.
  • the prior art does not provide methods of, and materials for, generating recombinant HSV which are easy to detect, may be designed to be specific null mutants and which may express a selected gene of interest.
  • First generation oncolytic viruses such as HSV-1 strain 17 mutant 1716 show significant therapeutic potential in tumour and gene therapy.
  • Overcoming the existing technical difficulties by enabling rapid generation and screening of second generation oncolytic viruses of this kind provides a significant improvement in the development of novel pharmaceutical compositions, vaccines and medicaments for the treatment of cancer and disease.
  • HSV 1716 is described in EP 0571410 and WO 92/13943 and has been deposited on 28 Jan. 1992 at the European Collection of Animal Cell Cultures, Vaccine Research and Production Laboratories, Public Health Laboratory Services, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number V92012803 in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (herein referred to as the ‘Budapest Treaty’).
  • RL1.dIRES-GFP provides a platform for generating a plurality of ‘shuttle vectors’ which can exploit the process of homologous recombination to transfer a nucleotide sequence of interest (downstream of a selected promoter) into the disabling RL1 locus of HSV-1, generating easily identifiable, oncolytic, ICP34.5 null HSV-1 mutants expressing the products of the nucleotide sequence of interest, e.g. an RNA transcript or a polypeptide, and GFP.
  • RL1.dIRES-GFP thus provides for ease of generation and purification of ICP34.5 null HSV.
  • RL1.dIRES-GFP is a useful vector for making second-generation oncolytic viruses having enhanced cytotoxic potential and which may express the product(s) of selected gene(s) to enhance the oncolytic and/or therapeutic effect of the administered virus.
  • the RL1.dIRES-GFP plasmid incorporates a multi-cloning sequence (MCS), upstream of an internal ribosome entry site (IRES), the GFP gene and SV40 polyadenylation sequences flanked by HSV-1 RL1 sequences.
  • MCS multi-cloning sequence
  • IRES internal ribosome entry site
  • EMCV IRES encephalomyocarditis virus IRES
  • recombinant HSV-1 expressing the desired nucleic acid transcript or protein can be generated and purified within 2 weeks. This compares with 2-3 months using prior art protocols.
  • ICP34.5 null HSV generated using the RL1.dIRES-GFP plasmid provided by the inventors transcription of both the nucleotide sequence of interest and GFP as a single transcript is controlled by the same promoter upstream of the nucleotide sequence of interest, the transcribed IRES directing cap-independent translation of GFP.
  • the generated ICP34.5 null HSV are non-neurovirulent.
  • RL1.dIRES-GFP is promoterless, thus enabling a promoter of choice to be incorporated in the homologously recombined shuttle vector for controlling expression of the nucleotide sequence of interest from the inserted cassette.
  • Plasmid RL1.dIRES-GFP or modified plasmid shuttle vectors thereof further comprising nucleotide sequence encoding a nucleic acid transcript or polypeptide of interest may be provided in isolated or purified form.
  • RL1.dIRES-GFP By using the plasmid RL1.dIRES-GFP to generate a shuttle vector, designated RL1.dCMV-NTR-GFP, containing the E. coli nitroreductase gene downstream of a CMV IE promoter, both inserted at the MCS, the inventors have further provided a novel second generation oncolytic mutant HSV.
  • the genome of this mutant HSV comprises the heterologous (i.e. non-HSV) E. coli nitroreductase protein coding sequence inserted at one or each ICP34.5 locus, disrupting the ICP34.5 protein coding sequence such that the ICP34.5 gene is non-functional and cannot express a functional ICP34.5 gene product.
  • the generated HSV is capable of expressing the E.
  • HSV1716/CMV-NTR/GFP The mutant virus is designated HSV1716/CMV-NTR/GFP.
  • RL1.dIRES-GFP As the plasmid RL1.dIRES-GFP is designed for tandem expression of a sequence of interest and the marker gene encoding green fluorescent protein (GFP).
  • the sequence of interest is cloned into RL1.dIRES-GFP along with its promoter (e.g. CMV) such that the promoter drives transcription of an mRNA for the sequence of interest along with the IRES-GFP.
  • CMV green fluorescent protein
  • Translation results in expression of the GFP from the internal ribosomal entry site and the gene of interest and promoter must be cloned into RL1.dIRES-GFP in the correct orientation to achieve this.
  • this tandem expression arrangement may be unsuitable and a variation of the cassette design is favourable.
  • siRNAs as short hairpin RNAs using RNA polIII promoters such as H1 or U6. These promoters are unable to drive the additional tandem expression of the IRES-GFP as the RNApolIII expression cassette is designed only to produce short transcripts. Additionally, sequences of interest derived from genomic DNA with strong mRNA shut-off signals in their 3′ untranslated regions may not support IRES-GFP expression.
  • a cassette may be provided in which the sequence of interest and marker are expressed separately from independent promoters.
  • One variant contains a cassette in which the ribosome binding site of plasmid RL1.dIRES-GFP is replaced with a regulatory nucleotide sequence, preferably a strong, constitutive promoter such as the Phosphoglycerokinase (PGK) promoter.
  • the marker is thereby expressed under the control of this (the ‘first’) regulatory sequence.
  • the nucleotide sequence of interest e.g. antisense or siRNA
  • This vector variant is particularly suitable for expression of siRNA where a weak promoter may be used for expression of the siRNA molecule.
  • nucleotide sequence of interest has a strong transcription and/or translation termination signal which may make it difficult to transcribe and/or translate a single bi- or poly-cistronic transcript encoding the sequence of interest and marker sequence.
  • the transformed virus containing the cassette integrated in the viral genome produces two separate transcripts under the control of the first and second promoters.
  • the present invention relates to: (i) a nucleic acid vector for delivery of a nucleic acid cassette to an insertion site in a selected viral genome; (ii) an herpes simplex virus wherein the herpes simplex virus genome comprises a nucleotide sequence of interest.
  • the present invention further comprises novel HSV mutants and viral vectors which may be generated using nucleic acid vectors of the present invention, or vectors derived therefrom, and methods for the generation of such vectors and HSV mutants.
  • nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding:
  • nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the ribosome binding site and the nucleic acid encoding the ribosome binding site is arranged upstream (5′) of the marker.
  • nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a nucleic acid cassette located between said first and second nucleotide sequences comprising:
  • nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site and the ribosome binding site is arranged upstream (5′) of the marker.
  • an herpes simplex virus wherein the herpes simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
  • the nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the ribosome binding site and the nucleic acid encoding the ribosome binding site is arranged upstream (5′) of the marker.
  • an herpes simplex virus wherein the herpes simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
  • the nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site and the ribosome binding site is arranged upstream (5′) of the marker.
  • the ribosome binding site may comprise an internal ribosome entry site (IRES).
  • IRES internal ribosome entry site
  • a transcription product of the cassette may be a bi- or poly-cistronic transcript comprising a first cistron encoded by the nucleotide sequence of interest and a second cistron encoding the marker nucleic acid wherein the ribosome binding site is located between said first and second cistrons.
  • nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding:
  • nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the regulatory sequence and the nucleic acid encoding the regulatory sequence is arranged upstream (5′) of the marker.
  • nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a nucleic acid cassette located between said first and second nucleotide sequences comprising:
  • nucleotide sequence of interest is arranged upstream (5′) of the regulatory sequence and the regulatory sequence is arranged upstream (5′) of the marker.
  • an herpes simplex virus wherein the herpes simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
  • nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the regulatory sequence and the nucleic acid encoding the regulatory sequence is arranged upstream (5′) of the marker.
  • an herpes simplex virus wherein the herpes-simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
  • nucleotide sequence of interest is arranged upstream (5′) of the regulatory sequence and the regulatory sequence is arranged upstream (5′) of the marker.
  • the encoded components of the cassette are preferably arranged in a predetermined order as described.
  • the first regulatory sequence may be operably linked to said marker and may comprise a constitutive or inducible promoter.
  • the first regulatory sequence may thus have a role in regulating transcription of the marker.
  • the nucleotide sequence of interest may encode an heterologous polypeptide, which may be selected from the group consisting of: a bacterial polypeptide; a mammalian polypeptide; a human polypeptide or more particularly from the group consisting of: Sodium iodide symporter (NIS); Nitroreductase (NTR); E. coli NTR; Endothelial nitric oxide synthase (eNOS); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); a cytokine.
  • NIS Sodium iodide symporter
  • NTR Nitroreductase
  • E. coli NTR Endothelial nitric oxide synthase
  • GM-CSF Granulocyte Macrophage Colony-Stimulating Factor
  • the nucleotide sequence of interest may encode a selected antisense nucleic acid or siRNA.
  • the cassette may further comprise a regulatory nucleotide sequence, located upstream (5′) of the nucleotide sequence of interest or insertion site(s), which has a role in regulating transcription of the nucleotide sequence of interest.
  • the cassette may comprise a plurality of insertion sites, each insertion site preferably formed by nucleic acid encoding a specific restriction endonuclease site (‘restriction site’). Together the restriction sites may form a multiple cloning site (MCS) comprising a series of overlapping or distinct restriction sites, preferably a series of distinct restriction sites comprising one or more of the ClaI, BglII, NruI, XhoI restriction sites.
  • MCS multiple cloning site
  • vectors and herpes simplex viruses according to the present invention may further comprise one or a plurality of insertion sites, more preferably restriction endonuclease sites encoded by nucleic acid of the cassette.
  • Each insertion site may be formed by nucleic acid encoding a restriction endonuclease site.
  • the insertion sites may comprise one or more of the ClaI, BglII, NruI and XhoI restriction endonuclease sites.
  • the predetermined insertion site is preferably in the RL1 locus of the genome of the selected herpes simplex virus.
  • the first and second nucleotide sequences may each comprise sequence corresponding to:
  • said first and second nucleotide sequences may comprise contiguous portions of nucleotide sequence of the ICP34.5 gene of a herpes simplex virus.
  • said first and second nucleotide sequences may comprise contiguous portions of nucleotide sequence encoding the ICP34.5 gene product of a herpes simplex virus.
  • the first and second nucleotide sequences may have at least 60% sequence identity to their corresponding sequence in the viral genome. More preferably said identity may be one of at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • first and second nucleotide sequences may hybridise to their corresponding nucleotide sequence in the HSV genome, or its complement, under high or very high stringency conditions.
  • the marker may be a defined nucleotide sequence encoding a polypeptide.
  • the marker may comprise the Green Fluorescent Protein (GFP) protein coding sequence or the enhanced Green Fluorescent Protein (EGFP) protein coding sequence.
  • GFP Green Fluorescent Protein
  • EGFP enhanced Green Fluorescent Protein
  • the marker may comprise a defined nucleotide sequence detectable by hybridisation under high or very high stringency conditions with a corresponding labelled nucleic acid probe.
  • the cassette may further comprise a nucleic acid encoding a polyadenylation sequence located downstream (3′) of the nucleic acid encoding the marker.
  • the polyadenylation sequence may comprise the Simian Virus 40 (SV40) polyadenylation sequence.
  • mutant HSV according to the present invention are generated by site directed insertion of the cassette into the viral genome, more preferably by homologous recombination.
  • the vector may further comprise nucleic acid encoding a second selectable marker, e.g. a marker conferring antibiotic resistance.
  • the vector is preferably a DNA vector, particularly a dsDNA vector and may be an expression vector.
  • the vector is plasmid RL1.dIRES-GFP deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 3 Sep. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03090303 in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (herein referred to as the ‘Budapest Treaty’).
  • the selected herpes simplex virus may be an HSV-1 or HSV-2.
  • mutant HSV according to the present invention may be derived from a strain of either HSV-1 or HSV-2. More preferably the selected HSV may be one of HSV-1 strains 17 or F or HSV-2 strain HG52.
  • herpes simplex viruses of the invention may be mutants of these preferred ‘parental’ viruses.
  • the cassette may be integrated in the HSV genome so as to disrupt a protein coding sequence in the HSV genome resulting in inactivation of the respective gene product.
  • Herpes simplex virus of the invention may be gene specific null mutants. They may be ICP34.5 null mutants.
  • the herpes simplex virus may lack at least one expressible ICP34.5 gene. In other aspects of the present invention the generated herpes simplex virus may lack only one expressible ICP34.5 gene.
  • Herpes simplex virus according to the present invention may be non-neurovirulent.
  • Vectors and herpes simplex viruses according to the present invention may be used in gene therapy.
  • a method of generating a herpes simplex virus which expresses a nucleotide sequence of interest, or polypeptide thereby encoded comprising the step of culturing a selected herpes simplex virus with a vector according to the present invention, thereby integrating components (a), (b) and (c) of said vector at said predetermined insertion site in the genome of the selected herpes simplex virus.
  • Said integration at the predetermined insertion site is preferably a permanent integration.
  • a method of generating a nucleic acid vector comprising the steps of:
  • the insertion site(s)/nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site/regulatory nucleotide sequence and the ribosome binding site/regulatory nucleotide sequence is arranged upstream (5′) of the marker.
  • Said predetermined second nucleotide sequence may preferably correspond to a selected nucleotide sequence in the RL1 locus of the genome of the selected HSV.
  • the inserted nucleotide sequence(s) may separate the second nucleotide sequence into two vector flanking sequences, the inserted nucleotide sequences forming a cassette therebetween.
  • the second nucleotide sequence may correspond to a:
  • the second nucleotide sequence may comprise a contiguous portion of nucleotide sequence of the ICP34.5 gene of a herpes simplex virus.
  • the second nucleotide sequence may comprise a contiguous portion of nucleotide sequence encoding the ICP34.5 gene product of a herpes simplex virus.
  • the second nucleotide sequence may have at least 60% sequence identity to the corresponding sequence in the viral genome. More preferably said identity may be one of at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • Said second nucleotide sequence may hybridise to the corresponding nucleotide sequence in the viral genome, or its complement, under high or very high stringency conditions.
  • a method of generating a mutant herpes simplex virus comprising inserting a nucleic acid cassette comprising nucleotide sequence(s) encoding:
  • the insertion site(s)/nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site/regulatory nucleotide sequence and the ribosome binding site/regulatory nucleotide sequence is arranged upstream (5′) of the marker.
  • the site of insertion may preferably be a predetermined insertion site in the RL1 locus of the selected HSV.
  • the method of generating a mutant herpes simplex virus may comprise the steps of:
  • the co-transfection may be carried out under conditions effective for homologous recombination of said cassette into an insertion site in the viral genome.
  • the method of generating a mutant herpes simplex virus may further comprise one or more of the steps of:
  • the nucleotide sequence of interest may be heterologous to the selected herpes simplex virus. It may encode an heterologous polypeptide which may be selected from the group consisting of: a bacterial polypeptide; a mammalian polypeptide; a human polypeptide or from the group consisting of: Sodium iodide symporter (NIS); Nitroreductase (NTR); E. coli NTR; Endothelial nitric oxide synthase (eNOS); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); a cytokine.
  • NIS Sodium iodide symporter
  • NTR Nitroreductase
  • eNOS Endothelial nitric oxide synthase
  • GM-CSF Granulocyte Macrophage Colony-Stimulating Factor
  • nucleotide sequence of interest may encode a selected antisense nucleic acid.
  • Herpes simplex viruses generated by such methods may be gene specific null mutants, e.g. ICP34.5 null mutants.
  • the present invention may also include the following aspects and features which may be provided in combination with any of the other aspects and features described.
  • the nucleotide sequence of interest contained in the cassette may encode a polypeptide of interest, or fragment thereof, or comprise selected antisense DNA, that is DNA corresponding to at least one gene component (e.g. regulatory sequence 5′ UTR, 3′UTR or protein coding sequence) or fragment of a gene component, which is inserted in the cassette in an orientation such that upon transcription an antisense RNA is obtained.
  • the expressed product of the nucleotide sequence of interest may ultimately be a polypeptide, complete or truncated (e.g. a polypeptide fragment), or an antisense nucleic acid, preferably RNA.
  • antisense nucleic acid is meant a nucleic acid having substantial sequence identity to the nucleic acid formed by the sequence of complementary bases to the single strand of a target nucleic acid.
  • the antisense nucleic acid is useful in binding the target nucleic acid and may be used as an inhibitor to prevent or disrupt the normal activity, folding or binding of the target nucleic acid.
  • the substantial sequence identity is preferably at least 50% sequence identity, more preferably at least 60, 70, 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, 99 or 100% identity. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • the polypeptide may be any selected polypeptide.
  • the polypeptide of interest is an heterologous or exogenous polypeptide (i.e. a non-HSV originating polypeptide), preferably a bacterial polypeptide, alternatively a mammalian polypeptide or a human polypeptide.
  • the heterologous polypeptide may be useful in gene directed enzyme-prodrug targeting techniques for tissue specific delivery of active pharmaceutical agents.
  • the polypeptide of interest may be the Sodium iodide symporter (NIS), Nitroreductase (NTR), preferably E. coli NTR, Endothelial nitric oxide synthase (eNOS), Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) or a cytokine.
  • NNS Sodium iodide symporter
  • NTR Nitroreductase
  • eNOS Endothelial nitric oxide synthase
  • the cassette preferably further comprises at least one regulatory nucleotide sequence such as one or more selected promoter or enhancer elements known to the person skilled in the art, e.g. the CytoMegalovirus (CMV) promoter or Phosphoglycerokinase (PGK) promoter.
  • CMV CytoMegalovirus
  • PGK Phosphoglycerokinase
  • a regulatory nucleotide sequence may be located upstream (i.e. 5′) of the nucleotide sequence of interest and have a role in controlling and regulating transcription of the nucleotide sequence of interest and hence expression of the resulting transcript or polypeptide.
  • another regulatory sequence may be located upstream (5′) of the marker sequence and downstream (3′) of the nucleotide sequence of interest and have a role in controlling and regulating transcription of the marker and hence expression of the resulting transcript or polypeptide. In some arrangements this latter regulatory sequence may take the place of the ribosome binding site.
  • the components of the cassette are preferably arranged in a predetermined order.
  • the nucleotide sequence of interest is arranged upstream (i.e. 5′) of the ribosome binding site and the ribosome binding site is arranged upstream (i.e. 5′) of the marker.
  • a single transcript may be produced from the cassette comprising a first cistron comprising the nucleotide sequence of interest and a second cistron encoding the marker wherein the ribosome binding site is located between the cistrons.
  • a suitable ribosome binding site may comprise a ribosome entry site permitting entry of a ribosome to the transcribed mRNA encoded by the nucleic acid of the cassette such that the ribosome binds to the translation start signal.
  • the ribosome entry site is an internal ribosome entry site (IRES), more preferably an encephalomyocarditis virus IRES, permitting cap-independent initiation of translation.
  • IRES internal ribosome entry site
  • the IRES thus enables translation of a coding sequence located internally of a bi- or poly-cistronic mRNA, i.e. of a cistron located downstream of an adjacent cistron on a single transcript.
  • the marker is a defined nucleotide sequence coding for a polypeptide which can be expressed in a cell line (e.g. BHK cells) infected with mutant herpes simplex virus into which the cassette has been recombined.
  • a cell line e.g. BHK cells
  • One function of the marker is to enable identification of virus plaques containing mutant virus transformed with the cassette.
  • the marker may comprise a defined nucleotide sequence which can be detected by hybridisation under high stringency conditions with a corresponding labelled nucleic acid probe, e.g. using a fluorescent- or radio-label.
  • the marker is preferably a detectable marker, more preferably an expressible marker polypeptide or protein comprising at least the coding sequence for the selected polypeptide or protein.
  • the nucleic acid encoding the marker may further comprise regulatory sequence upstream and/or downstream of the coding sequence having a role in control of transcription of the marker mRNA.
  • Preferred markers include the Green Fluorescent Protein (GFP) protein coding sequence or gene, preferably the enhanced Green Fluorescent Protein (EGFP) protein coding sequence or gene.
  • the cassette further comprises a polyadenylation sequence (‘polyA sequence’).
  • polyA sequence comprises the Simian Virus 40 (SV40) polyA sequence.
  • SV40 Simian Virus 40
  • the preferred location of the polyA sequence within the cassette is immediately downstream (i.e. 3′) of the marker.
  • the first and second nucleotide sequences preferably comprise nucleotide sequences having identity to regions of the genome surrounding the insertion site in the selected herpes simplex virus strain (the ‘viral insertion site’). These sequences enable the cassette to be incorporated at the viral insertion site by homologous recombination between the first and second nucleotide sequences and their respective corresponding sequences in the viral genome.
  • first and second nucleotide sequences are flanking sequences for homologous recombination with corresponding sequences of a selected viral genome, such homologous recombination resulting in insertion of the cassette at the viral insertion site.
  • the first and second nucleotide sequences correspond to nucleotide sequences flanking an insertion site in the RL1 locus of the HSV genome, more preferably in the ICP34.5 protein coding sequence of the HSV genome.
  • the first and second nucleotide sequences may each be at least 50 bp in length, more preferably at least 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900 or 4000 bp in length.
  • Each of the first and second nucleotide sequences may have at least 50% sequence identity to their corresponding sequence in the viral genome, more preferably at least 60%, 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% 99% or 100% identity. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • the first and second nucleotide sequences may be characterised by the ability of one strand of a given sequence to hybridise with the corresponding single-stranded complement of the HSV genome under varying hybridisation stringency conditions.
  • the first and second nucleotide sequences will hybridise with their corresponding complement under very low, low or intermediate stringency conditions, more preferably at high or very high stringency conditions.
  • the nucleotide sequence of interest which forms part of the inserted cassette may encode a full length transcript or polypeptide (i.e. comprise the complete protein coding sequence).
  • the nucleotide sequence of interest may comprise one or more fragments of the full length sequence respectively coding for a fragment of the full length transcript or a truncated polypeptide or antigenic peptide respectively.
  • a fragment may comprise a nucleotide sequence encoding at least 10% of the corresponding full length sequence, more preferably the fragment comprises at least 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98 or 99% of the corresponding full length sequence.
  • the fragment comprises at least, i.e.
  • the fragment has a minimum length of, 20 nucleotides, more preferably at least 30, 40, 50, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900 or 4000 nucleotides.
  • the fragment may have a maximum length, i.e.
  • the fragment length may be anywhere between said minimum and maximum length.
  • the viral insertion site is the position between the genomic nucleotide sequences corresponding to the first and second nucleotide sequences of the vector (the ‘genomic’ and ‘vector flanking sequences’ respectively) at which homologous recombination will occur and may be predetermined by selection of the vector flanking sequences. Where the genomic flanking sequences are immediately adjacent, the insertion site is the position between the peripheral and immediately adjacent bases of the two genomic flanking sequences, such that insertion of the cassette separates the genomic flanking sequences. Where the genomic flanking sequences are separated by one or a plurality of bases in the viral genome, the insertion site is formed by said one or a plurality of bases which are excised from the genome by the homologous recombination event.
  • the position of the viral insertion site may be accurately selected by careful selection and construction of the vector flanking sequences. Accordingly, the vector may be constructed such that homologous insertion of the cassette results in disruption of a chosen protein coding sequence and inactivation of the respective gene product or such that the cassette is inserted at a non-protein coding region of the viral genome.
  • the complete genome sequences of several herpes simplex virus strains have been reported and are publicly available.
  • the complete genome sequence for HSV-1 strain 17syn+ was reported by Dolan et al 3 (incorporated herein by reference) and the complete genome sequence of HSV-2 strain HG52 was reported by Dolan et al 4 (incorporated herein by reference) and is available from the EMBL database under accession code Z86099.
  • the vector of the present invention may preferably be designed for use in generating mutant HSV-1 (e.g. in strain 17 or F) or mutant HSV-2 (e.g. in strain HG52).
  • the first and second nucleotide sequences each comprise sequence corresponding to the RL terminal repeat region of the genome of the selected HSV (e.g. HSV-1 strains 17 or F or HSV-2 strain HG52). More preferably, vector flanking sequences comprise, consist or consist essentially of nucleotide sequences of the RL repeat region which flank the ICP34.5 protein coding sequence. In flanking the ICP34.5 coding sequence, one or both of the selected sequences may, in the corresponding HSV genome, overlap, i.e. extend into, the ICP34.5 protein coding sequence or one or both sequences may be selected so as to not overlap the ICP34.5 protein coding sequence or so as to be within it entirely.
  • the selected sequences may be chosen to overlap completely or partially other important encoded signals, e.g. transcription initiation site, polyadenylation site, defined promoters or enhancers.
  • the insertion site may thus comprise all or a part of the ICP34.5 protein coding sequence and/or be such that the inserted cassette disrupts the ICP34.5 protein coding sequence.
  • vectors according to the present invention comprising first and second nucleotide sequences corresponding to regions of the RL repeat region flanking and/or overlapping or being entirely within the ICP34.5 protein coding sequence may be used in the generation of ICP34.5 null mutants.
  • all or a portion of the ICP34.5 protein coding sequence may be excised and replaced during the homologous recombination event such that both copies of the ICP34.5 coding sequence are disrupted.
  • the recombination may result in an insertion of nucleic acid within the ICP34.5 protein coding sequence thereby disrupting that sequence.
  • successfully transformed virus are thus mutants incapable of generating the ICP34.5 active gene product from at least one copy, and preferably from both copies, of the ICP34.5 gene.
  • the virus is considered to be an ICP34.5 null mutant.
  • each component of the cassette is positioned substantially adjacent the neighbouring component such that a single bicistronic transcript comprising or consisting essentially of the mRNA encoding the nucleotide sequence of interest, ribosome binding site and marker is obtainable.
  • the vector further comprises, consists, or consists essentially of a nucleic acid encoding a selectable marker such as a polypeptide or protein conferring antibiotic resistance e.g. kanamycin resistance or ampicillin resistance.
  • a selectable marker such as a polypeptide or protein conferring antibiotic resistance e.g. kanamycin resistance or ampicillin resistance.
  • a vector of the present invention preferably comprises a DNA vector, particularly a dsDNA vector.
  • the vector may be provided as a linear or circular (plasmid) DNA vector.
  • the vector preferably contains nucleotide sequences, e.g. restriction endonuclease site(s), permitting transition between the two forms by use of DNA ligation and restriction materials (e.g. enzymes) and techniques known to the person skilled in the art.
  • the vector is preferably provided in linear form.
  • the vector is plasmid RL1.dIRES-GFP deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 3 Sep. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03090303 in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (herein referred to as the ‘Budapest Treaty’).
  • the vector is a variant of plasmid RL1.dIRES-GFP.
  • Variant vectors may incorporate a regulatory nucleotide sequence, e.g. promoter, in place of the ribosome binding site of RL1.dIRES-GFP to control transcription of the nucleic acid encoding the marker.
  • a regulatory nucleotide sequence e.g. promoter
  • Vectors according to the present invention are preferably constructed for use in generating engineered HSV-1 or HSV-2 by insertion of a nucleic acid cassette, which insertion may be through a mechanism of homologous recombination between nucleotide sequences flanking the cassette and corresponding sequences in the selected herpes simplex virus genome.
  • the cassette may thereby be permanently integrated at a selected site of the viral genome.
  • vectors according to the present invention may comprise and have use as:
  • Vectors according to the present invention may be used in the manufacture of engineered gene specific HSV null mutants, i.e. HSV mutants incapable of expressing an active gene product of a selected gene. Alternatively they may be used in the manufacture of engineered viruses which express a selected protein from only one gene copy the other gene copy being disrupted or modified such that it cannot express a functional gene product. Such vectors may also be used in the manufacture of a medicament, preferably comprising said gene specific HSV (null) mutant, for use in treating tumours, preferably by the oncolytic treatment of the tumour. Preferably, such tumours may be primary or secondary (metastatic) tumours originating either in the central or peripheral nervous system, e.g.
  • glioma medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma, or originating in non-nervous system tissue e.g. melanoma, mesothelioma, lymphoma, hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer cells, lung cancer cells or colon cancer cells.
  • HSV mutants generated using vectors of the present invention may be used to treat metastatic tumours of the central or peripheral nervous system which originated in a non-nervous system tissue.
  • Vectors according to the present invention may also be used in the manufacture of engineered HSV mutants wherein the genome of the mutant HSV comprises an exogenous or heterologous gene which may have been inserted in the HSV genome by homologous recombination of the cassette.
  • the exogenous/heterologous gene is expressed in the mutant HSV, which expression may be regulated by a regulatory element, e.g. promoter, forming part of the inserted cassette.
  • Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • Vectors according to the present invention may also be used in the manufacture of an engineered HSV mutant wherein the genome of the mutant HSV comprises an exogenous/heterologous gene (i.e. a non-HSV originating gene) which may have been inserted in a protein coding sequence of the HSV genome by homologous recombination of the cassette such that the mutant HSV is incapable of expressing the active gene encoded by said protein coding sequence and wherein the exogenous/heterologous gene product is expressed under the control of a regulatory element.
  • the regulatory element forms part of the cassette.
  • Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • Vectors according to the present invention may also be used in the manufacture of engineered HSV mutants wherein the genome of the mutant HSV comprises a nucleotide sequence which may have been inserted in the HSV genome by homologous recombination of the cassette such that the nucleotide sequence is arranged to be transcribed from the HSV genome under the control of a regulatory element e.g. promoter, preferably a regulatory element forming part of the inserted cassette, to produce an antisense transcript.
  • a regulatory element e.g. promoter, preferably a regulatory element forming part of the inserted cassette, to produce an antisense transcript.
  • the antisense nucleotide sequence is an exogenous/heterologous (i.e. non-HSV originating) sequence.
  • Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • Vectors according to the present invention may also be used in the manufacture of an engineered HSV mutant wherein the genome of the mutant HSV comprises a nucleotide sequence which may have been inserted in a protein coding sequence of the HSV genome by homologous recombination of the cassette such that the mutant HSV is incapable of expressing the active gene encoded by said protein coding sequence and wherein the inserted nucleotide sequence is expressed under the control of a regulatory element to produce an antisense transcript.
  • the regulatory element forms part of the cassette.
  • Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • a method of lysing or killing tumour cells in vitro or in vivo comprising the step of administering mutant HSV, having a mutation in each ICP34.5 protein coding sequence and generated by a method according to an aspect of the present invention, to tumour cells.
  • a method of treating a tumour comprising administering to a subject mutant HSV having a mutation in each ICP34.5 protein coding sequence and generated by a method according to an aspect of the present invention.
  • a medicament, pharmaceutical composition or vaccine comprising a mutant HSV generated by a method according to an aspect of the present invention.
  • the medicament, pharmaceutical composition or vaccine is preferably for use in the oncolytic treatment of tumours and may further comprise a pharmaceutically acceptable carrier, adjuvant or diluent.
  • kit of parts comprising a first container having a quantity of a vector according to an aspect of the present invention and a second container comprising a quantity of HSV genomic DNA.
  • the mutant is a gene specific null mutant, more preferably an HSV ICP34.5 null mutant, wherein the HSV genome comprises an inserted nucleotide sequence of interest encoding a selected antisense RNA or an heterologous polypeptide.
  • the nucleotide sequence of interest has been inserted in each RL region of the HSV genome, more preferably at both of the ICP34.5 loci, still more preferably the inserted heterologous nucleic acid disrupts the ICP34.5 protein coding sequence such that both ICP34.5 genes are non-functional and the mutant HSV is incapable of expressing an active ICP34.5 gene product from the disrupted ICP34.5 protein coding sequences.
  • the inserted heterologous nucleotide sequence is non-endogenous to HSV and encodes a polypeptide of interest selected from the group comprising or consisting of Sodium iodide symporter (NIS), Nitroreductase (NTR), preferably E. coli NTR, Endothelial nitric oxide synthase (eNOS), Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) or a cytokine.
  • NNS Sodium iodide symporter
  • the inserted nucleotide sequence of interest is preferably expressed or capable of expression under the control of an inserted regulatory element, preferably the CMV IE promoter.
  • the mutant HSV genome preferably encodes the GFP gene product. More preferably the GFP coding sequence and nucleotide sequence of interest are arranged to be transcribed on a single bi- or poly-cistronic transcript such that expression of GFP is an indicator of HSV gene specific null mutants transformed with the nucleotide sequence of interest.
  • the nucleic acid cassette may be of any size, e.g. up to 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 Kbp in length.
  • the mutant HSV is HSV1716/CMV-NTR/GFP deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 5 Nov. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03110501 in accordance with the provisions of the Budapest Treaty.
  • Medicaments comprising HSV mutants according to the present invention for use in oncotherapy and methods of treating tumours comprising administering to a patient in need of treatment an effective amount of a mutant HSV according to an aspect of the present invention or a medicament comprising or derived from such HSV are also provided.
  • mutant HSV in the treatment of disease, including methods for the treatment of tumours/cancer, preferably by oncolysis is provided.
  • Use of such mutant HSV in the manufacture of a medicament for use in these treatments is also provided.
  • the administration of herpes simplex virus may comprise parenteral administration.
  • administration of the herpes simplex virus is by injection, more preferably injection to the tumour which is to be treated.
  • injections may be intravenous.
  • Alternative administration routes may comprise oral or nasal administration.
  • Herpes simplex viruses according to the present invention may contain at least one copy of a nucleotide sequence of interest in each long repeat region (R L ), i.e. in the terminal and internal long repeat (TR L and IR L ) regions.
  • each exogenous/heterologous sequence or cassette is located in an RL1 locus of the herpes simplex virus genome, more preferably in the DNA of the herpes simplex virus genome encoding the ICP34.5 gene or protein coding sequence.
  • the herpes simplex virus thereby lacks neurovirulence.
  • the parent herpes simplex virus, from which a virus of the invention is derived may be of any kind, e.g. HSV-1 or HSV-2.
  • the herpes simplex virus is a variant of HSV-1 strain 17 and may be obtained by modification of the strain 17 genomic DNA. Suitable modifications include the insertion of the exogenous nucleotide sequence of interest or exogenous/heterologous cassette comprising said sequence into the herpes simplex virus genomic DNA. The insertion may be performed by homologous recombination of the exogenous nucleic acid sequence into the genome of the selected herpes simplex virus.
  • Herpes simplex viruses of the present invention may be variants of a known ‘parent’ strain from which the herpes simplex virus of the invention has been derived.
  • a particularly preferred parent strain is HSV-1 strain 17.
  • Other parent strains may include HSV-1 strain F or HSV-2 strain HG52.
  • a variant comprises an HSV in which the genome substantially resembles that of the parent, contains the nitroreductase nucleic acid sequence or cassette containing said sequence and may contain a limited number of other modifications, e.g.
  • one, two or three other specific mutations which may be introduced to disable the pathogenic properties of the herpes simplex virus, for example a mutation in the ribonucleotide reductase (RR) gene, the 65K trans inducing factor (TIF) and/or a small number of mutations resulting from natural variation, which may be incorporated naturally during replication and selection in vitro or in vivo. Otherwise the genome of the variant will be that of the parent strain.
  • RR ribonucleotide reductase
  • TIF 65K trans inducing factor
  • vectors and/or herpes simplex viruses according to the present invention are provided for use in a method of medical treatment. Suitably they are provided for use in the treatment of disease. Preferably they are provided for use in the treatment of cancer. Suitably they may be provided for use in the oncolytic treatment of cancer/tumour of any kind.
  • the use of vectors and/or herpes simplex viruses according to the present invention in the manufacture of a medicament for the treatment of cancer is also provided.
  • medicaments comprising herpes simplex virus mutants according to the present invention for use in oncotherapy and methods of treating tumours comprising administering to a patient in need of treatment an effective amount of a mutant HSV or a medicament comprising or derived from such HSV are also provided.
  • Methods of lysing or killing tumour cells in vitro or in vivo comprising the step of administering to a patient in need of treatment an amount of an Herpes simplex virus according to the present invention are also provided.
  • a medicament, pharmaceutical composition or vaccine comprising a vector or Herpes simplex virus according to the present invention is also provided.
  • the medicament, pharmaceutical composition or vaccine may further comprise a pharmaceutically acceptable carrier, adjuvant or diluent.
  • Herpes simplex viruses of the invention may be used in a method of medical treatment. This may involve treatment of diseases associated with or involving the proliferation of cells, or cancers or tumours of any kind. Treatment may involve the selective lysis of dividing cells. This may be oncolysis, i.e. lysis of tumour cells.
  • Tumours to be treated may be of any kind, may comprise cancers, neoplasms or neoplastic tissue and may be in any animal or human patient. Cancer/tumour types which may be treated may be primary or secondary (metastatic) tumours of any kind.
  • Treatable tumour types may include primary or secondary (metastatic) tumours originating either in the central or peripheral nervous system, e.g. glioma, medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma, or originating in non-nervous system tissue e.g. melanoma, mesothelioma, lymphoma, hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer cells, lung cancer cells or colon cancer cells.
  • Treatable metastatic tumours may be those of the central or peripheral nervous system which originated in a non-nervous system tissue.
  • Herpes simplex viruses of the invention may be used in ‘gene delivery’ methods in vitro or in vivo.
  • Non-neurovirulent herpes simplex viruses of the invention are expression vectors and may be used to infect selected cells or tissues in order to express the nucleotide sequence of interest encoded by the herpes simplex virus genome.
  • Mutant HSV may be useful in the treatment of disease by gene directed enzyme-prodrug therapy and/or the treatment of disease, including tumours, by the use of antisense RNA or siRNA technology.
  • cells may be taken from a patient, a donor or from any other source, infected with a herpes simplex virus of the invention, optionally screened for expression and/or function of the encoded nucleotide sequence of interest, and optionally returned/introduced to a patient's body, e.g. by injection.
  • Herpes simplex viruses of the invention may be performed using naked virus or by encapsulation of the virus in a carrier, e.g. nanoparticles, liposomes or other vesicles.
  • a carrier e.g. nanoparticles, liposomes or other vesicles.
  • in vitro cultured cells preferably human or mammalian cells, transformed with viruses of the present invention and preferably cells expressing the nucleotide sequence of interest as well as methods of transforming such cells in vitro with said viruses form further aspects of the present invention.
  • a nucleotide sequence of interest may be an exogenous/heterologous sequence, i.e. one not originating in the parent (wild-type) herpes simplex virus from which the herpes simplex virus of the invention is derived.
  • a mutant herpes simplex virus is a non-wild type herpes simplex virus and may be a recombinant herpes simplex virus.
  • Mutant herpes simplex viruses may comprise a genome containing modifications relative to the wild type.
  • a modification may include at least one deletion, insertion, addition or substitution.
  • Medicaments and pharmaceutical compositions according to aspects of the present invention may be formulated for administration by a number of routes, including but not limited to, parenteral, intravenous, intramuscular, intratumoural, oral and nasal.
  • the medicaments and compositions may be formulated in fluid or solid (e.g. tablet) form.
  • Fluid formulations may be formulated for administration by injection to a selected region of the human or animal body.
  • non-neurovirulence is defined by the ability to introduce a high titre of virus (approx 10 6 plaque forming units (pfu)) to an animal or patient 22, 23 without causing a lethal encephalitis such that the LD 50 in animals, e.g. mice, or human patients is in the approximate range of ⁇ 10 6 pfu 21 .
  • the virus is considered to be an ICP34.5 null mutant.
  • a regulatory sequence e.g. promoter
  • a regulatory sequence that is operably linked to a nucleotide sequence may be located adjacent to that sequence or in close proximity such that the regulatory sequence can effect and/or control expression of a product of the nucleotide sequence.
  • the encoded product of the nucleotide sequence may therefore be expressible from that regulatory sequence.
  • nucleic acid sequences may be identified by using hybridization and washing conditions of appropriate stringency.
  • Complementary nucleic acid sequences will hybridise to one another through Watson-Crick binding interactions. Sequences which are not 100% complementary may also hybridise but the strength of the hybridisation usually decreases with the decrease in complementarity. The strength of hybridisation can therefore be used to distinguish the degree of complementarity of sequences capable of binding to each other.
  • the stringency of a given reaction may depend upon factors such as probe length, washing temperature, and salt concentration. Higher temperatures are generally required for proper annealing of long probes, while shorter probes may be annealed at lower temperatures. The higher the degree of desired complementarity between the probe and hybridisable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so.
  • hybridizations may be performed, according to the method of Sambrook et al., (“Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989) using a hybridization solution comprising: 5 ⁇ SSC, 5 ⁇ Denhardt's reagent, 0.5-1.0% SDS, 100 ⁇ g/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide.
  • Hybridization is carried out at 37-42° C. for at least six hours.
  • filters are washed as follows: (1) 5 minutes at room temperature in 2 ⁇ SSC and 1% SDS; (2) 15 minutes at room temperature in 2 ⁇ SSC and 0.1% SDS; (3) 30 minutes-1 hour at 37° C. in 1 ⁇ SSC and 1% SDS; (4) 2 hours at 42-65° C. in 1 ⁇ SSC and 1% SDS, changing the solution every 30 minutes.
  • T m melting temperature
  • the T m is 57° C.
  • the T m of a DNA duplex decreases by 1-1.5° C. with every 1% decrease in sequence complementarity.
  • nucleotide sequences can be categorised by an ability to hybridise to a target sequence under different hybridisation and washing stringency conditions which can be selected by using the above equation.
  • the T m may be used to provide an indicator of the strength of the hybridisation.
  • Sequences exhibiting 95-100% sequence complementarity may be considered to hybridise under very high stringency conditions, sequences exhibiting 85-95% complementarity may be considered to hybridise under high stringency conditions, sequences exhibiting 70-85% complementarity may be considered to hybridise under intermediate stringency conditions, sequences exhibiting 60-70% complementarity may be considered to hybridise under low stringency conditions and sequences exhibiting 50-60%% complementarity may be considered to hybridise under very low stringency conditions.
  • the invention includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
  • FIG. 1 Generation of plasmid RL1.dIRES-GFP from plasmids pNAT-IRES-GFP and RL1.del.
  • FIG. 2 Agarose gel electrophoresis of HpaI digested, CIP treated, RL1.del. RL1.del was digested with HpaI. The digested DNA was then treated with Calf Intestinal Phosphatase (CIP) to prevent the vector re-annealing to itself in subsequent ligation reactions. A sample of the digested/CIP treated DNA was electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel. HpaI linearises the vector at 8.6 Kbp.
  • CIP Calf Intestinal Phosphatase
  • FIG. 3 Agarose gel electrophoresis of NsiI/SspI digested pNAT-IRES-GFP (A) and purified/blunt-ended pCMV-NAT-IRES-GFP-PolyA (B).
  • A NsiI/SspI digested pNAT-IRES-GFP
  • B purified/blunt-ended pCMV-NAT-IRES-GFP-PolyA
  • FIG. 4 Identification of RL1.del clones containing the pCMV-NAT-IRES-GFP-PolyA insert. Ligation reactions were set up with the purified, blunt ended pCMV-NAT-IRES-GFP-PolyA fragment and HpaI digested, CIP treated RL1.del. Bacteria were transformed with samples from the ligation reactions and plated out onto LBA (Amp r ) plates. Colonies were picked and plasmid DNA was extracted and digested with AflII. Digested samples were electrophoresed, beside a 1 Kbp DNA ladder (L) (Promega), on a 1% agarose gel.
  • LBA Amp r
  • FIG. 5 Determination of the orientation of pCMV-NAT-IRES-GFP-PolyA in clone 5 (RL1.dCMV-NAT-GFPb).
  • pCMV-NAT-IRES-GFP-PolyA blue ended
  • the plasmid was digested with XhoI and the digested DNA electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel.
  • FIG. 6 Removal of pCMV-NAT from clone 5 (A) and large scale plasmid preparation of RL1.dIRES-GFP (B).
  • A Four samples of clone 5 were digested with XhoI and electrophoresed, beside a 1 Kbp DNA ladder (L) (Promega), on a 1% agarose gel (A). The larger fragment of DNA generated from this digestion (10.2 Kbp) was purified from the gel and ligated back together, at the XhoI sites, to form a single XhoI site in a new plasmid, designated RL1.dIRES-GFP.
  • a large-scale plasmid preparation was grown up and the preparation checked by digesting with XhoI.
  • FIG. 7 Generation, detection and purification of ICP34.5 null HSV-1 expressing a gene product of interest.
  • FIG. 8 Strategy used to clone pCMV-NTR from pPS949 into RL1.dIRES-GFP.
  • the pPS949 plasmid was a kind gift from Professor Lawrence Young (University of Birmingham) and contains the E. coli nitroreductase (NTR) gene downstream of the CMV-IE promoter (pCMV) in pLNCX (Clontech).
  • NTR E. coli nitroreductase
  • FIG. 9 Agarose gel electrophoresis of BamHI digested pPS949 (A) and the purified pCMV-NTR fragment (B).
  • A BamHI digested pPS949
  • B purified pCMV-NTR fragment
  • FIG. 10 Agarose gel electrophoresis of BglII digested, CIP treated RL1.dIRES-GFP.RL1.dIRES.GFP was digested with BglII. The digested plasmid was then treated with Calf Intestinal Phosphatase (CIP) to prevent the vector re-annealing to itself in subsequent ligation reactions. A sample of the digested/CIP treated DNA was electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel to check its concentration. pCMV-NTR from pPS949 was subsequently cloned into this digested/CIP treated vector.
  • CIP Calf Intestinal Phosphatase
  • FIG. 11 Determination of the orientation of pCMV-NTR in clone 4.
  • pCMV-NTR (BamHI ends) could have been cloned into the BglII site of RL1.dIRES-GFP in two orientations.
  • clone 4 was digested with BglII and XhoI and the digested DNA electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel. If the insert was in the desired orientation (A), two fragments (11.5 Kbp and 300 bp) would be generated. If in the opposite orientation, two fragments of 10.5 Kbp and 1.3 Kbp would be generated. The presence of a band at ⁇ 300 bp (and the absence of a band at 1.3 Kbp) confirmed that the pCMV-NTR fragment had been cloned into the vector in the desired orientation.
  • FIG. 12 Agarose gel electrophoresis of ScaI digested clone 4 (A) and HSV1716/CMV-NTR/GFP viral titres (B).
  • Clone 4 (RL1.dCMV-NTR-GFP) was digested with ScaI, the digested DNA purified and 5 ⁇ l electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel, to check its concentration.
  • 80% confluent BHK cells were then co-transfected with 10 ⁇ l HSV17 + DNA and an appropriate volume of the remaining digested clone 4. The cells were incubated at 37° C. for 3 days until cpe was evident.
  • Recombinant viral plaques were picked under the fluorescent microscope, purified and a virus stock, named HSV1716/CMV-NTR/GFP, grown up.
  • the cell-associated and cell-released fraction of the virus stock was titrated on BHK cells.
  • FIG. 13 Growth kinetics of HSV17 + , HSV1716 and HSV1716/CMV-NTR/GFP in confluent BHK and 3T6 cells.
  • Confluent BHK and 3T6 cells were infected at a MOI of 0.1 pfu/cell. Infected cells were harvested at 0, 4, 24, 48 and 72 hrs post infection, sonicated and progeny virus titrated on BHK cell monolayers. All viruses replicated with similar kinetics in BHK cells (A); HSV1716 and HSV1716/CMV-NTR/GFP both failed to replicate efficiently in confluent 3T6 cells (B).
  • FIG. 14 Western blot analysis of ICP34.5 expression in HSV17 + and HSV1716/CMV-NTR/GFP infected BHK cells.
  • BHK cells were infected with HSV17 + and HSV1716/CMV-NTR/GFP at a MOI of 10 pfu/cell. 16 hrs post infection, the cells were harvested and protein extracts analysed using 10% SDS-PAGE in a Western blot using a polyclonal anti-ICP34.5 antibody.
  • ICP34.5 was strongly expressed in HSV17 + infected cells but was not expressed in HSV1716/CMV-NTR/GFP infected cells.
  • FIG. 15 Western blot analysis of NTR expression in HSV1716/CMV-NTR/GFP infected cell lines.
  • BHK, C8161, VM and 3T6 cells were infected with 10 pfu/cell HSV1716/CMV-NTR/GFP, HSV17 + or mock infected. 16 hrs post infection, the cells were harvested and protein extracts analysed in a Western blot using a polyclonal NTR-specific antibody. Significant NTR expression was detected in all the HSV1716/CMV-NTR/GFP infected cells. No NTR expression was detected in the mock or HSV17 + infected cells.
  • FIG. 16 Effect of HSV1716/CMV-NTR/GFP and HSV1716-GFP with or without CB1954 (50 ⁇ M) on confluent 3T6 cells.
  • Confluent 3T6 cells in three wells of a 96-well plate were mock infected, infected with 1 or 10 pfu/cell HSV1716/CMV-NTR/GFP or infected with 1 pfu/cell of HSV1716-GFP. 45 minutes later, infected cells were overlaid with media containing 50 ⁇ M CB1954 or with media alone and incubated at 37° C.
  • FIG. 17 Effect of HSV1716/CMV-NTR/GFP and HSV1716-GFP with or without CB1954 (50 ⁇ M) on confluent C8161 cells.
  • Confluent C8161 cells in three wells of a 96-well plate were mock infected, infected with 1 or 10 pfu/cell HSV1716/CMV-NTR/GFP or infected with 1 pfu/cell of HSV1716-GFP. 45 minutes later, infected cells were overlaid with media containing 50 ⁇ M CB1954 or with media alone and incubated at 37° C.
  • FIG. 18 Confluent 3T6 cells 72 hrs post treatment with 10 pfu/cell HSV1716/CMV-NTR/GFP (A), or 10 pfu/cell HSV1716/CMV-NTR/GFP with 50 ⁇ M CB1954 (B).
  • the extent of cell death is significantly more pronounced in HSV1716/CMV-NTR/GFP infected cells overlaid with media containing 50M C1954 than in HSV1716/CMV-NTR/GFP infected cells overlaid with normal media.
  • the extent of cell death following infection of these cells with 10 pfu/cell HSV1716, with or without CB1954 is comparable to that seen in A (data not shown). 50 ⁇ M CB1954 alone has no effect on these cells.
  • FIG. 19 Confluent C8161 cells 72 hrs post treatment with 10 pfu/cell HSV1716/CMV-NTR/GFP (A), or 10 pfu/cell HSV1716/CMV-NTR/GFP with 50 ⁇ M CB1954 (B).
  • the extent of cell death is significantly more pronounced in HSV1716/CMV-NTR/GFP infected cells overlaid with media containing 50 ⁇ M CB1954 than in HSV1716/CMV-NTR/GFP infected cells overlaid with normal media.
  • the extent of cell death following infection of these cells with 10 pfu/cell HSV1716, with or without CB1954 is comparable to that seen in A (data not shown). 50 ⁇ M CB1954 alone has no effect on these cells.
  • A2780 xenografts at date of intratumoural injection (Day 0) are between 0.5-1 mm in diameter. The xenografts have reached this size 12 days after injection with 10 million A2780 cells subcutaneously on the flank of female athymic nude mice.
  • FIG. 21 Change in tumour volume over time in athymic nude mice with A2780 xenografts after intratumoural injection of HSV 1790.
  • FIG. 22 Starting tumour sizes of mice.
  • FIG. 23 Alterations in weight after treatment with CMV-ntr, CB1954 or a combination of both.
  • FIG. 24 Change in tumour volume after treatment with CMV-ntr, CB1954 or a combination of both.
  • FIG. 25 Starting tumour volume of each treatment group (see Table 2).
  • FIG. 26 Weight (as a measurement of health) in athymic nude mice with A2780 xenograft treated with either HSV 1790, HSV 1716, CB 1954 or a combination of them.
  • FIG. 27 Change in tumour volume of xenografts treated with the prodrug CB1954.
  • FIG. 28 Changes in tumour volume in xenograft treated with 10 5 PFU HSV 1790 and CB1954.
  • FIG. 29 Changes in tumour volume in xenografts treated with 10 6 PFU HSV 1790 and CB1954.
  • FIG. 30 Changes in tumour volume in xenografts treated with 10 5 PFU HSV 1716 and CB1954.
  • FIG. 31 Comparison of 10 5 PFU, 10 6 PFU HSV 1790 and 10 5 PFU HSV 1716.
  • Plasmid RL1.dIRES-GFP was generated in three stages, illustrated in FIG. 1 .
  • the DNA sequences containing the CMV IE promoter (pCMV), the NAT gene, the internal ribosome entry site (IRES), the GFP reporter gene and the SV40 polyadenylation sequences were excised from pNAT-IRES-GFP using NsiI and SspI and purified.
  • RL1.dCMV-NAT-GFP The pCMV-NAT DNA sequences of RL1.dCMV-NAT-GFP were excised using XhoI and the remainder of the plasmid re-ligated to form a novel plasmid designated RL1.dIRES-GFP.
  • This novel plasmid contained a multi-cloning site (all sites shown are unique) upstream of an IRES, the GFP gene and the SV40 polyA sequences all within the HSV-1 RL1 flanking sequences.
  • Recombinant ICP34.5 null HSV-1 expressing a gene of interest in the RL1 locus, can be generated by cloning the gene of interest (downstream of a suitable promoter) into the multi-cloning site and co-transfecting BHK cells with the plasmid and HSV-1 DNA.
  • Recombinant virus expressing the target gene can be identified using GFP fluorescence.
  • RL1.dCMV-NAT-GFP a novel plasmid containing a multi-cloning site (MCS), upstream of the encephalomyocarditis virus internal ribosome entry site (EMCV IRES), the GFP reporter gene and the SV40 PolyA sequences, all within RL1 flanking sequences.
  • MCS multi-cloning site
  • EMCV IRES encephalomyocarditis virus internal ribosome entry site
  • GFP reporter gene and the SV40 PolyA sequences all within RL1 flanking sequences.
  • This novel arrangement of DNA sequences or ‘smart cassette’ allows ICP34.5 null HSV-1, expressing a gene of interest in the RL1 locus, to be easily generated by simply inserting the desired transgene (downstream of a suitable promoter) into the MCS and co-transfecting BHK cells with the plasmid and HSV-1 DNA.
  • the IRES situated between the GFP gene and the MCS permits expression of two genes from the same promoter and so recombinant virus expressing the gene of interest also expresses GFP and can therefore be easily identified under a fluorescence microscope and purified.
  • 4 ⁇ 1 ⁇ g of pNAT-IRES-GFP** was digested with 10 units of NsiI and 10 units of SspI in a suitable volume of 10 ⁇ buffer (Promega) and nuclease free water (Promega) at 37° C. for 16 hrs.
  • the reaction mixture was electrophoresed in a 1% agarose gel for 1 hr at 110 volts.
  • Ligation reactions were carried out in small eppendorf tubes containing 5 units T4 DNA Ligase (Promega), a suitable volume of 10 ⁇ DNA Ligase Buffer (Promega), nuclease free water (Promega) and various volumes of the HpaI digested/CIP treated RL1.del and blunt ended pCMV-NAT-IRES-GFP-SV40 Poly A DNA, at 16° C. overnight. Competent JM109 bacterial cells (Promega) were then transformed with various aliquots of the ligation reactions***. Colonies formed on the plates were picked, had their plasmid DNA extracted using a Qiagen Plasmid Mini kit and screened for inserts using AflII (New England Biolabs) restriction enzyme analysis.
  • Plasmid DNA containing the insert would produce two fragments of 4.8 Kbp and 9.2 Kbp following digestion with AflII.
  • Two clones contained the insert ( FIG. 4 ).
  • the orientation of the insert in clone 5 was determined using XhoI restriction enzyme analysis ( FIG. 5 ).
  • the CMV-NAT portion of the CMV-NAT-IRES-GFP-SV40 PolyA insert was removed by digesting 4 ⁇ 500 ng of clone 5 with 10 units of XhoI in a suitable volume of buffer and water (Promega), overnight at 37° C.
  • the digested DNA was electrophoresed on a 1% agarose gel at 110 volts for 1 hr ( FIG. 6A ).
  • the 10.2 Kbp fragment consisting of the IRES, the GFP gene, the SV40 PolyA sequences and RL1 flanking sequences in a pGEM3Zf( ⁇ ) (Promega) backbone was excised using a sterile scalpel and the DNA purified from the gel using a QIAquick Gel Extraction kit.
  • Ligation reactions were performed in small eppendorf tubes containing 10 ng-500 ng purified DNA, 3 units T4 DNA Ligase (Promega), a suitable volume of 10 ⁇ DNA Ligase Buffer (Promega) and nuclease free water (Promega) overnight at 16° C. Competent JM109 bacterial cells (Promega) were then transformed with various aliquots of the ligation reactions***. Colonies formed on the plates were picked, had their plasmid DNA extracted using a Qiagen Plasmid Mini kit and screened using XhoI (Promega) restriction enzyme analysis.
  • Colonies containing plasmid DNA from which CMV-NAT had been removed would produce one fragment of 10.2 Kbp when digested with XhoI.
  • Several positive clones were found, one was isolated, and a large-scale plasmid preparation undertaken using Promega's Wizard Plus Maxipreps kit. The large-scale plasmid preparation was checked by digesting with XhoI ( FIG. 6B ). This plasmid DNA was subsequently named ‘RL1.dIRES-GFP’.
  • Plasmid RL1.dIRES-GFP has been deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 3 Sep. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03090303 in accordance with the provisions of the Budapest Treaty.
  • *RL1.del was provided by Dr. E. McKie and is the pGEM-3Zf( ⁇ ) plasmid (Promega) into which has been cloned an HSV-1 fragment (123459-129403) consisting of the RL1 gene and its flanking sequences.
  • the 477 bp PflMI-BstEII fragment of the RL1 gene (125292-125769) has been removed and replaced with a multi-cloning site (MCS) to form RL1.del.
  • ** pNAT-IRES-GFP was supplied by Dr. Marie Boyd (CRUK Beatson Laboratories) and is the pIRES2-EGFP plasmid (BD Biosciences Clontech) into which she has cloned the bovine noradrenaline transporter (NAT) gene (3.2 Kbp), at the NheI and XhoI sites.
  • NAT bovine noradrenaline transporter
  • the cells were then resuspended in 1/10 th volume of transformation and storage buffer (10 mM MgCl 2 , 10 mM Mg(SO) 4 , 10% (w/v) PEG 3,500, 5% (v/v) DMSO). The cells were placed on ice for between 10 minutes and 2 hrs, after which time they were considered competent for transformation.
  • 1-10 ⁇ l of DNA was mixed with 100 ⁇ l of competent bacteria in eppendorf tubes, and the tubes placed on ice for 30 minutes. After this, the samples were ‘heat shocked’ by incubating the tubes in a 42° C. water bath for exactly 45 seconds before placing them on ice for a further 2 minutes. 1 ml of L-Broth was added, the tube inverted 2-3 times, and the bacteria incubated for 1 hr at 37° C. 100 ⁇ l of the transformed bacteria was plated out onto L-broth agar plates containing 100 ⁇ g/ml of the appropriate antibiotic (usually ampicillin or kanamycin). Plates were allowed to dry at room temperature, before incubating in an inverted position at 37° C. overnight.
  • the appropriate antibiotic usually ampicillin or kanamycin
  • FIG. 7 illustrates the method steps involved.
  • plasmid DNA containing the gene of interest and the desired promoter (X), is digested with restriction endonucleases to release the promoter/gene fragment.
  • the promoter/gene fragment is purified and cloned into the multi-cloning site (MCS) of RL1.dIRES.GFP forming a shuttle vector suitable for generating oncolytic HSV-1 ( FIG. 7B ).
  • MCS multi-cloning site
  • This vector contains HSV-1 sequences that flank the essential RL1 gene but does not contain the RL1 gene.
  • the plasmid also contains the gene for Green Fluorescent Protein (GFP) downstream of an internal ribosome entry site (IRES).
  • GFP Green Fluorescent Protein
  • IRES permits expression of both the gene of interest and the GFP gene from the same upstream promoter.
  • BHK cells are then co-transfected with linearised RL1.dIRES.GFP, now containing the gene of interest, and HSV-1 DNA ( FIG. 7C ).
  • designer virus expressing the gene of interest and GFP, is generated and can be distinguished from wild type virus (also generated but not expressing GFP) under a fluorescence microscope.
  • Viral plaques, expressing GFP (and hence the gene of interest), are picked under the fluorescence microscope and purified until all wild-type HSV-1 has been removed.
  • the recombinant HSV-1 is considered 100% pure when all the viral plaques are expressing GFP ( FIG. 7D ).
  • Oncolytic HSV-1 expressing a gene product of interest from a selected promoter, is then ready for characterisation and in vitro examination of its tumour killing potential.
  • the gene of interest To generate replication restricted HSV-1, expressing the gene of interest and GFP, the gene of interest must be cloned into RL1.dIRES-GFP downstream of a suitable promoter (e.g. CMV IE).
  • the promoter is required upstream of the gene of interest for the production of a bicistronic mRNA transcript.
  • the IRES sequence between the two open reading frames in the transcript functions as a ribosome binding site for efficient cap-independent internal initiation of translation.
  • the design enables coupled transcription of both the gene of interest and GFP, followed by cap-dependent initiation of translation of the first gene (gene of interest) and IRES-directed, cap-independent translation of GFP. Co-ordinate gene expression is thus ensured in this configuration.
  • HSV-1 (17 + ) DNA and 0.1-1 ⁇ g linearized SMART cassette containing the gene and promoter of interest is pipetted into 1.5 ml eppendorf tubes containing 1 ⁇ l of calf thymus DNA (10 ⁇ g/ml) and an appropriate volume of distilled water to give a final volume of 165 ⁇ l.
  • the solutions are very gently mixed using a 200 ⁇ l pipette tip.
  • 388 ⁇ l of HEBS, pH 7.5, (130 mM NaCl, 4.9 mM KCl, 1.6 mM Na 2 HPO 4 , 5.5 mM D-glucose, 21 mM HEPES) is then added, the solution mixed, before adding 26.5 ⁇ l of 2M CaCl 2 dropwise and flicking the eppendorf tube two or three times.
  • the samples are left at room temperature for 10-15 minutes then added dropwise to 80% confluent BHK's in 60 mm petri dishes from which the medium has been removed. Following incubation at 37° C. for 45 minutes, the cells are overlaid with 5 ml of ETC10 and incubated at 37° C.
  • the media is removed and the plates washed with ETC10.
  • the cells are overlaid with 1 ml 25% (v/v) DMSO in HEBS at room temperature. After the 4 minutes, the cells are immediately washed three times with 5 ml ETC10 before overlaying with 5 ml of ETC10 and returning to the incubator. The following day, fresh medium is added to the cells. Two days later, when cpe is evident, cells are scraped into the medium, transferred to small tended and sonicated thoroughly. The sample is then stored at ⁇ 70° C. until required (see section below on plaque purification).
  • the volume of virus DNA to add is determined by undertaking the above procedure without plasmid DNA, using a range of virus DNA volumes and choosing the volume that gives the greatest number of viral plaques on the BHK monolayer after 2 or 3 days.
  • Sonicated samples from co-transfection plates are thawed and serially diluted 10 fold in ETC10.
  • 100 ⁇ l from neat to the 10 5 dilution is plated out on confluent BHK's in 60 mm petri dishes from which the media has been removed. After 45 minutes incubation at 37° C., the cells are overlaid with 5 ml EMC10 and incubated at 37° C. for 48 hrs.
  • the plates are then checked for the presence of viral plaques and those dishes with the fewest, most separated plaques are placed under a fluorescent stereomicroscope.
  • Recombinant virus designed to express the green fluorescent protein (GFP) in addition to the gene of interest, can clearly be distinguished from wild type virus using a GFP filter.
  • GFP green fluorescent protein
  • Fluorescent plaques are picked using a 20 ⁇ l pipette and placed (including the tip) into an eppendorf tube containing 1 ml ETC10. The sample is thoroughly sonicated before making serial 10 fold dilutions in ETC10 and repeating the above purification procedure. The process is repeated typically 3-4 times until every plaque on the BHK monolayer is fluorescent. Once this has been achieved, 50 ⁇ l of this sample is used to infect BHK cells in roller bottles, in 50 ml ETC10, and a virus stock grown.
  • BHK21/C13 cells are grown in Eagle's medium (Gibco) supplemented with 10% newborn calf serum (Gibco) and 10% (v/v) tryptose phosphate broth. This is referred to as ETC10.
  • ETC10 Eagle's medium containing 1.5% methylcellulose and 10% newborn calf serum
  • EMC10 is used to overlay the cells.
  • HSV1716/CMV-NTR/GFP was generated by cloning a 1.6 Kbp BamHI fragment from pPS949 10 , consisting of the E. coli nitroreductase (NTR) gene downstream of the CMV IE promoter (pCMV), into the MCS of the RL1.dIRES-GFP smart cassette, in the forward orientation with respect to the GFP gene in RL1.dIRES-GFP ( FIG. 8 ).
  • the resultant plasmid named RL1.dCMV-NTR-GFP, was then linearised and recombinant virus generated and purified as described above.
  • the plasmid pPS949 (referred to as ‘pxLNC-ntr’ in Ref 10) containing the NTR gene downstream of the CMV IE promoter (pCMV-NTR) in a pLNCX (Clontech) backbone, was a kind gift from Professor Lawrence Young, University of Birmingham, UK.
  • pPS949 4 ⁇ 1 ⁇ g of pPS949 was digested with 10 units of BamHI (Promega), in a suitable volume of 10 ⁇ buffer (Promega) and nuclease free water (Promega), at 37° C. for 16 hrs.
  • the reaction mixture was electrophoresed in a 1% agarose gel for 1 hr at 110 volts.
  • the 1.6 Kbp DNA fragment consisting of the CMV promoter upstream of the NTR gene (pCMV-NTR) was excised using a sterile scalpel and the DNA purified from the gel using a QIAquick Gel Extraction kit (Qiagen). 5 ⁇ l of the purified DNA fragment was electrophoresed on a 1% agarose gel to check its concentration ( FIG. 9 ).
  • 2 ⁇ g of the RL1.dIRES-GFP smart cassette was then digested with 15 units of BglII (Promega), in a suitable volume of 10 ⁇ buffer (Promega) and nuclease free water (Promega), at 37° C. for 16 hrs.
  • the digested plasmid was then purified using the QIAquick PCR purification kit (Qiagen), treated with 10 units of Calf Intestinal Phosphatase (Promega), in a suitable volume of 10 ⁇ CIP buffer and nuclease free water for 4 hrs at 37° C., before being purified again using the Qiaquick PCR purification kit.
  • 5 ⁇ l of the purified DNA was electrophoresed on a 1% agarose gel to check its concentration ( FIG. 10 ).
  • Ligation reactions were carried out in small eppendorf tubes containing 5 units T4 DNA Ligase (Promega), a suitable volume of 10 ⁇ DNA Ligase Buffer (Promega), nuclease free water (Promega) and various volumes of the BglII digested/CIP treated RL1.dIRES-GFP smart cassette and pCMV-NTR (BamHI ends), at 16° C. overnight. Competent JM109 bacterial cells (Promega) were then transformed with various aliquots of the ligation reactions. Colonies formed on the plates were picked, had their plasmid DNA extracted using a Qiagen Plasmid Mini kit and screened for inserts using BglII/XhoI (Promega) restriction enzyme analysis.
  • RL1.dIRES-GFP plasmid DNA containing the pCMV-NTR insert in the correct orientation would produce two fragments of 11.5 Kbp and 300 bp following digestion with BglII and XhoI.
  • One clone (clone 4) was found to contain the insert in the correct orientation ( FIG. 11 ). This plasmid was named ‘RL1.dCMV-NTR-GFP’.
  • RL1.dCMV-NTR-GFP was linearized by digesting with 10 units of ScaI (Promega), in a suitable volume of 10 ⁇ buffer (Promega) and nuclease free water (Promega), at 37° C. for 16 hrs.
  • a sample (5 ⁇ l) of the digested DNA was electrophoresed on a 1% agarose gel for 1 hr at 110 volts to check that it had been linearized.
  • 80% confluent BHK cells were then co-transfected with a suitable volume of the remaining linearised DNA and HSV-1 DNA.
  • HSV1716/CMV-NTR/GFP Recombinant HSV-1, expressing GFP (and hence NTR) was identified and purified using a fluorescent microscope and a virus stock, named HSV1716/CMV-NTR/GFP, was grown and titrated on BHK cells ( FIG. 12 ).
  • HSV1716/CMV-NTR/GFP has been deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 5 Nov. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03110501 in accordance with the provisions of the Budapest Treaty.
  • HSV1716/CMV-NTR/GFP replicates with almost identical kinetics to HSV1716 in BHK cells and 3T6 cells.
  • BHK cells support the replication of ICP34.5 null HSV while confluent 3T6 cells do not.
  • FIG. 13 shows that HSV1716/CMV-NTR/GFP will replicate as well as HSV1716 in permissive cell lines and that the introduction of exogenous genes, e.g. NTR and GFP, has not reduced the oncolytic potential of the ICP34.5 null HSV.
  • the fact that HSV1716/CMV-NTR/GFP fails to replicate in 3T6 cells also indicates that this recombinant HSV is an ICP34.5 null mutant.
  • FIG. 14 is a Western blot demonstrating that no ICP34.5 polypeptide is expressed from HSV1716/CMV-NTR/GFP, and that the virus is thus useful as a gene therapy vector.
  • FIG. 15 is another Western blot demonstrating expression of NTR in a variety of cell lines infected with HSV1716/CMV-NTR/GFP, including a human malignant melanoma cell line (C8161) and confluent 3T6 cells in which ICP34.5 null HSV does not replicate.
  • Some tumour cells in vivo will not support the replication of ICP34.5 null HSV and as such, will not be killed with HSV1716.
  • FIG. 16 shows the results from a cytotoxicity assay performed in confluent 3T6 cells.
  • Infecting confluent 3T6 cells with an ICP34.5 null mutant (HSV1716/CMV-NTR/GFP), at a multiplicity of infection (MOI) of 1 plaque forming units (pfu)/cell does not result in any significant cell death, neither does separate incubation of the cells with 50 ⁇ M CB1954.
  • MOI multiplicity of infection
  • pfu plaque forming units
  • C8161 melanoma cells do support the replication of ICP34.5 null HSV. Therefore, cell death will occur following infection of the cells with ICP34.5 null HSV, at 1 pfu/cell.
  • CB1954 is included in the overlay of HSV1716/CMV-NTR/GFP infected cells, the cells are killed more efficiently and more quickly. No enhanced cell killing is evident when CB1954 is included in the overlay of cells infected with HSV1716-GFP.
  • FIGS. 18 and 19 Cell culture images for the cytotoxicity assays performed in confluent 3T6 and human C8161 melanoma cells are shown in FIGS. 18 and 19 .
  • HSV 1716 is a selectively replication competent mutant of the herpes simplex virus 1 (HSV 1) which lacks both copies of the RL1 gene that encodes the protein ICP 34.5.
  • HSV 1 herpes simplex virus 1
  • This protein is a specific determinant of virulence. The function of this protein has been described at length elsewhere 12 .
  • the virus can grow only in cells that have a high level of functional PCNA. High levels of PCNA are found only in cells that are dividing such as tumour cells and not normal differentiated cells.
  • HSV 1716 can achieve selective tumour cell killing with minimal toxicity and improved survival times in a number of animal models 13 .
  • Initial phase 1 clinical trials using HSV1716 virus in patients has also meet with some success 14, 15 .
  • HSV1716 selectivity replicates in tumour reducing the tumour bulk by cell lysis the inventors did not anticipate HSV1716 to lytically replicate in all cells in the tumour due to the heterogeneity of the cell type and growth state.
  • the inventors have constructed a derivative HSV1790 of HSV1716 that expresses the E. Coli nitroreductase gene (ntr) under the control of a CMV early promoter (see example 3 above).
  • the enzyme ntr converts the inactive prodrug CB1954 to a functional cytotoxic alkylating agent that kills both dividing and non-dividing cells by apoptosis.
  • This active drug is diffusible and membrane permeable resulting in an efficient bystander effect, i.e. wherein the activated drug may have an effect on surrounding cells.
  • prodrug will only be converted to its active form in the tumour which has been infected with ntr expressing virus, toxicity to normal cells is avoided hence improving the therapeutic index following systemic delivery of this compound.
  • Months 1-3 were taken up mainly by in vitro work. During this time period high titre, sterile virus stock was generated for use in the xenograft models.
  • Xenograft models were also generated in athymic nude mice using the cell line A2780, a human ovarian epithelial carcinoma line initially derived from a tumour sample from an untreated patient (European Collection of Cell Cultures (ECACC) CAMR, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom, accession number 93112520).
  • ECACC European Collection of Cell Cultures
  • A2780 have a Take Rate of approximately 50%—that is 50% of mice that are injected with 5 million cells per flank subcutaneously will develop xenografts. When the number of cells injected was increased to 10 million or more an increase in take rate of approximately 15-25% was seen, giving an overall take rate of 65-75%.
  • mice Before the mice can be treated with a combination of virus and prodrug, first one must carry out experiments to make informed decisions about how much of the virus, and the prodrug to give.
  • a dose response experiment will allow one to find both the most appropriate does of the virus to use in the experiments and the maximum tolerated dose (MTD) of the virus, that is, the largest amount of the virus that can be given to a single mouse without adverse side effects.
  • MTD maximum tolerated dose
  • Small groups of tumour bearing mice are given a small dose of virus. Assuming they do not have any adverse effects another group is given a larger dose of virus. This continues until either the mice start to suffer ill effects or we reach a maximum dose.
  • the maximum amount of virus that can be intratumourally injected is 100 ⁇ l, hence the maximum dose from our current stock is 10 9 PFU per injection.
  • FIG. 20 shows the weight change in the mice after injection with a variety of doses of virus.
  • Weight is a good indicator of the animals overall health. Any loss of weight signifies that the treatment is not being well tolerated. Where an animal loses more than 20% of its initial body weight it was sacrificed immediately.
  • a dose of 10 9 PFU of the HSV 1790 virus is not tolerated by these mice, they rapidly lost body weight and were sacrificed at Day 3 post injection. Doses of 10 8 PFU or less were better tolerated, the mice initially lost weight in the days following injection but quickly recovered to approximately their initial body weights.
  • Tumour volume was measured daily after intratumoural injection of the HSV 1790 virus to look for any growth delay or regression of the tumours.
  • FIG. 21 shows the change in tumour volume as measured over a period of 100 days. If the tumour was injected with PBS only as a control the tumour increased in size rapidly and by approximately Day 13 post injection the tumours had become too large and the animals had to be sacrificed.
  • mice injected with 10 6 PFU virus tumours survived for an extra 23 days compared to the control group before the tumours became prohibitively large.
  • the group of mice injected with 10 8 PFU of virus survived only slightly longer than the control group. It is possible there were a large number of non infectious particles or that sheer number of particles caused the cells which the virus would have grown in to be killed.
  • mice treated with 10 7 PFU of virus survived the longest and indeed two out of three of the mice did not have any visible signs of tumour when sacrificed at day 100.
  • FIG. 22 shows the starting tumour diameters for the mice used in this experiment.
  • Two groups of mice were administered CMV-ntr plasmid by direct intratumoural injection at a dose of 0.2 mg DNA per injection.
  • One of these groups was then administered with a single dose of 80 mg/kg of CB1954 on Day 2 by intra-peritoneal injection.
  • the third group of mice had a single administration of CB1954 (80 mg/kg) by intra-peritoneal injection on Day 2 following intratumoural injection of saline control at Day 0. Animals were weighed daily ( FIG.
  • a dose of 10 7 PFU virus per mouse resulted in a great reduction in tumour growth, indeed after 100 days two out of three of the mice in the group had no visible tumour. This is very encouraging—the virus only at high doses may be enough to delay growth or cause tumour regression.
  • the inventors proceeded to investigate two doses of the virus in combination with CB1954.
  • the doses selected were 10 5 PFU and 10 6 PFU. Both these doses caused some tumour growth delay in earlier experiments.
  • the prodrug is given as an 80 mg/kg intra-peritoneal injection, after dissolving the powdered form in 10% acetone and then making up the volume with peanut oil.
  • the prodrug will only be converted to an active substrate in the presence of NTR it was considered that the virus containing the NTR will have to been given first. It was also considered that if the virus is given time to replicate and produce more NTR then the prodrug may have a more pronounced effect.
  • FIG. 25 shows the starting tumour volumes of each of the groups.
  • Treatment groups 1 10 5 HSV 1790 + drug (Day 2) + Drug (Day10) 2 10 5 HSV 1790 + drug (Day 2) + vehicle (Day 10) 3 10 5 HSV 1790 + vehicle (Day 2) + drug (Day 10) 4 10 5 HSV 1790 + vehicle (Day 2) + vehicle (Day 10) 5 No virus + drug (Day 2) + drug (Day 10) 6 No virus + drug (Day 2) + vehicle (Day 10) 7 No virus + vehicle (Day 2) + drug (Day 10) 8 No virus + vehicle (Day 2) + vehicle (Day 10) 9 10 6 HSV 1790 + vehicle (Day 2) + vehicle (Day 10) 10 10 6 HSV 1790 + drug (Day 2) + vehicle (Day 10) 11 10 6 HSV 1790 + drug (Day 2) + drug (Day 10) 12 10 6 HSV 1790 + drug (Day 2) +
  • the treatment groups were administered with a single direct intratumoural injection of the virus and dose determined for that group.
  • the virus was diluted PBS+10% serum.
  • ‘No virus’ control groups received an intratumoural injection of 100 ⁇ l of PBS+10% serum. This day was designated as Experimental Day 0.
  • tumours bleed slightly after injection but not to a great degree.
  • the animals did not lose body weight ( FIG. 26 ) and their behaviour did not appear to alter.
  • the following day the healing process had begun and within 3-5 days there was little evidence of any puncture wound on any tumour.
  • CB1954 Injections of CB1954 were given to the appropriate groups at days 2, 10 and 15. A dose of 80 mg/kg—the equivalent of approx. 2 mg per mouse—was given.
  • the powdered form of the CB1954 drug (from Sigma) was dissolved in acetone to 10% of the final volume (10 ⁇ l per 2 mg). The volume was then made up to 2 mg CB1954 in 100 ⁇ l using peanut oil. A syringe was used to mix the drug as peanut oil is thick and viscous. The drug was made up fresh every time.
  • Control groups which were not receiving drug were injected intra-peritoneal with a 100 ⁇ l solution of 10% acetone in peanut oil.
  • mice No swelling or irritation at the site of injection was noted on any of the mice either at time of injection or at any later time point.
  • the mice appeared slightly lethargic for a short period after the injection but did not lose any body weight ( FIG. 26 ) or show signs of lethargy the following day.
  • FIG. 27 shows that there is little effect on tumour growth when CB1954 is given alone.
  • tumours treated with either virus only or virus and prodrug did not grow as large as the untreated tumour.
  • the tumour treated with the virus grew only to approximately half the size of the untreated control.
  • tumours which grew to only approx 2-3 mm 3 in volume. This is significantly less than the untreated tumours which grew in size to approx 20 mm 3 .
  • FIG. 29 shows the changes in tumour volume over time after treatment with a higher dose of virus, 10 6 PFU per injection, in combination with the prodrug, given as described in Table 2.
  • virus 10 6 PFU per injection
  • prodrug given as described in Table 2.
  • treatment with either virus only, or in combination with CB1954 results in significantly smaller tumours compared to the untreated controls.
  • the combination of the virus and the prodrug appeared to produce some reduction in tumour growth compared to the untreated control tumours.
  • the groups used in these results contained only 2 or 3 animals.
  • the animals used were also older and their tumours had taken longer to grow than those used in previous experiments. Hence it is possible that repeating the experiment with a larger number, with younger mice or quicker forming tumours may result in a more marked growth delay after treatment with the HSV 1716 virus.
  • FIG. 31 shows a comparison between the two doses of the HSV 1790 virus in combination with the prodrug and the HSV 1716 prodrug combination.
  • the parental virus HSV 1716 shows some growth delay in comparison with the untreated control. We would assume that this growth delay is due to the oncolytic effect of the virus as the NTR gene is not present to alter the inactive prodrug into its active form.
  • Tumour growth is reduced further when the tumour is treated with the HSV 1790 virus containing the NTR gene. This appears to be dose dependent—the higher dose of the virus results in a greater growth delay than the lower dose.
  • the virus may have replicated and killed as many cells by oncolysis as possible. It is anticipated that due to heterogeneity of the cell type and growth state that all the cells within a tumour would not be susceptible to lysis by the virus.
  • the drug then comes in and ‘mops up’ by killing any cells that are supporting viral growth (hence containing the NTR gene) but were not susceptible to oncolysis.
  • the active drug is diffusible and membrane permeable it may have a bystander effect—killing not only the cells infected with the virus but also its near neighbours.
  • a plasmid that contains the siRNA construct designed to target expression of the SCCRO gene (SEQ ID No. 1) and designated 339i was provided by Dr Bhuv Singh, MSKCC, New York.
  • DNA sequences for the two constructs are as follows: 339isiRNA (SEQ ID No.1): gatcCCCGTTCAGAGCAGCAACACAGTTCAAGAGACTGTGTTGCTGCTCT GAACTTTTTGGAAA
  • ConisiRNA (SEQ ID No.2): gatcCCCCGTCTACCTACACTCCCTCTTCAAGAGAGAGGGAGTGTAGGTA GACGTTTTTA
  • RNA polIII only transcribes short RNA molecules and the H1 promoter would be insufficient to drive expression of IRES-gfp from the normal recombinant virus producing shuttle vector RL1-del.IRES.gfp so an alternative cloning strategy was adopted.
  • a cassette was constructed in the following manner.
  • the 1.3 kbp blunt-ended EcoRI/AflII fragment that contains the PGK promoter/GFP gene was obtained by restriction digestion followed by Klenow treatment from the vector pSNRG and cloned into the RL1-del vector cut with the restriction enzyme NruI that generates blunt ends.
  • Successful insertion of the PGK/GFP DNA was confirmed by BamHI digestion and the orientation of the inserted DNA identified using the unique XhoI site in RL1-del and the BsrGI site at the 3′ end of PGK/GFP.
  • Plasmids with PGK/GFP in both forward and reverse orientation were obtained and the plasmids were designated RL1-dPGK/GFPfor and RL1-dPGK/GFPrev. Expression of GFP was confirmed in BHK cells transfected with the forward and reverse orientation plasmids.
  • sequences of interest along with their own promoters can then be cloned into either RL1-dPGK/GFPfor or RL1-dPGK/GFPrev in either orientation using the remaining unique BglII, XhoI or HpaI unique restriction enzyme sites.
  • the resulting plasmid can be used to derive recombinant HSV in which the marker GFP gene and the gene of interest are expressed independently from their own promoters
  • a green fluorescent protein (gfp) expression cassette comprising the gfp gene with a Phosphoglycerokinase (PGK) promoter.
  • PGK Phosphoglycerokinase
  • the blunt-ended fragment was ligated into the RL1-del shuttle vector which had been digested with the restriction enzyme Nru1 that produces a blunt-ended cut.
  • Nru1 restriction enzyme
  • the Nru1-cut RL1-del was gel purified and phosphatase-treated using Calf Intestinal Alkaline Phosphatase.
  • the reaction mix was used to transform DH5alpha cells and these were plated-out on LB amp plates. After overnight incubation at 37° C., individual clones from each of the LB amp plates were grown overnight in 3 ml of LB broth and plasmid DNA extracted.
  • plasmids were initially digested with BamHI, as insertion of the H1/siRNA and PGK/gfp cassette increases the size of the RL1 BamHI fragment in the plasmid from 5.4 kbp to 7.0 kbp.
  • 1/24 clones screened demonstrated a 7.0 kbp BamHI fragment and the presence of the H1/siRNA and PGK/EGFP cassette in these plasmids was confirmed by EcoR1, EcoR1/HindIII and EcoR1/SalI digests, the inserted H1/siRNA and PGK/EGFP cassette introduces a novel EcoR1 site into the RL1-del vector.
  • plasmid was prepared and used to transfect BHK cells. Fifty microlitres (50 ⁇ l) of plasmid was mixed with 6 ⁇ l lipofectamine 2000 in a final volume of 100 ⁇ l serum free medium and used to transfect BHK cells plated out on a 13 mm glass coverslip in a 24-well plate. After 48 hrs of transfection the cells were washed once in PBS, incubated for 2 hrs in 4% paraformaldehyde, washed once more in PBS and mounted on microscope slides using Vectashield. The presence of c5% gfp-positive cells following transfection with the RL1-del/339i and RL1-del/Coni plasmids confirmed the presence of the PGK/GFP cassette.
  • the RL1-del/339i and RL1-del/Coni plasmids were linearized using either of the restriction enzymes ScaI and XmnI and the linearized plasmid was used along with viral DNA to transfect BHK cells plated out to c80% confluency in 60 mm dishes.
  • 50 ⁇ l of HSV-1 strain 17+ DNA was added along with 20 ⁇ l lipofectamine 2000 in a final volume of 5001 serum free medium and the mix added to the BHK cells. After 4 hrs of transfection, the cells were shocked with 25% DMSO in HBSS for exactly 4 minutes, washed ⁇ 3 with medium and returned to 37° C.
  • Each of the six plaques of Coni and 339i virus was used to infect a T175 flask of Vero cells, after 72 hrs of infection virus was harvested and titred. For 3 each of the Coni and 339i viruses that gave the highest titres 0.5 ml was used to infect a second T175 flask for 24 hrs. Viral DNA was then harvested from each of the 6 flasks. The BamHI-digested viral DNA was Southern blotted with the Alu/Rsa RL1 probe and the band pattern compared to wild type and HSV1716 DNA digested also with BamHI.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A nucleic acid vector comprising first and second nucleotide sequences corresponding to nucleotide sequences flanking an insertion site in the genome of a selected herpes simplex virus strain; and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding: (a) one or a plurality of insertion sites and/or a nucleotide sequence of interest; and (b) a ribosome binding site or a regulatory nucleotide sequence; and (c) a marker is disclosed. Herpes simplex viruses generated using said vector, methods for their generation and herpes simplex viruses having a genome comprising heterologous nucleic acid are also disclosed.

Description

    FIELD OF THE INVENTION
  • The present invention relates to nucleic acid vectors for delivery of a nucleic acid cassette to an insertion site in a selected viral genome, to methods of generating mutant virus using said vectors and to the mutant viruses generated, and particularly, although not exclusively, to mutant herpes simplex viruses and nucleic acid vectors for use in generating mutant herpes simplex viruses.
    • BACKGROUND TO THE INVENTION
  • Existing procedure for generating herpes simplex virus (HSV) mutants requires generation of a unique plasmid by cloning an entire expression cassette consisting of a promoter, gene of interest and polyadenylation sequences into a plasmid separately constructed to contain the relevant flanking sequences and then co-transfecting BHK cells with the resultant plasmid and HSV-1 DNA. Homologous recombination drives the formation of recombinant HSV-1 expressing the gene of interest, which is identified by Southern blotting. The recombinant virus is plaque purified 3-4 times by Southern blotting. This process takes several months.
  • This approach was taken by Liu et al1 in generating two distinct plasmids, the first consisting of HSV-1 strain 17+ Sau3A fragment derived sequences flanking an expression cassette consisting of a CytoMegalovirus (CMV) promoter, Green Fluorescent Protein (GFP) gene and bGH polyadenylation (polyA) signal and the second wherein the GFP gene is replaced with either a human or mouse Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) gene.
  • Shuttle vectors have been used to generate recombinant adenoviral vectors, e.g. the pAdEasy™ system of vectors (Stratagene), for use in overexpressing recombinant proteins in mammalian cells. However, these vectors require the cloning of the gene of interest into a first shuttle vector which is then co-transformed into a specially constructed cell line to generate a recombinant adenoviral plasmid which is transfected into a separate specially constructed mammalian cell line in which the recombinant adenoviral plasmid is directly packaged into virus particles.
  • The HSV genome comprises two covalently linked segments, designated long (L) and short (S). Each segment contains a unique sequence flanked by a pair of inverted terminal repeat sequences. The long repeat (RL or RL) and the short repeat (RS or RS) are distinct.
  • The HSV ICP34.5 (also γ34.5) gene, which has been extensively studied1,6,7,8, has been sequenced in HSV-1 strains F9 and syn17+3 and in HSV-2 strain HG524. One copy of the ICP34.5 gene is located within each of the RL repeat regions. Mutants inactivating both copies of the ICP34.5 gene (i.e. null mutants), e.g. HSV-1 strain 17 mutant 17162 (HSV1716) or the mutants R3616 or R4009 in strain F5, are known to lack neurovirulence, i.e. be avirulent, and have utility as both gene delivery vectors or in the treatment of tumours by oncolysis. HSV1716 has a 759 bp deletion in each copy of the ICP34.5 gene located within the BamHI s restriction fragment of each RL repeat.
  • ICP34.5 null mutants such as HSV1716 are, in effect, first-generation oncolytic viruses. Most tumours exhibit individual characteristics and the ability of a broad spectrum first generation oncolytic virus to replicate in or provide an effective treatment for all tumour types is not guaranteed.
  • The prior art provides technically challenging, procedurally slow and inefficient materials and methods for generating recombinant HSV. In particular the prior art does not provide methods of, and materials for, generating recombinant HSV which are easy to detect, may be designed to be specific null mutants and which may express a selected gene of interest.
  • First generation oncolytic viruses such as HSV-1 strain 17 mutant 1716 show significant therapeutic potential in tumour and gene therapy. Overcoming the existing technical difficulties by enabling rapid generation and screening of second generation oncolytic viruses of this kind provides a significant improvement in the development of novel pharmaceutical compositions, vaccines and medicaments for the treatment of cancer and disease.
  • HSV 1716 is described in EP 0571410 and WO 92/13943 and has been deposited on 28 Jan. 1992 at the European Collection of Animal Cell Cultures, Vaccine Research and Production Laboratories, Public Health Laboratory Services, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number V92012803 in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (herein referred to as the ‘Budapest Treaty’).
    • SUMMARY OF THE INVENTION
  • The inventors have provided a generic plasmid vector designated RL1.dIRES-GFP. RL1.dIRES-GFP provides a platform for generating a plurality of ‘shuttle vectors’ which can exploit the process of homologous recombination to transfer a nucleotide sequence of interest (downstream of a selected promoter) into the disabling RL1 locus of HSV-1, generating easily identifiable, oncolytic, ICP34.5 null HSV-1 mutants expressing the products of the nucleotide sequence of interest, e.g. an RNA transcript or a polypeptide, and GFP. RL1.dIRES-GFP thus provides for ease of generation and purification of ICP34.5 null HSV.
  • RL1.dIRES-GFP is a useful vector for making second-generation oncolytic viruses having enhanced cytotoxic potential and which may express the product(s) of selected gene(s) to enhance the oncolytic and/or therapeutic effect of the administered virus.
  • The RL1.dIRES-GFP plasmid incorporates a multi-cloning sequence (MCS), upstream of an internal ribosome entry site (IRES), the GFP gene and SV40 polyadenylation sequences flanked by HSV-1 RL1 sequences. Incorporation of the encephalomyocarditis virus IRES (EMCV IRES) permits translation of two open reading frames from a single transcribed mRNA.
  • Following generation of a specific shuttle vector by cloning of the nucleotide sequence of interest (and the selected promoter) into RL1.dIRES-GFP, recombinant HSV-1 expressing the desired nucleic acid transcript or protein, can be generated and purified within 2 weeks. This compares with 2-3 months using prior art protocols.
  • In the ICP34.5 null HSV generated using the RL1.dIRES-GFP plasmid provided by the inventors transcription of both the nucleotide sequence of interest and GFP as a single transcript is controlled by the same promoter upstream of the nucleotide sequence of interest, the transcribed IRES directing cap-independent translation of GFP. The generated ICP34.5 null HSV are non-neurovirulent. By modifying the RL1.dIRES-GFP plasmid to incorporate appropriate flanking sequences surrounding the cassette other gene-specific HSV null mutants expressing GFP can be generated.
  • RL1.dIRES-GFP is promoterless, thus enabling a promoter of choice to be incorporated in the homologously recombined shuttle vector for controlling expression of the nucleotide sequence of interest from the inserted cassette.
  • Plasmid RL1.dIRES-GFP or modified plasmid shuttle vectors thereof further comprising nucleotide sequence encoding a nucleic acid transcript or polypeptide of interest may be provided in isolated or purified form.
  • By using the plasmid RL1.dIRES-GFP to generate a shuttle vector, designated RL1.dCMV-NTR-GFP, containing the E. coli nitroreductase gene downstream of a CMV IE promoter, both inserted at the MCS, the inventors have further provided a novel second generation oncolytic mutant HSV. The genome of this mutant HSV comprises the heterologous (i.e. non-HSV) E. coli nitroreductase protein coding sequence inserted at one or each ICP34.5 locus, disrupting the ICP34.5 protein coding sequence such that the ICP34.5 gene is non-functional and cannot express a functional ICP34.5 gene product. The generated HSV is capable of expressing the E. coli nitroreductase gene product under control of the inserted promoter. This virus thus has the oncolytic activity of HSV strain 1716 and can be used in gene directed enzyme-prodrug therapy and has shown significantly enhanced tumour cell killing in vitro and in vivo when used with the prodrug CB1954. The mutant virus is designated HSV1716/CMV-NTR/GFP.
  • As the plasmid RL1.dIRES-GFP is designed for tandem expression of a sequence of interest and the marker gene encoding green fluorescent protein (GFP). The sequence of interest is cloned into RL1.dIRES-GFP along with its promoter (e.g. CMV) such that the promoter drives transcription of an mRNA for the sequence of interest along with the IRES-GFP. Translation results in expression of the GFP from the internal ribosomal entry site and the gene of interest and promoter must be cloned into RL1.dIRES-GFP in the correct orientation to achieve this. There are a number of instances where this tandem expression arrangement may be unsuitable and a variation of the cassette design is favourable.
  • One example is the expression of siRNAs as short hairpin RNAs using RNA polIII promoters such as H1 or U6. These promoters are unable to drive the additional tandem expression of the IRES-GFP as the RNApolIII expression cassette is designed only to produce short transcripts. Additionally, sequences of interest derived from genomic DNA with strong mRNA shut-off signals in their 3′ untranslated regions may not support IRES-GFP expression.
  • Thus in some cases a cassette may be provided in which the sequence of interest and marker are expressed separately from independent promoters.
  • One variant contains a cassette in which the ribosome binding site of plasmid RL1.dIRES-GFP is replaced with a regulatory nucleotide sequence, preferably a strong, constitutive promoter such as the Phosphoglycerokinase (PGK) promoter. The marker is thereby expressed under the control of this (the ‘first’) regulatory sequence. The nucleotide sequence of interest (e.g. antisense or siRNA) is expressed under the control of a second regulatory sequence upstream (5′) of the nucleotide sequence of interest, e.g. the CMV promoter. This vector variant is particularly suitable for expression of siRNA where a weak promoter may be used for expression of the siRNA molecule. It may also be useful where the nucleotide sequence of interest has a strong transcription and/or translation termination signal which may make it difficult to transcribe and/or translate a single bi- or poly-cistronic transcript encoding the sequence of interest and marker sequence. In this arrangement the transformed virus containing the cassette integrated in the viral genome produces two separate transcripts under the control of the first and second promoters.
  • At its most general the present invention relates to: (i) a nucleic acid vector for delivery of a nucleic acid cassette to an insertion site in a selected viral genome; (ii) an herpes simplex virus wherein the herpes simplex virus genome comprises a nucleotide sequence of interest.
  • The present invention further comprises novel HSV mutants and viral vectors which may be generated using nucleic acid vectors of the present invention, or vectors derived therefrom, and methods for the generation of such vectors and HSV mutants.
  • According to one aspect of the present invention there is provided a nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding:
      • (a) one or a plurality of insertion sites; and
      • (b) a ribosome binding site; and
      • (c) a marker.
  • Preferably the nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the ribosome binding site and the nucleic acid encoding the ribosome binding site is arranged upstream (5′) of the marker.
  • According to another aspect of the present invention there is provided a nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a nucleic acid cassette located between said first and second nucleotide sequences comprising:
      • (a) a third nucleotide sequence being of interest; and nucleic acid encoding:
      • (b) a ribosome binding site; and
      • (c) a marker.
  • Preferably the nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site and the ribosome binding site is arranged upstream (5′) of the marker.
  • According to another aspect of the present invention there is provided an herpes simplex virus wherein the herpes simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
      • (a) one or a plurality of insertion sites; and
      • (b) a ribosome binding site, and a
      • (c) marker.
  • Preferably, the nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the ribosome binding site and the nucleic acid encoding the ribosome binding site is arranged upstream (5′) of the marker.
  • According to another aspect of the present invention there is provided an herpes simplex virus wherein the herpes simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
      • (a) a nucleotide sequence of interest; and nucleic acid encoding:
      • (b) a ribosome binding site; and
      • (c) a marker.
  • Preferably, the nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site and the ribosome binding site is arranged upstream (5′) of the marker.
  • In various aspects of the present invention the ribosome binding site may comprise an internal ribosome entry site (IRES). A transcription product of the cassette may be a bi- or poly-cistronic transcript comprising a first cistron encoded by the nucleotide sequence of interest and a second cistron encoding the marker nucleic acid wherein the ribosome binding site is located between said first and second cistrons.
  • According to another aspect of the present invention there is provided a nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding:
      • (a) one or a plurality of insertion sites; and
      • (b) a first regulatory nucleotide sequence; and
      • (c) a marker.
  • Preferably the nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the regulatory sequence and the nucleic acid encoding the regulatory sequence is arranged upstream (5′) of the marker.
  • According to another aspect of the present invention there is provided a nucleic acid vector comprising, consisting or consisting essentially of:
  • first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the genome of a selected herpes simplex virus (HSV); and a nucleic acid cassette located between said first and second nucleotide sequences comprising:
      • (a) a third nucleotide sequence being of interest; and nucleic acid encoding:
      • (b) a first regulatory nucleotide sequence; and
      • (c) a marker.
  • Preferably the nucleotide sequence of interest is arranged upstream (5′) of the regulatory sequence and the regulatory sequence is arranged upstream (5′) of the marker.
  • According to another aspect of the present invention there is provided an herpes simplex virus wherein the herpes simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
      • (a) one or a plurality of insertion sites; and
      • (b) a first regulatory nucleotide sequence; and
      • (c) a marker.
  • Preferably the nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the regulatory sequence and the nucleic acid encoding the regulatory sequence is arranged upstream (5′) of the marker.
  • According to another aspect of the present invention there is provided an herpes simplex virus wherein the herpes-simplex virus (HSV) comprises a nucleic acid cassette integrated in the HSV genome, the cassette comprising, consisting or consisting essentially of nucleic acid encoding:
      • (a) a nucleotide sequence of interest; and nucleic acid encoding:
      • (b) a first regulatory nucleotide sequence; and
      • (c) a marker.
  • Preferably the nucleotide sequence of interest is arranged upstream (5′) of the regulatory sequence and the regulatory sequence is arranged upstream (5′) of the marker.
  • In the various aspects the encoded components of the cassette are preferably arranged in a predetermined order as described.
  • The first regulatory sequence may be operably linked to said marker and may comprise a constitutive or inducible promoter. The first regulatory sequence may thus have a role in regulating transcription of the marker.
  • The nucleotide sequence of interest may encode an heterologous polypeptide, which may be selected from the group consisting of: a bacterial polypeptide; a mammalian polypeptide; a human polypeptide or more particularly from the group consisting of: Sodium iodide symporter (NIS); Nitroreductase (NTR); E. coli NTR; Endothelial nitric oxide synthase (eNOS); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); a cytokine.
  • Alternatively, the nucleotide sequence of interest may encode a selected antisense nucleic acid or siRNA.
  • The cassette may further comprise a regulatory nucleotide sequence, located upstream (5′) of the nucleotide sequence of interest or insertion site(s), which has a role in regulating transcription of the nucleotide sequence of interest.
  • The cassette may comprise a plurality of insertion sites, each insertion site preferably formed by nucleic acid encoding a specific restriction endonuclease site (‘restriction site’). Together the restriction sites may form a multiple cloning site (MCS) comprising a series of overlapping or distinct restriction sites, preferably a series of distinct restriction sites comprising one or more of the ClaI, BglII, NruI, XhoI restriction sites.
  • Accordingly, vectors and herpes simplex viruses according to the present invention may further comprise one or a plurality of insertion sites, more preferably restriction endonuclease sites encoded by nucleic acid of the cassette. Each insertion site may be formed by nucleic acid encoding a restriction endonuclease site. The insertion sites may comprise one or more of the ClaI, BglII, NruI and XhoI restriction endonuclease sites.
  • The predetermined insertion site is preferably in the RL1 locus of the genome of the selected herpes simplex virus.
  • The first and second nucleotide sequences may each comprise sequence corresponding to:
      • (a) nucleotide sequences in the RL terminal or internal repeat region of the genome of the selected HSV;
      • (b) nucleotide sequences in the RL1 locus of the genome of the selected HSV;
      • (c) nucleotide sequences flanking a predetermined insertion site formed in, or comprising all or a part of, the ICP34.5 protein coding sequence of the genome of a selected herpes simplex virus;
  • In other arrangements said first and second nucleotide sequences may comprise contiguous portions of nucleotide sequence of the ICP34.5 gene of a herpes simplex virus. Or said first and second nucleotide sequences may comprise contiguous portions of nucleotide sequence encoding the ICP34.5 gene product of a herpes simplex virus.
  • The first and second nucleotide sequences may have at least 60% sequence identity to their corresponding sequence in the viral genome. More preferably said identity may be one of at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • In certain arrangements the first and second nucleotide sequences may hybridise to their corresponding nucleotide sequence in the HSV genome, or its complement, under high or very high stringency conditions.
  • The marker may be a defined nucleotide sequence encoding a polypeptide. In one arrangement the marker may comprise the Green Fluorescent Protein (GFP) protein coding sequence or the enhanced Green Fluorescent Protein (EGFP) protein coding sequence.
  • In another arrangement the marker may comprise a defined nucleotide sequence detectable by hybridisation under high or very high stringency conditions with a corresponding labelled nucleic acid probe.
  • The cassette may further comprise a nucleic acid encoding a polyadenylation sequence located downstream (3′) of the nucleic acid encoding the marker. The polyadenylation sequence may comprise the Simian Virus 40 (SV40) polyadenylation sequence.
  • Preferably, mutant HSV according to the present invention are generated by site directed insertion of the cassette into the viral genome, more preferably by homologous recombination.
  • The vector may further comprise nucleic acid encoding a second selectable marker, e.g. a marker conferring antibiotic resistance.
  • The vector is preferably a DNA vector, particularly a dsDNA vector and may be an expression vector.
  • In one preferred arrangement, the vector is plasmid RL1.dIRES-GFP deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 3 Sep. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03090303 in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (herein referred to as the ‘Budapest Treaty’).
  • The selected herpes simplex virus may be an HSV-1 or HSV-2. Thus, mutant HSV according to the present invention may be derived from a strain of either HSV-1 or HSV-2. More preferably the selected HSV may be one of HSV-1 strains 17 or F or HSV-2 strain HG52. Thus, herpes simplex viruses of the invention may be mutants of these preferred ‘parental’ viruses.
  • In herpes simplex viruses according to the present invention the cassette may be integrated in the HSV genome so as to disrupt a protein coding sequence in the HSV genome resulting in inactivation of the respective gene product.
  • Herpes simplex virus of the invention may be gene specific null mutants. They may be ICP34.5 null mutants.
  • In some aspects of the present invention the herpes simplex virus may lack at least one expressible ICP34.5 gene. In other aspects of the present invention the generated herpes simplex virus may lack only one expressible ICP34.5 gene.
  • Herpes simplex virus according to the present invention may be non-neurovirulent.
  • Vectors and herpes simplex viruses according to the present invention may be used in gene therapy.
  • According to another aspect of the present invention there is provided a method of generating a herpes simplex virus which expresses a nucleotide sequence of interest, or polypeptide thereby encoded, comprising the step of culturing a selected herpes simplex virus with a vector according to the present invention, thereby integrating components (a), (b) and (c) of said vector at said predetermined insertion site in the genome of the selected herpes simplex virus.
  • Said integration at the predetermined insertion site is preferably a permanent integration.
  • According to another aspect of the present invention there is provided a method of generating a nucleic acid vector comprising the steps of:
      • i) providing a first nucleotide sequence comprising a predetermined second nucleotide sequence corresponding to a selected nucleotide sequence in the genome of a selected Herpes simplex virus; and
      • ii) inserting nucleotide sequence(s) in said second nucleotide sequence encoding:
        • a) one or a plurality of insertion sites and/or a nucleotide sequence of interest; and
        • b) a ribosome binding site or a regulatory nucleotide sequence; and
        • c) a marker.
  • Preferably the insertion site(s)/nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site/regulatory nucleotide sequence and the ribosome binding site/regulatory nucleotide sequence is arranged upstream (5′) of the marker.
  • Said predetermined second nucleotide sequence may preferably correspond to a selected nucleotide sequence in the RL1 locus of the genome of the selected HSV.
  • The inserted nucleotide sequence(s) may separate the second nucleotide sequence into two vector flanking sequences, the inserted nucleotide sequences forming a cassette therebetween.
  • The second nucleotide sequence may correspond to a:
      • (a) nucleotide sequence in the RL terminal or internal repeat region of the genome of the selected herpes simplex virus;
      • (b) nucleotide sequence in the RL1 locus of the genome of the selected herpes simplex virus;
      • (c) a nucleotide sequence formed in, or comprising all or a part of, the ICP34.5 protein coding sequence of the genome of a selected herpes simplex virus.
  • The second nucleotide sequence may comprise a contiguous portion of nucleotide sequence of the ICP34.5 gene of a herpes simplex virus. Alternatively the second nucleotide sequence may comprise a contiguous portion of nucleotide sequence encoding the ICP34.5 gene product of a herpes simplex virus.
  • The second nucleotide sequence may have at least 60% sequence identity to the corresponding sequence in the viral genome. More preferably said identity may be one of at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100%. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • Said second nucleotide sequence may hybridise to the corresponding nucleotide sequence in the viral genome, or its complement, under high or very high stringency conditions.
  • According to another aspect of the present invention there is provided a method of generating a mutant herpes simplex virus (HSV) comprising inserting a nucleic acid cassette comprising nucleotide sequence(s) encoding:
      • a) one or a plurality of insertion sites and/or a nucleotide sequence of interest; and
      • b) a ribosome binding site or a regulatory nucleotide sequence; and
      • d) a marker
        into the genome of a selected HSV.
  • Preferably the insertion site(s)/nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site/regulatory nucleotide sequence and the ribosome binding site/regulatory nucleotide sequence is arranged upstream (5′) of the marker.
  • The site of insertion may preferably be a predetermined insertion site in the RL1 locus of the selected HSV.
  • The method of generating a mutant herpes simplex virus may comprise the steps of:
      • i) providing a vector according to the present invention;
      • ii) where the vector is a plasmid, linearising the vector; and
      • iii) co-transfecting a cell culture with the linearised vector and genomic DNA from said HSV.
  • The co-transfection may be carried out under conditions effective for homologous recombination of said cassette into an insertion site in the viral genome.
  • The method of generating a mutant herpes simplex virus may further comprise one or more of the steps of:
      • 1) screening said co-transfected cell culture to detect mutant HSV expressing said marker; and/or
      • 2) isolating said mutant HSV; and/or
      • 3) screening said mutant HSV for expression of the nucleotide sequence of interest or the RNA or polypeptide thereby encoded; and/or
      • 4) screening said mutant HSV for lack of an active gene product; and/or
      • 5) testing the oncolytic ability of said mutant HSV to kill tumour cells in vitro.
  • In the method of generating a mutant herpes simplex virus the nucleotide sequence of interest may be heterologous to the selected herpes simplex virus. It may encode an heterologous polypeptide which may be selected from the group consisting of: a bacterial polypeptide; a mammalian polypeptide; a human polypeptide or from the group consisting of: Sodium iodide symporter (NIS); Nitroreductase (NTR); E. coli NTR; Endothelial nitric oxide synthase (eNOS); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); a cytokine.
  • Alternatively the nucleotide sequence of interest may encode a selected antisense nucleic acid.
  • In another aspect of the present invention there is provided a mutant herpes simplex virus generated by the method of generation disclosed herein. Herpes simplex viruses generated by such methods may be gene specific null mutants, e.g. ICP34.5 null mutants.
  • The present invention may also include the following aspects and features which may be provided in combination with any of the other aspects and features described.
  • In aspects of the present invention the nucleotide sequence of interest contained in the cassette may encode a polypeptide of interest, or fragment thereof, or comprise selected antisense DNA, that is DNA corresponding to at least one gene component (e.g. regulatory sequence 5′ UTR, 3′UTR or protein coding sequence) or fragment of a gene component, which is inserted in the cassette in an orientation such that upon transcription an antisense RNA is obtained. Thus the expressed product of the nucleotide sequence of interest may ultimately be a polypeptide, complete or truncated (e.g. a polypeptide fragment), or an antisense nucleic acid, preferably RNA.
  • By antisense nucleic acid is meant a nucleic acid having substantial sequence identity to the nucleic acid formed by the sequence of complementary bases to the single strand of a target nucleic acid. Thus, the antisense nucleic acid is useful in binding the target nucleic acid and may be used as an inhibitor to prevent or disrupt the normal activity, folding or binding of the target nucleic acid. The substantial sequence identity is preferably at least 50% sequence identity, more preferably at least 60, 70, 75, 80, 85, 90, 92, 94, 95, 96, 97, 98, 99 or 100% identity. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • Where the nucleotide sequence of interest encodes a polypeptide of interest the polypeptide may be any selected polypeptide. Preferably, the polypeptide of interest is an heterologous or exogenous polypeptide (i.e. a non-HSV originating polypeptide), preferably a bacterial polypeptide, alternatively a mammalian polypeptide or a human polypeptide. The heterologous polypeptide may be useful in gene directed enzyme-prodrug targeting techniques for tissue specific delivery of active pharmaceutical agents. For example, the polypeptide of interest may be the Sodium iodide symporter (NIS), Nitroreductase (NTR), preferably E. coli NTR, Endothelial nitric oxide synthase (eNOS), Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) or a cytokine.
  • The cassette preferably further comprises at least one regulatory nucleotide sequence such as one or more selected promoter or enhancer elements known to the person skilled in the art, e.g. the CytoMegalovirus (CMV) promoter or Phosphoglycerokinase (PGK) promoter. A regulatory nucleotide sequence may be located upstream (i.e. 5′) of the nucleotide sequence of interest and have a role in controlling and regulating transcription of the nucleotide sequence of interest and hence expression of the resulting transcript or polypeptide. In certain arrangements another regulatory sequence may be located upstream (5′) of the marker sequence and downstream (3′) of the nucleotide sequence of interest and have a role in controlling and regulating transcription of the marker and hence expression of the resulting transcript or polypeptide. In some arrangements this latter regulatory sequence may take the place of the ribosome binding site.
  • The components of the cassette are preferably arranged in a predetermined order. In certain aspects, the nucleotide sequence of interest is arranged upstream (i.e. 5′) of the ribosome binding site and the ribosome binding site is arranged upstream (i.e. 5′) of the marker. Thus during transcription a single transcript may be produced from the cassette comprising a first cistron comprising the nucleotide sequence of interest and a second cistron encoding the marker wherein the ribosome binding site is located between the cistrons.
  • A suitable ribosome binding site may comprise a ribosome entry site permitting entry of a ribosome to the transcribed mRNA encoded by the nucleic acid of the cassette such that the ribosome binds to the translation start signal. Preferably, the ribosome entry site is an internal ribosome entry site (IRES), more preferably an encephalomyocarditis virus IRES, permitting cap-independent initiation of translation. The IRES thus enables translation of a coding sequence located internally of a bi- or poly-cistronic mRNA, i.e. of a cistron located downstream of an adjacent cistron on a single transcript.
  • Preferably the marker is a defined nucleotide sequence coding for a polypeptide which can be expressed in a cell line (e.g. BHK cells) infected with mutant herpes simplex virus into which the cassette has been recombined. One function of the marker is to enable identification of virus plaques containing mutant virus transformed with the cassette.
  • Alternatively, the marker may comprise a defined nucleotide sequence which can be detected by hybridisation under high stringency conditions with a corresponding labelled nucleic acid probe, e.g. using a fluorescent- or radio-label.
  • The marker is preferably a detectable marker, more preferably an expressible marker polypeptide or protein comprising at least the coding sequence for the selected polypeptide or protein. The nucleic acid encoding the marker may further comprise regulatory sequence upstream and/or downstream of the coding sequence having a role in control of transcription of the marker mRNA. Preferred markers include the Green Fluorescent Protein (GFP) protein coding sequence or gene, preferably the enhanced Green Fluorescent Protein (EGFP) protein coding sequence or gene.
  • In another preferred arrangement, the cassette further comprises a polyadenylation sequence (‘polyA sequence’). Preferably the polyA sequence comprises the Simian Virus 40 (SV40) polyA sequence. The preferred location of the polyA sequence within the cassette is immediately downstream (i.e. 3′) of the marker.
  • The first and second nucleotide sequences preferably comprise nucleotide sequences having identity to regions of the genome surrounding the insertion site in the selected herpes simplex virus strain (the ‘viral insertion site’). These sequences enable the cassette to be incorporated at the viral insertion site by homologous recombination between the first and second nucleotide sequences and their respective corresponding sequences in the viral genome.
  • Thus the first and second nucleotide sequences are flanking sequences for homologous recombination with corresponding sequences of a selected viral genome, such homologous recombination resulting in insertion of the cassette at the viral insertion site.
  • Preferably, the first and second nucleotide sequences correspond to nucleotide sequences flanking an insertion site in the RL1 locus of the HSV genome, more preferably in the ICP34.5 protein coding sequence of the HSV genome.
  • The first and second nucleotide sequences may each be at least 50 bp in length, more preferably at least 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900 or 4000 bp in length. Each of the first and second nucleotide sequences may have at least 50% sequence identity to their corresponding sequence in the viral genome, more preferably at least 60%, 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% 99% or 100% identity. Identity of sequences is determined across the entire length of a given nucleotide sequence. Where sequences are of different length, sequence identity of the shorter sequence is determined over the entire length of the longer sequence.
  • The first and second nucleotide sequences may be characterised by the ability of one strand of a given sequence to hybridise with the corresponding single-stranded complement of the HSV genome under varying hybridisation stringency conditions. Suitably, the first and second nucleotide sequences will hybridise with their corresponding complement under very low, low or intermediate stringency conditions, more preferably at high or very high stringency conditions.
  • The nucleotide sequence of interest which forms part of the inserted cassette may encode a full length transcript or polypeptide (i.e. comprise the complete protein coding sequence). Alternatively, the nucleotide sequence of interest may comprise one or more fragments of the full length sequence respectively coding for a fragment of the full length transcript or a truncated polypeptide or antigenic peptide respectively. A fragment may comprise a nucleotide sequence encoding at least 10% of the corresponding full length sequence, more preferably the fragment comprises at least 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98 or 99% of the corresponding full length sequence. Preferably, the fragment comprises at least, i.e. has a minimum length of, 20 nucleotides, more preferably at least 30, 40, 50, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900 or 4000 nucleotides. The fragment may have a maximum length, i.e. be no longer than, 20 nucleotides, more preferably no longer than 30, 40, 50, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900 or 4000. The fragment length may be anywhere between said minimum and maximum length.
  • The viral insertion site is the position between the genomic nucleotide sequences corresponding to the first and second nucleotide sequences of the vector (the ‘genomic’ and ‘vector flanking sequences’ respectively) at which homologous recombination will occur and may be predetermined by selection of the vector flanking sequences. Where the genomic flanking sequences are immediately adjacent, the insertion site is the position between the peripheral and immediately adjacent bases of the two genomic flanking sequences, such that insertion of the cassette separates the genomic flanking sequences. Where the genomic flanking sequences are separated by one or a plurality of bases in the viral genome, the insertion site is formed by said one or a plurality of bases which are excised from the genome by the homologous recombination event.
  • The position of the viral insertion site may be accurately selected by careful selection and construction of the vector flanking sequences. Accordingly, the vector may be constructed such that homologous insertion of the cassette results in disruption of a chosen protein coding sequence and inactivation of the respective gene product or such that the cassette is inserted at a non-protein coding region of the viral genome. The complete genome sequences of several herpes simplex virus strains have been reported and are publicly available. The complete genome sequence for HSV-1 strain 17syn+ was reported by Dolan et al3 (incorporated herein by reference) and the complete genome sequence of HSV-2 strain HG52 was reported by Dolan et al4 (incorporated herein by reference) and is available from the EMBL database under accession code Z86099. Using this information, the vector of the present invention may preferably be designed for use in generating mutant HSV-1 (e.g. in strain 17 or F) or mutant HSV-2 (e.g. in strain HG52).
  • Preferably the first and second nucleotide sequences (vector flanking sequences) each comprise sequence corresponding to the RL terminal repeat region of the genome of the selected HSV (e.g. HSV-1 strains 17 or F or HSV-2 strain HG52). More preferably, vector flanking sequences comprise, consist or consist essentially of nucleotide sequences of the RL repeat region which flank the ICP34.5 protein coding sequence. In flanking the ICP34.5 coding sequence, one or both of the selected sequences may, in the corresponding HSV genome, overlap, i.e. extend into, the ICP34.5 protein coding sequence or one or both sequences may be selected so as to not overlap the ICP34.5 protein coding sequence or so as to be within it entirely. In a similar manner, the selected sequences may be chosen to overlap completely or partially other important encoded signals, e.g. transcription initiation site, polyadenylation site, defined promoters or enhancers. In this preferred arrangement the insertion site may thus comprise all or a part of the ICP34.5 protein coding sequence and/or be such that the inserted cassette disrupts the ICP34.5 protein coding sequence.
  • Thus, vectors according to the present invention comprising first and second nucleotide sequences corresponding to regions of the RL repeat region flanking and/or overlapping or being entirely within the ICP34.5 protein coding sequence may be used in the generation of ICP34.5 null mutants. In such mutants all or a portion of the ICP34.5 protein coding sequence may be excised and replaced during the homologous recombination event such that both copies of the ICP34.5 coding sequence are disrupted. Alternatively, the recombination may result in an insertion of nucleic acid within the ICP34.5 protein coding sequence thereby disrupting that sequence. In that case, successfully transformed virus are thus mutants incapable of generating the ICP34.5 active gene product from at least one copy, and preferably from both copies, of the ICP34.5 gene.
  • Where all copies of the ICP34.5 gene present in the herpes simplex virus genome (two copies are normally present) are disrupted such that the herpes simplex virus is incapable of producing a functional ICP34.5 gene product, the virus is considered to be an ICP34.5 null mutant.
  • Preferably, each component of the cassette is positioned substantially adjacent the neighbouring component such that a single bicistronic transcript comprising or consisting essentially of the mRNA encoding the nucleotide sequence of interest, ribosome binding site and marker is obtainable.
  • Preferably, the vector further comprises, consists, or consists essentially of a nucleic acid encoding a selectable marker such as a polypeptide or protein conferring antibiotic resistance e.g. kanamycin resistance or ampicillin resistance.
  • A vector of the present invention preferably comprises a DNA vector, particularly a dsDNA vector. The vector may be provided as a linear or circular (plasmid) DNA vector. The vector preferably contains nucleotide sequences, e.g. restriction endonuclease site(s), permitting transition between the two forms by use of DNA ligation and restriction materials (e.g. enzymes) and techniques known to the person skilled in the art. To achieve homologous recombination with a selected HSV strain, the vector is preferably provided in linear form.
  • In one preferred arrangement, the vector is plasmid RL1.dIRES-GFP deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 3 Sep. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03090303 in accordance with the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure (herein referred to as the ‘Budapest Treaty’).
  • In another preferred arrangement, the vector is a variant of plasmid RL1.dIRES-GFP.
  • Variant vectors may incorporate a regulatory nucleotide sequence, e.g. promoter, in place of the ribosome binding site of RL1.dIRES-GFP to control transcription of the nucleic acid encoding the marker.
  • Vectors according to the present invention are preferably constructed for use in generating engineered HSV-1 or HSV-2 by insertion of a nucleic acid cassette, which insertion may be through a mechanism of homologous recombination between nucleotide sequences flanking the cassette and corresponding sequences in the selected herpes simplex virus genome. The cassette may thereby be permanently integrated at a selected site of the viral genome.
  • Thus, vectors according to the present invention may comprise and have use as:
      • i) gene delivery (gene therapy) vectors for delivery of a selected protein coding sequence or antisense nucleic acid to a specific locus of the HSV genome; and/or
      • ii) expression vectors for expression of the delivered protein coding sequence or antisense nucleic acid of i) from the HSV genome under the control of a selected regulatory element; and/or
      • iii) vectors for the generation of HSV gene-specific mutants (optionally null mutants) wherein the cassette is inserted at a selected genomic location to disrupt the protein coding sequence of a selected HSV gene such that the gene product is inactive in the resultant mutant virus.
  • Vectors according to the present invention may be used in the manufacture of engineered gene specific HSV null mutants, i.e. HSV mutants incapable of expressing an active gene product of a selected gene. Alternatively they may be used in the manufacture of engineered viruses which express a selected protein from only one gene copy the other gene copy being disrupted or modified such that it cannot express a functional gene product. Such vectors may also be used in the manufacture of a medicament, preferably comprising said gene specific HSV (null) mutant, for use in treating tumours, preferably by the oncolytic treatment of the tumour. Preferably, such tumours may be primary or secondary (metastatic) tumours originating either in the central or peripheral nervous system, e.g. glioma, medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma, or originating in non-nervous system tissue e.g. melanoma, mesothelioma, lymphoma, hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer cells, lung cancer cells or colon cancer cells. HSV mutants generated using vectors of the present invention may be used to treat metastatic tumours of the central or peripheral nervous system which originated in a non-nervous system tissue.
  • Vectors according to the present invention may also be used in the manufacture of engineered HSV mutants wherein the genome of the mutant HSV comprises an exogenous or heterologous gene which may have been inserted in the HSV genome by homologous recombination of the cassette. Preferably, the exogenous/heterologous gene is expressed in the mutant HSV, which expression may be regulated by a regulatory element, e.g. promoter, forming part of the inserted cassette. Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • Vectors according to the present invention may also be used in the manufacture of an engineered HSV mutant wherein the genome of the mutant HSV comprises an exogenous/heterologous gene (i.e. a non-HSV originating gene) which may have been inserted in a protein coding sequence of the HSV genome by homologous recombination of the cassette such that the mutant HSV is incapable of expressing the active gene encoded by said protein coding sequence and wherein the exogenous/heterologous gene product is expressed under the control of a regulatory element. Preferably, the regulatory element forms part of the cassette. Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • Vectors according to the present invention may also be used in the manufacture of engineered HSV mutants wherein the genome of the mutant HSV comprises a nucleotide sequence which may have been inserted in the HSV genome by homologous recombination of the cassette such that the nucleotide sequence is arranged to be transcribed from the HSV genome under the control of a regulatory element e.g. promoter, preferably a regulatory element forming part of the inserted cassette, to produce an antisense transcript. Preferably the antisense nucleotide sequence is an exogenous/heterologous (i.e. non-HSV originating) sequence. Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • Vectors according to the present invention may also be used in the manufacture of an engineered HSV mutant wherein the genome of the mutant HSV comprises a nucleotide sequence which may have been inserted in a protein coding sequence of the HSV genome by homologous recombination of the cassette such that the mutant HSV is incapable of expressing the active gene encoded by said protein coding sequence and wherein the inserted nucleotide sequence is expressed under the control of a regulatory element to produce an antisense transcript. Preferably, the regulatory element forms part of the cassette. Such vectors may be used in the manufacture of a medicament, preferably comprising the engineered HSV mutant, for use in the treatment of disease, including the oncolytic treatment of tumours.
  • In another aspect of the present invention there is provided a method of lysing or killing tumour cells in vitro or in vivo comprising the step of administering mutant HSV, having a mutation in each ICP34.5 protein coding sequence and generated by a method according to an aspect of the present invention, to tumour cells.
  • In another aspect of the present invention there is provided a method of treating a tumour comprising administering to a subject mutant HSV having a mutation in each ICP34.5 protein coding sequence and generated by a method according to an aspect of the present invention.
  • In another aspect of the present invention there is provided a medicament, pharmaceutical composition or vaccine comprising a mutant HSV generated by a method according to an aspect of the present invention. The medicament, pharmaceutical composition or vaccine is preferably for use in the oncolytic treatment of tumours and may further comprise a pharmaceutically acceptable carrier, adjuvant or diluent.
  • In another aspect of the present invention there is provided a kit of parts comprising a first container having a quantity of a vector according to an aspect of the present invention and a second container comprising a quantity of HSV genomic DNA.
  • In another aspect of the present invention there is provided a mutant HSV generated using the vector of, or vectors derived from, an aspect of the present invention. Preferably, the mutant is a gene specific null mutant, more preferably an HSV ICP34.5 null mutant, wherein the HSV genome comprises an inserted nucleotide sequence of interest encoding a selected antisense RNA or an heterologous polypeptide. Preferably the nucleotide sequence of interest has been inserted in each RL region of the HSV genome, more preferably at both of the ICP34.5 loci, still more preferably the inserted heterologous nucleic acid disrupts the ICP34.5 protein coding sequence such that both ICP34.5 genes are non-functional and the mutant HSV is incapable of expressing an active ICP34.5 gene product from the disrupted ICP34.5 protein coding sequences. Preferably, the inserted heterologous nucleotide sequence is non-endogenous to HSV and encodes a polypeptide of interest selected from the group comprising or consisting of Sodium iodide symporter (NIS), Nitroreductase (NTR), preferably E. coli NTR, Endothelial nitric oxide synthase (eNOS), Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) or a cytokine.
  • The inserted nucleotide sequence of interest is preferably expressed or capable of expression under the control of an inserted regulatory element, preferably the CMV IE promoter. The mutant HSV genome preferably encodes the GFP gene product. More preferably the GFP coding sequence and nucleotide sequence of interest are arranged to be transcribed on a single bi- or poly-cistronic transcript such that expression of GFP is an indicator of HSV gene specific null mutants transformed with the nucleotide sequence of interest.
  • The nucleic acid cassette may be of any size, e.g. up to 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 Kbp in length.
  • In one preferred arrangement, the mutant HSV is HSV1716/CMV-NTR/GFP deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 5 Nov. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03110501 in accordance with the provisions of the Budapest Treaty.
  • Medicaments comprising HSV mutants according to the present invention for use in oncotherapy and methods of treating tumours comprising administering to a patient in need of treatment an effective amount of a mutant HSV according to an aspect of the present invention or a medicament comprising or derived from such HSV are also provided.
  • The use of such mutant HSV in the treatment of disease, including methods for the treatment of tumours/cancer, preferably by oncolysis is provided. Use of such mutant HSV in the manufacture of a medicament for use in these treatments is also provided.
  • Suitably, the administration of herpes simplex virus may comprise parenteral administration. Preferably administration of the herpes simplex virus is by injection, more preferably injection to the tumour which is to be treated.
  • Alternatively injections may be intravenous. Alternative administration routes may comprise oral or nasal administration.
  • Herpes simplex viruses according to the present invention may contain at least one copy of a nucleotide sequence of interest in each long repeat region (RL), i.e. in the terminal and internal long repeat (TRL and IRL) regions. In a preferred arrangement each exogenous/heterologous sequence or cassette is located in an RL1 locus of the herpes simplex virus genome, more preferably in the DNA of the herpes simplex virus genome encoding the ICP34.5 gene or protein coding sequence. The herpes simplex virus thereby lacks neurovirulence.
  • The parent herpes simplex virus, from which a virus of the invention is derived may be of any kind, e.g. HSV-1 or HSV-2. In one preferred arrangement the herpes simplex virus is a variant of HSV-1 strain 17 and may be obtained by modification of the strain 17 genomic DNA. Suitable modifications include the insertion of the exogenous nucleotide sequence of interest or exogenous/heterologous cassette comprising said sequence into the herpes simplex virus genomic DNA. The insertion may be performed by homologous recombination of the exogenous nucleic acid sequence into the genome of the selected herpes simplex virus.
  • Herpes simplex viruses of the present invention may be variants of a known ‘parent’ strain from which the herpes simplex virus of the invention has been derived. A particularly preferred parent strain is HSV-1 strain 17. Other parent strains may include HSV-1 strain F or HSV-2 strain HG52. A variant comprises an HSV in which the genome substantially resembles that of the parent, contains the nitroreductase nucleic acid sequence or cassette containing said sequence and may contain a limited number of other modifications, e.g. one, two or three other specific mutations, which may be introduced to disable the pathogenic properties of the herpes simplex virus, for example a mutation in the ribonucleotide reductase (RR) gene, the 65K trans inducing factor (TIF) and/or a small number of mutations resulting from natural variation, which may be incorporated naturally during replication and selection in vitro or in vivo. Otherwise the genome of the variant will be that of the parent strain.
  • In other aspects of the present invention vectors and/or herpes simplex viruses according to the present invention are provided for use in a method of medical treatment. Suitably they are provided for use in the treatment of disease. Preferably they are provided for use in the treatment of cancer. Suitably they may be provided for use in the oncolytic treatment of cancer/tumour of any kind. The use of vectors and/or herpes simplex viruses according to the present invention in the manufacture of a medicament for the treatment of cancer is also provided.
  • In another aspect of the present invention medicaments comprising herpes simplex virus mutants according to the present invention for use in oncotherapy and methods of treating tumours comprising administering to a patient in need of treatment an effective amount of a mutant HSV or a medicament comprising or derived from such HSV are also provided. Methods of lysing or killing tumour cells in vitro or in vivo comprising the step of administering to a patient in need of treatment an amount of an Herpes simplex virus according to the present invention are also provided.
  • A medicament, pharmaceutical composition or vaccine comprising a vector or Herpes simplex virus according to the present invention is also provided. The medicament, pharmaceutical composition or vaccine may further comprise a pharmaceutically acceptable carrier, adjuvant or diluent.
  • Herpes simplex viruses of the invention may be used in a method of medical treatment. This may involve treatment of diseases associated with or involving the proliferation of cells, or cancers or tumours of any kind. Treatment may involve the selective lysis of dividing cells. This may be oncolysis, i.e. lysis of tumour cells.
  • Tumours to be treated may be of any kind, may comprise cancers, neoplasms or neoplastic tissue and may be in any animal or human patient. Cancer/tumour types which may be treated may be primary or secondary (metastatic) tumours of any kind.
  • Treatable tumour types may include primary or secondary (metastatic) tumours originating either in the central or peripheral nervous system, e.g. glioma, medulloblastoma, meningioma, neurofibroma, ependymoma, Schwannoma, neurofibrosarcoma, astrocytoma and oligodendroglioma, or originating in non-nervous system tissue e.g. melanoma, mesothelioma, lymphoma, hepatoma, epidermoid carcinoma, prostate carcinoma, breast cancer cells, lung cancer cells or colon cancer cells. Treatable metastatic tumours may be those of the central or peripheral nervous system which originated in a non-nervous system tissue.
  • Herpes simplex viruses of the invention may be used in ‘gene delivery’ methods in vitro or in vivo. Non-neurovirulent herpes simplex viruses of the invention are expression vectors and may be used to infect selected cells or tissues in order to express the nucleotide sequence of interest encoded by the herpes simplex virus genome.
  • Mutant HSV according to aspects of the present invention may be useful in the treatment of disease by gene directed enzyme-prodrug therapy and/or the treatment of disease, including tumours, by the use of antisense RNA or siRNA technology.
  • In one arrangement, cells may be taken from a patient, a donor or from any other source, infected with a herpes simplex virus of the invention, optionally screened for expression and/or function of the encoded nucleotide sequence of interest, and optionally returned/introduced to a patient's body, e.g. by injection.
  • Delivery of herpes simplex viruses of the invention to the selected cells may be performed using naked virus or by encapsulation of the virus in a carrier, e.g. nanoparticles, liposomes or other vesicles.
  • In vitro cultured cells, preferably human or mammalian cells, transformed with viruses of the present invention and preferably cells expressing the nucleotide sequence of interest as well as methods of transforming such cells in vitro with said viruses form further aspects of the present invention.
  • A nucleotide sequence of interest may be an exogenous/heterologous sequence, i.e. one not originating in the parent (wild-type) herpes simplex virus from which the herpes simplex virus of the invention is derived.
  • In this specification, a mutant herpes simplex virus is a non-wild type herpes simplex virus and may be a recombinant herpes simplex virus. Mutant herpes simplex viruses may comprise a genome containing modifications relative to the wild type. A modification may include at least one deletion, insertion, addition or substitution.
  • Medicaments and pharmaceutical compositions according to aspects of the present invention may be formulated for administration by a number of routes, including but not limited to, parenteral, intravenous, intramuscular, intratumoural, oral and nasal. The medicaments and compositions may be formulated in fluid or solid (e.g. tablet) form. Fluid formulations may be formulated for administration by injection to a selected region of the human or animal body.
  • In this specification, non-neurovirulence is defined by the ability to introduce a high titre of virus (approx 106 plaque forming units (pfu)) to an animal or patient22, 23 without causing a lethal encephalitis such that the LD50 in animals, e.g. mice, or human patients is in the approximate range of ≧106 pfu21.
  • Where all copies of the ICP34.5 gene present in the herpes simplex virus genome (two copies are normally present) are disrupted such that the herpes simplex virus is incapable of producing a functional ICP34.5 gene product, the virus is considered to be an ICP34.5 null mutant.
  • A regulatory sequence (e.g. promoter) that is operably linked to a nucleotide sequence may be located adjacent to that sequence or in close proximity such that the regulatory sequence can effect and/or control expression of a product of the nucleotide sequence. The encoded product of the nucleotide sequence may therefore be expressible from that regulatory sequence.
  • Hybridisation Stringency
  • In accordance with the present invention, nucleic acid sequences may be identified by using hybridization and washing conditions of appropriate stringency.
  • Complementary nucleic acid sequences will hybridise to one another through Watson-Crick binding interactions. Sequences which are not 100% complementary may also hybridise but the strength of the hybridisation usually decreases with the decrease in complementarity. The strength of hybridisation can therefore be used to distinguish the degree of complementarity of sequences capable of binding to each other.
  • The “stringency” of a hybridization reaction can be readily determined by a person skilled in the art.
  • The stringency of a given reaction may depend upon factors such as probe length, washing temperature, and salt concentration. Higher temperatures are generally required for proper annealing of long probes, while shorter probes may be annealed at lower temperatures. The higher the degree of desired complementarity between the probe and hybridisable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so.
  • For example, hybridizations may be performed, according to the method of Sambrook et al., (“Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989) using a hybridization solution comprising: 5×SSC, 5× Denhardt's reagent, 0.5-1.0% SDS, 100 μg/ml denatured, fragmented salmon sperm DNA, 0.05% sodium pyrophosphate and up to 50% formamide. Hybridization is carried out at 37-42° C. for at least six hours. Following hybridization, filters are washed as follows: (1) 5 minutes at room temperature in 2×SSC and 1% SDS; (2) 15 minutes at room temperature in 2×SSC and 0.1% SDS; (3) 30 minutes-1 hour at 37° C. in 1×SSC and 1% SDS; (4) 2 hours at 42-65° C. in 1×SSC and 1% SDS, changing the solution every 30 minutes.
  • One common formula for calculating the stringency conditions required to achieve hybridization between nucleic acid molecules is to calculate the melting temperature Tm (Sambrook et al., 1989):
    T m=81.5° C.+16.6 Log [Na+]+0.41(% G+C)−0.63(% formamide)−600/n
    where n is the number of bases in the oligonucleotide.
  • As an illustration of the above formula, using [Na+]=[0.368] and 50% formamide, with GC content of 42% and an average probe size of 200 bases, the Tm is 57° C. The Tm of a DNA duplex decreases by 1-1.5° C. with every 1% decrease in sequence complementarity.
  • Accordingly, nucleotide sequences can be categorised by an ability to hybridise to a target sequence under different hybridisation and washing stringency conditions which can be selected by using the above equation. The Tm may be used to provide an indicator of the strength of the hybridisation.
  • The concept of distinguishing sequences based on the stringency of the conditions is well understood by the person skilled in the art and may be readily applied.
  • Sequences exhibiting 95-100% sequence complementarity may be considered to hybridise under very high stringency conditions, sequences exhibiting 85-95% complementarity may be considered to hybridise under high stringency conditions, sequences exhibiting 70-85% complementarity may be considered to hybridise under intermediate stringency conditions, sequences exhibiting 60-70% complementarity may be considered to hybridise under low stringency conditions and sequences exhibiting 50-60%% complementarity may be considered to hybridise under very low stringency conditions.
  • The invention includes the combination of the aspects and preferred features described except where such a combination is clearly impermissible or expressly avoided.
  • Aspects and embodiments of the present invention will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1. Generation of plasmid RL1.dIRES-GFP from plasmids pNAT-IRES-GFP and RL1.del.
  • FIG. 2. Agarose gel electrophoresis of HpaI digested, CIP treated, RL1.del. RL1.del was digested with HpaI. The digested DNA was then treated with Calf Intestinal Phosphatase (CIP) to prevent the vector re-annealing to itself in subsequent ligation reactions. A sample of the digested/CIP treated DNA was electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel. HpaI linearises the vector at 8.6 Kbp.
  • FIG. 3. Agarose gel electrophoresis of NsiI/SspI digested pNAT-IRES-GFP (A) and purified/blunt-ended pCMV-NAT-IRES-GFP-PolyA (B). Four NsiI/SspI digestions of pNAT-IRES-GFP were electrophoresed, beside a 1 Kbp DNA Ladder (Promega) on a 1% agarose gel. The 5.4 Kbp fragments (pCMV-NAT-IRES-GFP-PolyA) were purified from the gel. The purified DNA was blunt ended using Klenow polymerase and a sample electrophoresed on an agarose gel to check its concentration.
  • FIG. 4. Identification of RL1.del clones containing the pCMV-NAT-IRES-GFP-PolyA insert. Ligation reactions were set up with the purified, blunt ended pCMV-NAT-IRES-GFP-PolyA fragment and HpaI digested, CIP treated RL1.del. Bacteria were transformed with samples from the ligation reactions and plated out onto LBA (Ampr) plates. Colonies were picked and plasmid DNA was extracted and digested with AflII. Digested samples were electrophoresed, beside a 1 Kbp DNA ladder (L) (Promega), on a 1% agarose gel.
  • * Clones 5 and 8 contained the pCMV-NAT-IRES-GFP-PolyA insert as two fragments of the predicted size—4.8 Kbp and 9.2 Kbp—were generated from AflII digestion. Clones without inserts would not be digested with AflII as there is no AflII site in RL1.del.
  • N.B. Inserts could have been cloned in two orientations, both of which were acceptable.
  • FIG. 5. Determination of the orientation of pCMV-NAT-IRES-GFP-PolyA in clone 5 (RL1.dCMV-NAT-GFPb). pCMV-NAT-IRES-GFP-PolyA (blunt ended) could have been cloned into the HpaI site of RL1.del in two orientations. To determine the orientation of the insert in clone 5, the plasmid was digested with XhoI and the digested DNA electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel. If the insert had been cloned in the orientation shown in A, two fragments of 10.2 Kbp and 3.8 Kbp would be generated from XhoI digestion. If it had been cloned in the opposite orientation (B), two fragments of 12.4 Kbp and 1.6 Kbp would be generated. The presence of two fragments of 10.2 Kbp and 3.8 Kbp in the gel confirmed that the insert had been cloned in the orientation shown in A.
  • *This XhoI site was present in the initial cloning vector (RL1.del), upstream of the HpaI site into which pCMV-NAT-IRES-GFP-PolyA was cloned.
  • FIG. 6. Removal of pCMV-NAT from clone 5 (A) and large scale plasmid preparation of RL1.dIRES-GFP (B). Four samples of clone 5 were digested with XhoI and electrophoresed, beside a 1 Kbp DNA ladder (L) (Promega), on a 1% agarose gel (A). The larger fragment of DNA generated from this digestion (10.2 Kbp) was purified from the gel and ligated back together, at the XhoI sites, to form a single XhoI site in a new plasmid, designated RL1.dIRES-GFP. A large-scale plasmid preparation was grown up and the preparation checked by digesting with XhoI. 1 μl and 4 μl of the digested DNA was electrophoresed, beside a 1 Kbp DNA ladder (L) (Promega), on a 1% agarose gel (B). The DNA should produce a single fragment of 10.2 Kbp when digested with XhoI. The ClaI, BglII, NruI and XhoI sites of RL1.dIRES-GFP are all unique.
  • *Clone 5 is the RL1.del plasmid into which has been cloned the 5.4 Kbp pCMV-NAT-IRES-GFP-PolyA fragment from pNAT-IRES-GFP.
  • FIG. 7. Generation, detection and purification of ICP34.5 null HSV-1 expressing a gene product of interest.
  • FIG. 8. Strategy used to clone pCMV-NTR from pPS949 into RL1.dIRES-GFP. (1) Digest pPS949 with BamH1 and purify the 1.6 Kbp pCMV-NTR fragment; (2) Digest RL1.dIRES-GFP with BglII and treat with Calf Intestinal Phosphatase (CIP); (3) Clone the pCMV-NTR fragment (BamHI ends) into the BglII site of RL1.dIRES-GFP.
  • * The pPS949 plasmid was a kind gift from Professor Lawrence Young (University of Birmingham) and contains the E. coli nitroreductase (NTR) gene downstream of the CMV-IE promoter (pCMV) in pLNCX (Clontech).
  • FIG. 9. Agarose gel electrophoresis of BamHI digested pPS949 (A) and the purified pCMV-NTR fragment (B). Four samples of pPS949 were digested with BamHI and electrophoresed, beside a 1 Kbp DNA ladder (L) (New England Biolabs), on a 1% agarose gel. The 1.6 Kbp fragments, consisting of the E. coli nitroreductase (NTR) gene downstream of the CMV IE promoter (pCMV), were purified from the gel and a sample of the purified DNA was electrophoresed on an agarose gel to check its concentration.
  • FIG. 10. Agarose gel electrophoresis of BglII digested, CIP treated RL1.dIRES-GFP.RL1.dIRES.GFP was digested with BglII. The digested plasmid was then treated with Calf Intestinal Phosphatase (CIP) to prevent the vector re-annealing to itself in subsequent ligation reactions. A sample of the digested/CIP treated DNA was electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel to check its concentration. pCMV-NTR from pPS949 was subsequently cloned into this digested/CIP treated vector.
  • FIG. 11. Determination of the orientation of pCMV-NTR in clone 4. pCMV-NTR (BamHI ends) could have been cloned into the BglII site of RL1.dIRES-GFP in two orientations. To determine the orientation, clone 4 was digested with BglII and XhoI and the digested DNA electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel. If the insert was in the desired orientation (A), two fragments (11.5 Kbp and 300 bp) would be generated. If in the opposite orientation, two fragments of 10.5 Kbp and 1.3 Kbp would be generated. The presence of a band at ˜300 bp (and the absence of a band at 1.3 Kbp) confirmed that the pCMV-NTR fragment had been cloned into the vector in the desired orientation.
  • FIG. 12. Agarose gel electrophoresis of ScaI digested clone 4 (A) and HSV1716/CMV-NTR/GFP viral titres (B). Clone 4 (RL1.dCMV-NTR-GFP) was digested with ScaI, the digested DNA purified and 5 μl electrophoresed, beside a 1 Kbp DNA ladder (Promega), on a 1% agarose gel, to check its concentration. 80% confluent BHK cells were then co-transfected with 10 μl HSV17+ DNA and an appropriate volume of the remaining digested clone 4. The cells were incubated at 37° C. for 3 days until cpe was evident. Recombinant viral plaques were picked under the fluorescent microscope, purified and a virus stock, named HSV1716/CMV-NTR/GFP, grown up. The cell-associated and cell-released fraction of the virus stock was titrated on BHK cells.
  • FIG. 13. Growth kinetics of HSV17+, HSV1716 and HSV1716/CMV-NTR/GFP in confluent BHK and 3T6 cells. Confluent BHK and 3T6 cells were infected at a MOI of 0.1 pfu/cell. Infected cells were harvested at 0, 4, 24, 48 and 72 hrs post infection, sonicated and progeny virus titrated on BHK cell monolayers. All viruses replicated with similar kinetics in BHK cells (A); HSV1716 and HSV1716/CMV-NTR/GFP both failed to replicate efficiently in confluent 3T6 cells (B).
  • FIG. 14. Western blot analysis of ICP34.5 expression in HSV17+ and HSV1716/CMV-NTR/GFP infected BHK cells. BHK cells were infected with HSV17+ and HSV1716/CMV-NTR/GFP at a MOI of 10 pfu/cell. 16 hrs post infection, the cells were harvested and protein extracts analysed using 10% SDS-PAGE in a Western blot using a polyclonal anti-ICP34.5 antibody. ICP34.5 was strongly expressed in HSV17+ infected cells but was not expressed in HSV1716/CMV-NTR/GFP infected cells.
  • FIG. 15. Western blot analysis of NTR expression in HSV1716/CMV-NTR/GFP infected cell lines. BHK, C8161, VM and 3T6 cells were infected with 10 pfu/cell HSV1716/CMV-NTR/GFP, HSV17+ or mock infected. 16 hrs post infection, the cells were harvested and protein extracts analysed in a Western blot using a polyclonal NTR-specific antibody. Significant NTR expression was detected in all the HSV1716/CMV-NTR/GFP infected cells. No NTR expression was detected in the mock or HSV17+ infected cells.
  • FIG. 16. Effect of HSV1716/CMV-NTR/GFP and HSV1716-GFP with or without CB1954 (50 μM) on confluent 3T6 cells. Confluent 3T6 cells in three wells of a 96-well plate were mock infected, infected with 1 or 10 pfu/cell HSV1716/CMV-NTR/GFP or infected with 1 pfu/cell of HSV1716-GFP. 45 minutes later, infected cells were overlaid with media containing 50 μM CB1954 or with media alone and incubated at 37° C. 24, 48, 72, 96, and 120 hrs later, % cell survival was determined relative to that of mock infected cells without prodrug using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega). Figures shown represent the mean of 3 values+/−standard error of the mean.
  • FIG. 17. Effect of HSV1716/CMV-NTR/GFP and HSV1716-GFP with or without CB1954 (50 μM) on confluent C8161 cells. Confluent C8161 cells in three wells of a 96-well plate were mock infected, infected with 1 or 10 pfu/cell HSV1716/CMV-NTR/GFP or infected with 1 pfu/cell of HSV1716-GFP. 45 minutes later, infected cells were overlaid with media containing 50 μM CB1954 or with media alone and incubated at 37° C. 24, 48 and 72 hrs later, % cell survival was determined relative to that of mock infected cells without prodrug using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega). Figures shown represent the mean of 3 values+/−standard error of the mean.
  • FIG. 18. Confluent 3T6 cells 72 hrs post treatment with 10 pfu/cell HSV1716/CMV-NTR/GFP (A), or 10 pfu/cell HSV1716/CMV-NTR/GFP with 50 μM CB1954 (B). The extent of cell death is significantly more pronounced in HSV1716/CMV-NTR/GFP infected cells overlaid with media containing 50M C1954 than in HSV1716/CMV-NTR/GFP infected cells overlaid with normal media. The extent of cell death following infection of these cells with 10 pfu/cell HSV1716, with or without CB1954, is comparable to that seen in A (data not shown). 50 μM CB1954 alone has no effect on these cells.
  • FIG. 19. Confluent C8161 cells 72 hrs post treatment with 10 pfu/cell HSV1716/CMV-NTR/GFP (A), or 10 pfu/cell HSV1716/CMV-NTR/GFP with 50 μM CB1954 (B). The extent of cell death is significantly more pronounced in HSV1716/CMV-NTR/GFP infected cells overlaid with media containing 50 μM CB1954 than in HSV1716/CMV-NTR/GFP infected cells overlaid with normal media. The extent of cell death following infection of these cells with 10 pfu/cell HSV1716, with or without CB1954, is comparable to that seen in A (data not shown). 50 μM CB1954 alone has no effect on these cells.
  • FIG. 20. Weight change (as a guide to health) in athymic nude mice with subcutaneous A2780 (xenograft) tumours injected intratumourally with HSV 1790. Group size=3 mice per dose. A2780 xenografts at date of intratumoural injection (Day 0) are between 0.5-1 mm in diameter. The xenografts have reached this size 12 days after injection with 10 million A2780 cells subcutaneously on the flank of female athymic nude mice.
  • FIG. 21. Change in tumour volume over time in athymic nude mice with A2780 xenografts after intratumoural injection of HSV 1790.
  • FIG. 22. Starting tumour sizes of mice.
  • FIG. 23. Alterations in weight after treatment with CMV-ntr, CB1954 or a combination of both.
  • FIG. 24. Change in tumour volume after treatment with CMV-ntr, CB1954 or a combination of both.
  • FIG. 25. Starting tumour volume of each treatment group (see Table 2).
  • FIG. 26. Weight (as a measurement of health) in athymic nude mice with A2780 xenograft treated with either HSV 1790, HSV 1716, CB 1954 or a combination of them.
  • FIG. 27. Change in tumour volume of xenografts treated with the prodrug CB1954.
  • FIG. 28. Changes in tumour volume in xenograft treated with 105 PFU HSV 1790 and CB1954.
  • FIG. 29. Changes in tumour volume in xenografts treated with 106 PFU HSV 1790 and CB1954.
  • FIG. 30. Changes in tumour volume in xenografts treated with 105 PFU HSV 1716 and CB1954.
  • FIG. 31. Comparison of 105 PFU, 106 PFU HSV 1790 and 105 PFU HSV 1716.
    • DETAILED DESCRIPTION OF THE BEST MODE OF THE INVENTION
  • Specific details of the best mode contemplated by the inventors for carrying out the invention are set forth below, by way of example. It will be apparent to one skilled in the art that the present invention may be practiced without limitation to these specific details.
    • Example 1 Construction of Plasmid RL1.dIRES-GFP
  • General Approach
  • Plasmid RL1.dIRES-GFP was generated in three stages, illustrated in FIG. 1.
  • 1. The DNA sequences containing the CMV IE promoter (pCMV), the NAT gene, the internal ribosome entry site (IRES), the GFP reporter gene and the SV40 polyadenylation sequences were excised from pNAT-IRES-GFP using NsiI and SspI and purified.
  • 2. The purified pCMV-NAT-IRES-GFP-PolyA DNA fragment was cloned into RL1.del to form a new plasmid designated RL1.dCMV-NAT-GFP.
  • 3. The pCMV-NAT DNA sequences of RL1.dCMV-NAT-GFP were excised using XhoI and the remainder of the plasmid re-ligated to form a novel plasmid designated RL1.dIRES-GFP. This novel plasmid contained a multi-cloning site (all sites shown are unique) upstream of an IRES, the GFP gene and the SV40 polyA sequences all within the HSV-1 RL1 flanking sequences. Recombinant ICP34.5 null HSV-1, expressing a gene of interest in the RL1 locus, can be generated by cloning the gene of interest (downstream of a suitable promoter) into the multi-cloning site and co-transfecting BHK cells with the plasmid and HSV-1 DNA. Recombinant virus expressing the target gene can be identified using GFP fluorescence.
  • Removal of the CMV promoter and noradrenaline transporter gene (pCMV-NAT) from RL1.dCMV-NAT-GFP, followed by re-ligation of the remainder of the plasmid, resulted in a novel plasmid (RL1.dIRES-GFP) containing a multi-cloning site (MCS), upstream of the encephalomyocarditis virus internal ribosome entry site (EMCV IRES), the GFP reporter gene and the SV40 PolyA sequences, all within RL1 flanking sequences. This novel arrangement of DNA sequences or ‘smart cassette’ allows ICP34.5 null HSV-1, expressing a gene of interest in the RL1 locus, to be easily generated by simply inserting the desired transgene (downstream of a suitable promoter) into the MCS and co-transfecting BHK cells with the plasmid and HSV-1 DNA. The IRES situated between the GFP gene and the MCS permits expression of two genes from the same promoter and so recombinant virus expressing the gene of interest also expresses GFP and can therefore be easily identified under a fluorescence microscope and purified.
  • Materials and Methods
  • 1 μg of RL1.del* was digested with 10 units HpaI (Promega) in a suitable volume of 10× buffer (Promega) and nuclease free water (Promega) at 37° C. for 16 hrs. The digested plasmid was then purified using the QIAquick PCR purification kit (Qiagen), treated with 10 units of Calf Intestinal Phosphatase (Promega), in a suitable volume of 10×CIP buffer and nuclease free water for 4 hrs at 37° C., before being purified again using a Qiaquick PCR purification kit. 5 μl of the purified DNA was electrophoresed on a 1% agarose gel to check its concentration (FIG. 2).
  • 4×1 μg of pNAT-IRES-GFP** was digested with 10 units of NsiI and 10 units of SspI in a suitable volume of 10× buffer (Promega) and nuclease free water (Promega) at 37° C. for 16 hrs. The reaction mixture was electrophoresed in a 1% agarose gel for 1 hr at 110 volts. The 5.4 Kbp DNA fragment consisting of the CMV IE promoter (pCMV), upstream of the noradrenaline transporter gene (NAT), the encephalomyocarditis virus internal ribosome entry site (IRES), the gene for green fluorescent protein (GFP) and the SV40 polyadenylation sequences (SV40 Poly A), was excised using a sterile scalpel and the DNA purified from the gel using a QIAquick Gel Extraction kit (Qiagen). The eluted DNA was blunt ended using 3 units Klenow Polymerase (Promega) in accordance with the manufacturers instructions and the DNA purified using a QIAquick PCR purification kit (Qiagen). 5 μl of the purified DNA fragment was electrophoresed on a 1% agarose gel to check its concentration (FIG. 3).
  • Ligation reactions were carried out in small eppendorf tubes containing 5 units T4 DNA Ligase (Promega), a suitable volume of 10×DNA Ligase Buffer (Promega), nuclease free water (Promega) and various volumes of the HpaI digested/CIP treated RL1.del and blunt ended pCMV-NAT-IRES-GFP-SV40 Poly A DNA, at 16° C. overnight. Competent JM109 bacterial cells (Promega) were then transformed with various aliquots of the ligation reactions***. Colonies formed on the plates were picked, had their plasmid DNA extracted using a Qiagen Plasmid Mini kit and screened for inserts using AflII (New England Biolabs) restriction enzyme analysis. Plasmid DNA containing the insert would produce two fragments of 4.8 Kbp and 9.2 Kbp following digestion with AflII. Two clones (clone 5 and 8) contained the insert (FIG. 4). The orientation of the insert in clone 5 (RL1.dCMV-NAT-GFP) was determined using XhoI restriction enzyme analysis (FIG. 5).
  • To generate RL1.dIRES-GFP from clone 5, the CMV-NAT portion of the CMV-NAT-IRES-GFP-SV40 PolyA insert was removed by digesting 4×500 ng of clone 5 with 10 units of XhoI in a suitable volume of buffer and water (Promega), overnight at 37° C. The digested DNA was electrophoresed on a 1% agarose gel at 110 volts for 1 hr (FIG. 6A). The 10.2 Kbp fragment consisting of the IRES, the GFP gene, the SV40 PolyA sequences and RL1 flanking sequences in a pGEM3Zf(−) (Promega) backbone, was excised using a sterile scalpel and the DNA purified from the gel using a QIAquick Gel Extraction kit.
  • Ligation reactions were performed in small eppendorf tubes containing 10 ng-500 ng purified DNA, 3 units T4 DNA Ligase (Promega), a suitable volume of 10×DNA Ligase Buffer (Promega) and nuclease free water (Promega) overnight at 16° C. Competent JM109 bacterial cells (Promega) were then transformed with various aliquots of the ligation reactions***. Colonies formed on the plates were picked, had their plasmid DNA extracted using a Qiagen Plasmid Mini kit and screened using XhoI (Promega) restriction enzyme analysis. Colonies containing plasmid DNA from which CMV-NAT had been removed would produce one fragment of 10.2 Kbp when digested with XhoI. Several positive clones were found, one was isolated, and a large-scale plasmid preparation undertaken using Promega's Wizard Plus Maxipreps kit. The large-scale plasmid preparation was checked by digesting with XhoI (FIG. 6B). This plasmid DNA was subsequently named ‘RL1.dIRES-GFP’.
  • Plasmid RL1.dIRES-GFP has been deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 3 Sep. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03090303 in accordance with the provisions of the Budapest Treaty.
  • RL1.del
  • *RL1.del was provided by Dr. E. McKie and is the pGEM-3Zf(−) plasmid (Promega) into which has been cloned an HSV-1 fragment (123459-129403) consisting of the RL1 gene and its flanking sequences. The 477 bp PflMI-BstEII fragment of the RL1 gene (125292-125769) has been removed and replaced with a multi-cloning site (MCS) to form RL1.del.
  • pNAT-IRES-GFP
  • ** pNAT-IRES-GFP was supplied by Dr. Marie Boyd (CRUK Beatson Laboratories) and is the pIRES2-EGFP plasmid (BD Biosciences Clontech) into which she has cloned the bovine noradrenaline transporter (NAT) gene (3.2 Kbp), at the NheI and XhoI sites.
  • ***Transformation of Bacterial Cells
  • 10 μl of a glycerol E. coli stock was added to 10 ml 2YT medium in a 20 ml griener tube. This was placed in a 37° C. shaking incubator for 16-24 hrs until a saturated culture was obtained. 1 ml of this culture was then added to 100 ml of 2YT in a 500 ml sterile glass bottle and placed in the 37° C. shaking incubator for 3 hrs. The bacterial cells were pelleted by centrifugation at 2,000 rpm for 10 minutes (Beckman). The cells were then resuspended in 1/10th volume of transformation and storage buffer (10 mM MgCl2, 10 mM Mg(SO)4, 10% (w/v) PEG 3,500, 5% (v/v) DMSO). The cells were placed on ice for between 10 minutes and 2 hrs, after which time they were considered competent for transformation.
  • 1-10 μl of DNA was mixed with 100 μl of competent bacteria in eppendorf tubes, and the tubes placed on ice for 30 minutes. After this, the samples were ‘heat shocked’ by incubating the tubes in a 42° C. water bath for exactly 45 seconds before placing them on ice for a further 2 minutes. 1 ml of L-Broth was added, the tube inverted 2-3 times, and the bacteria incubated for 1 hr at 37° C. 100 μl of the transformed bacteria was plated out onto L-broth agar plates containing 100 μg/ml of the appropriate antibiotic (usually ampicillin or kanamycin). Plates were allowed to dry at room temperature, before incubating in an inverted position at 37° C. overnight.
    • Example 2 Generation of ICP34.5 Null HSV-1 Expressing a Gene Product of Interest and GFP Using Plasmid RL1.dIRES-GFP
  • General Approach
  • Generation of ICP34.5 null HSV-1 expressing a gene product of interest requires insertion of nucleotide sequence encoding the gene product (polypeptide) of interest, and often a desired promoter, at the MCS of RL1.dIRES.GFP followed by co-transfection of BHK cells with the linearised plasmid, containing the gene of interest, and HSV DNA. Following homologous recombination viral plaques expressing GFP are identified. FIG. 7 illustrates the method steps involved.
  • Referring to FIG. 7A plasmid DNA, containing the gene of interest and the desired promoter (X), is digested with restriction endonucleases to release the promoter/gene fragment.
  • The promoter/gene fragment is purified and cloned into the multi-cloning site (MCS) of RL1.dIRES.GFP forming a shuttle vector suitable for generating oncolytic HSV-1 (FIG. 7B). This vector contains HSV-1 sequences that flank the essential RL1 gene but does not contain the RL1 gene. The plasmid also contains the gene for Green Fluorescent Protein (GFP) downstream of an internal ribosome entry site (IRES). The IRES permits expression of both the gene of interest and the GFP gene from the same upstream promoter.
  • BHK cells are then co-transfected with linearised RL1.dIRES.GFP, now containing the gene of interest, and HSV-1 DNA (FIG. 7C). Following homologous recombination, designer virus, expressing the gene of interest and GFP, is generated and can be distinguished from wild type virus (also generated but not expressing GFP) under a fluorescence microscope.
  • Viral plaques, expressing GFP (and hence the gene of interest), are picked under the fluorescence microscope and purified until all wild-type HSV-1 has been removed. The recombinant HSV-1 is considered 100% pure when all the viral plaques are expressing GFP (FIG. 7D).
  • Once the recombinant virus is completely pure, an isolated plaque is picked and a highly concentrated stock is grown and titrated (FIG. 7E). Oncolytic HSV-1, expressing a gene product of interest from a selected promoter, is then ready for characterisation and in vitro examination of its tumour killing potential.
  • Materials and Methods
  • To generate recombinant ICP34.5 null HSV-1 expressing a gene of interest and GFP, requires the gene of interest, and often a suitable promoter, to be cloned into the MCS of RL1.dIRES-GFP in the forward orientation with respect to the GFP gene in this plasmid. Once this has been achieved the plasmid is linearised (i.e. digested with a restriction enzyme that cuts only once, usually SspI or ScaI) in an irrelevant region. 80% confluent BHK cells in 60 mm petri dishes are then co-transfected with HSV-1 DNA and linearised plasmid DNA as described below.
  • To generate replication restricted HSV-1, expressing the gene of interest and GFP, the gene of interest must be cloned into RL1.dIRES-GFP downstream of a suitable promoter (e.g. CMV IE). The promoter is required upstream of the gene of interest for the production of a bicistronic mRNA transcript. The IRES sequence between the two open reading frames in the transcript functions as a ribosome binding site for efficient cap-independent internal initiation of translation. The design enables coupled transcription of both the gene of interest and GFP, followed by cap-dependent initiation of translation of the first gene (gene of interest) and IRES-directed, cap-independent translation of GFP. Co-ordinate gene expression is thus ensured in this configuration.
  • Co-Transfection of Virus and Plasmid DNA by CaPO4 and DMSO Boost
  • HSV-1 (17+) DNA and 0.1-1 μg linearized SMART cassette containing the gene and promoter of interest is pipetted into 1.5 ml eppendorf tubes containing 1 μl of calf thymus DNA (10 μg/ml) and an appropriate volume of distilled water to give a final volume of 165 μl. The solutions are very gently mixed using a 200 μl pipette tip. 388 μl of HEBS, pH 7.5, (130 mM NaCl, 4.9 mM KCl, 1.6 mM Na2HPO4, 5.5 mM D-glucose, 21 mM HEPES) is then added, the solution mixed, before adding 26.5 μl of 2M CaCl2 dropwise and flicking the eppendorf tube two or three times. The samples are left at room temperature for 10-15 minutes then added dropwise to 80% confluent BHK's in 60 mm petri dishes from which the medium has been removed. Following incubation at 37° C. for 45 minutes, the cells are overlaid with 5 ml of ETC10 and incubated at 37° C. Three to four hours later, the media is removed and the plates washed with ETC10. For exactly 4 minutes, the cells are overlaid with 1 ml 25% (v/v) DMSO in HEBS at room temperature. After the 4 minutes, the cells are immediately washed three times with 5 ml ETC10 before overlaying with 5 ml of ETC10 and returning to the incubator. The following day, fresh medium is added to the cells. Two days later, when cpe is evident, cells are scraped into the medium, transferred to small bijoux and sonicated thoroughly. The sample is then stored at −70° C. until required (see section below on plaque purification).
  • N.B. The volume of virus DNA to add is determined by undertaking the above procedure without plasmid DNA, using a range of virus DNA volumes and choosing the volume that gives the greatest number of viral plaques on the BHK monolayer after 2 or 3 days.
  • Plaque Purification
  • Sonicated samples from co-transfection plates are thawed and serially diluted 10 fold in ETC10. 100 μl from neat to the 105 dilution is plated out on confluent BHK's in 60 mm petri dishes from which the media has been removed. After 45 minutes incubation at 37° C., the cells are overlaid with 5 ml EMC10 and incubated at 37° C. for 48 hrs. The plates are then checked for the presence of viral plaques and those dishes with the fewest, most separated plaques are placed under a fluorescent stereomicroscope. Recombinant virus, designed to express the green fluorescent protein (GFP) in addition to the gene of interest, can clearly be distinguished from wild type virus using a GFP filter. Fluorescent plaques are picked using a 20 μl pipette and placed (including the tip) into an eppendorf tube containing 1 ml ETC10. The sample is thoroughly sonicated before making serial 10 fold dilutions in ETC10 and repeating the above purification procedure. The process is repeated typically 3-4 times until every plaque on the BHK monolayer is fluorescent. Once this has been achieved, 50 μl of this sample is used to infect BHK cells in roller bottles, in 50 ml ETC10, and a virus stock grown.
  • Tissue Culture Media
  • BHK21/C13 cells are grown in Eagle's medium (Gibco) supplemented with 10% newborn calf serum (Gibco) and 10% (v/v) tryptose phosphate broth. This is referred to as ETC10. For virus titrations and plaque purification, EMC10 (Eagles medium containing 1.5% methylcellulose and 10% newborn calf serum) is used to overlay the cells.
    • Example 3 Construction of HSV1716/CMV-NTR/GFP
  • General Approach
  • HSV1716/CMV-NTR/GFP was generated by cloning a 1.6 Kbp BamHI fragment from pPS94910, consisting of the E. coli nitroreductase (NTR) gene downstream of the CMV IE promoter (pCMV), into the MCS of the RL1.dIRES-GFP smart cassette, in the forward orientation with respect to the GFP gene in RL1.dIRES-GFP (FIG. 8). The resultant plasmid, named RL1.dCMV-NTR-GFP, was then linearised and recombinant virus generated and purified as described above. The plasmid pPS949 (referred to as ‘pxLNC-ntr’ in Ref 10) containing the NTR gene downstream of the CMV IE promoter (pCMV-NTR) in a pLNCX (Clontech) backbone, was a kind gift from Professor Lawrence Young, University of Birmingham, UK.
  • Materials and Methods
  • 4×1 μg of pPS949 was digested with 10 units of BamHI (Promega), in a suitable volume of 10× buffer (Promega) and nuclease free water (Promega), at 37° C. for 16 hrs. The reaction mixture was electrophoresed in a 1% agarose gel for 1 hr at 110 volts. The 1.6 Kbp DNA fragment consisting of the CMV promoter upstream of the NTR gene (pCMV-NTR), was excised using a sterile scalpel and the DNA purified from the gel using a QIAquick Gel Extraction kit (Qiagen). 5 μl of the purified DNA fragment was electrophoresed on a 1% agarose gel to check its concentration (FIG. 9).
  • 2 μg of the RL1.dIRES-GFP smart cassette was then digested with 15 units of BglII (Promega), in a suitable volume of 10× buffer (Promega) and nuclease free water (Promega), at 37° C. for 16 hrs. The digested plasmid was then purified using the QIAquick PCR purification kit (Qiagen), treated with 10 units of Calf Intestinal Phosphatase (Promega), in a suitable volume of 10×CIP buffer and nuclease free water for 4 hrs at 37° C., before being purified again using the Qiaquick PCR purification kit. 5 μl of the purified DNA was electrophoresed on a 1% agarose gel to check its concentration (FIG. 10).
  • Ligation reactions were carried out in small eppendorf tubes containing 5 units T4 DNA Ligase (Promega), a suitable volume of 10×DNA Ligase Buffer (Promega), nuclease free water (Promega) and various volumes of the BglII digested/CIP treated RL1.dIRES-GFP smart cassette and pCMV-NTR (BamHI ends), at 16° C. overnight. Competent JM109 bacterial cells (Promega) were then transformed with various aliquots of the ligation reactions. Colonies formed on the plates were picked, had their plasmid DNA extracted using a Qiagen Plasmid Mini kit and screened for inserts using BglII/XhoI (Promega) restriction enzyme analysis. RL1.dIRES-GFP plasmid DNA containing the pCMV-NTR insert in the correct orientation would produce two fragments of 11.5 Kbp and 300 bp following digestion with BglII and XhoI. One clone (clone 4) was found to contain the insert in the correct orientation (FIG. 11). This plasmid was named ‘RL1.dCMV-NTR-GFP’.
  • 0.1-1 μg of RL1.dCMV-NTR-GFP was linearized by digesting with 10 units of ScaI (Promega), in a suitable volume of 10× buffer (Promega) and nuclease free water (Promega), at 37° C. for 16 hrs. A sample (5 μl) of the digested DNA was electrophoresed on a 1% agarose gel for 1 hr at 110 volts to check that it had been linearized. 80% confluent BHK cells were then co-transfected with a suitable volume of the remaining linearised DNA and HSV-1 DNA. Recombinant HSV-1, expressing GFP (and hence NTR), was identified and purified using a fluorescent microscope and a virus stock, named HSV1716/CMV-NTR/GFP, was grown and titrated on BHK cells (FIG. 12).
  • HSV1716/CMV-NTR/GFP has been deposited in the name of Crusade Laboratories Limited having an address at Department of Neurology Southern General Hospital 1345 Govan Road Govan Glasgow G51 5TF Scotland on 5 Nov. 2003 at the European Collection of Cell Cultures (ECACC), Health Protection Agency, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom under accession number 03110501 in accordance with the provisions of the Budapest Treaty.
  • HSV1716/CMV-NTR/GFP Cell Killing
  • HSV1716/CMV-NTR/GFP replicates with almost identical kinetics to HSV1716 in BHK cells and 3T6 cells. BHK cells support the replication of ICP34.5 null HSV while confluent 3T6 cells do not. FIG. 13 shows that HSV1716/CMV-NTR/GFP will replicate as well as HSV1716 in permissive cell lines and that the introduction of exogenous genes, e.g. NTR and GFP, has not reduced the oncolytic potential of the ICP34.5 null HSV. The fact that HSV1716/CMV-NTR/GFP fails to replicate in 3T6 cells also indicates that this recombinant HSV is an ICP34.5 null mutant.
  • FIG. 14 is a Western blot demonstrating that no ICP34.5 polypeptide is expressed from HSV1716/CMV-NTR/GFP, and that the virus is thus useful as a gene therapy vector.
  • FIG. 15 is another Western blot demonstrating expression of NTR in a variety of cell lines infected with HSV1716/CMV-NTR/GFP, including a human malignant melanoma cell line (C8161) and confluent 3T6 cells in which ICP34.5 null HSV does not replicate. Expression of NTR in confluent 3T6 cells, following infection with HSV1716/CMV-NTR/GFP, is encouraging as it demonstrates that replication of this ICP34.5 null mutant is not required for expression of the prodrug-activating gene (i.e. NTR). Some tumour cells in vivo will not support the replication of ICP34.5 null HSV and as such, will not be killed with HSV1716.
  • FIG. 16 shows the results from a cytotoxicity assay performed in confluent 3T6 cells. Infecting confluent 3T6 cells with an ICP34.5 null mutant (HSV1716/CMV-NTR/GFP), at a multiplicity of infection (MOI) of 1 plaque forming units (pfu)/cell, does not result in any significant cell death, neither does separate incubation of the cells with 50 μM CB1954. However, significant cell death is evident 72 hrs post infection with 1 pfu/cell HSV1716/CMV-NTR/GFP when 50 μM CB1954 is included in the growth medium. This clearly demonstrates that when there is no replication of the virus, substantial cell death is still possible from virus directed enzyme prodrug therapy (VDEPT).
  • Infecting confluent 3T6 cells with an ICP34.5 null mutant at a MOI of 10 pfu/cell will result in cell death, by a mechanism known as ‘viral antigen overload’. However, the level of cell killing is even more pronounced (approximately 20% more), when 50 μM CB1954 is included in the growth medium.
  • A similar cytotoxicity assay was performed in human C8161 melanoma cells, the results are set out in FIG. 17. Unlike confluent 3T6 cells, C8161 cells do support the replication of ICP34.5 null HSV. Therefore, cell death will occur following infection of the cells with ICP34.5 null HSV, at 1 pfu/cell. However, when CB1954 is included in the overlay of HSV1716/CMV-NTR/GFP infected cells, the cells are killed more efficiently and more quickly. No enhanced cell killing is evident when CB1954 is included in the overlay of cells infected with HSV1716-GFP. These results demonstrate that enhanced cell killing is possible in human tumour cells.
  • Cell culture images for the cytotoxicity assays performed in confluent 3T6 and human C8161 melanoma cells are shown in FIGS. 18 and 19.
    • Example 4 In Vivo Evaluation of the Anti-Tumour Activity of a Selectively Replication Competent Herpes Simplex Virus in Combination with Enzyme Pro-Drug Therapy
  • The anti-tumour activity of a selectively replication competent herpes simplex virus in combination with an enzyme prodrug therapy approach in appropriate animal models in vivo was investigated.
  • The parental virus, HSV 1716 is a selectively replication competent mutant of the herpes simplex virus 1 (HSV 1) which lacks both copies of the RL1 gene that encodes the protein ICP 34.5. This protein is a specific determinant of virulence. The function of this protein has been described at length elsewhere12. The virus can grow only in cells that have a high level of functional PCNA. High levels of PCNA are found only in cells that are dividing such as tumour cells and not normal differentiated cells.
  • It has already been shown that HSV 1716 can achieve selective tumour cell killing with minimal toxicity and improved survival times in a number of animal models13. Initial phase 1 clinical trials using HSV1716 virus in patients has also meet with some success14, 15.
  • Although HSV1716 selectivity replicates in tumour reducing the tumour bulk by cell lysis the inventors did not anticipate HSV1716 to lytically replicate in all cells in the tumour due to the heterogeneity of the cell type and growth state.
  • In order to enhance the efficacy of the tumour cell killing—hence kill the entire tumour—the inventors have constructed a derivative HSV1790 of HSV1716 that expresses the E. Coli nitroreductase gene (ntr) under the control of a CMV early promoter (see example 3 above). The enzyme ntr converts the inactive prodrug CB1954 to a functional cytotoxic alkylating agent that kills both dividing and non-dividing cells by apoptosis. This active drug is diffusible and membrane permeable resulting in an efficient bystander effect, i.e. wherein the activated drug may have an effect on surrounding cells.
  • As the prodrug will only be converted to its active form in the tumour which has been infected with ntr expressing virus, toxicity to normal cells is avoided hence improving the therapeutic index following systemic delivery of this compound.
  • Initial in vitro experiments using this combination have already shown enhanced cell kill using this virus in combination with CB1954 in a number of cell lines.
  • This example further evaluates this combination approach in vivo in appropriate animal models.
  • Results
  • Months 1-3
  • Months 1-3 were taken up mainly by in vitro work. During this time period high titre, sterile virus stock was generated for use in the xenograft models.
  • Xenograft models were also generated in athymic nude mice using the cell line A2780, a human ovarian epithelial carcinoma line initially derived from a tumour sample from an untreated patient (European Collection of Cell Cultures (ECACC) CAMR, Porton Down, Salisbury, Wiltshire, SP4 0JG, United Kingdom, accession number 93112520).
  • Generation of a gliomal xenograft model was attempted using 2 gliomal lines that were available in house, LN-18 and U373MG. There are reports in the literature of both being successfully grown as xenografts in athymic mice.
  • However, as shown in the table below the inventors failed to see any xenograft growth up to 28 days after injection with 5 million cells subcutaneously.
    TABLE 1
    Presence of
    xenograft 28
    No of cells days after
    injected per Number of cell
    Cell Line mice mice injection
    LN 18 5 million 5 0/5
    U373 MG 5 million 5 0/5

    A2780 Tumour Take
  • As reported previously A2780 have a Take Rate of approximately 50%—that is 50% of mice that are injected with 5 million cells per flank subcutaneously will develop xenografts. When the number of cells injected was increased to 10 million or more an increase in take rate of approximately 15-25% was seen, giving an overall take rate of 65-75%.
  • Thus increasing the number of gliomal cells injected may increase the take rate of these cell lines
  • Dose Response to the HSV 1790 Virus
  • Before the mice can be treated with a combination of virus and prodrug, first one must carry out experiments to make informed decisions about how much of the virus, and the prodrug to give.
  • A dose response experiment will allow one to find both the most appropriate does of the virus to use in the experiments and the maximum tolerated dose (MTD) of the virus, that is, the largest amount of the virus that can be given to a single mouse without adverse side effects. Small groups of tumour bearing mice are given a small dose of virus. Assuming they do not have any adverse effects another group is given a larger dose of virus. This continues until either the mice start to suffer ill effects or we reach a maximum dose.
  • The maximum amount of virus that can be intratumourally injected is 100 μl, hence the maximum dose from our current stock is 109 PFU per injection.
  • FIG. 20 shows the weight change in the mice after injection with a variety of doses of virus. Weight is a good indicator of the animals overall health. Any loss of weight signifies that the treatment is not being well tolerated. Where an animal loses more than 20% of its initial body weight it was sacrificed immediately.
  • A dose of 109 PFU of the HSV 1790 virus is not tolerated by these mice, they rapidly lost body weight and were sacrificed at Day 3 post injection. Doses of 108 PFU or less were better tolerated, the mice initially lost weight in the days following injection but quickly recovered to approximately their initial body weights.
  • It should be pointed out that as the experiment progresses the animals appear to be increasing in weight. This is almost certainly due to the fact that it is total body weight that is measured, which includes the weight of any tumour that is forming.
  • Response of the Tumour to HSV 1790 Treatment
  • Tumour volume was measured daily after intratumoural injection of the HSV 1790 virus to look for any growth delay or regression of the tumours.
  • FIG. 21 shows the change in tumour volume as measured over a period of 100 days. If the tumour was injected with PBS only as a control the tumour increased in size rapidly and by approximately Day 13 post injection the tumours had become too large and the animals had to be sacrificed.
  • Treatment with all doses of virus appeared to delay the growth of the tumour to some degree. Doses of 105 PFU increased the longevity of the mice by approximately 12 days while mice injected with 106 PFU virus tumours survived for an extra 23 days compared to the control group before the tumours became prohibitively large. Perhaps surprisingly the group of mice injected with 108 PFU of virus survived only slightly longer than the control group. It is possible there were a large number of non infectious particles or that sheer number of particles caused the cells which the virus would have grown in to be killed.
  • The group of mice treated with 107 PFU of virus survived the longest and indeed two out of three of the mice did not have any visible signs of tumour when sacrificed at day 100.
  • Naked DNA Experiments
  • In order to check the alterations in tumour growth are due to the virus itself and not a result of the CMV-ntr plasmid DNA that had been introduced to the HSV 1716 virus, an experiment was set up looking at the effect of the CMV-ntr plasmid DNA alone and in combination with the prodrug CB1954.
  • Mice were randomised into treatment groups of 6 animals each when tumour diameters are approximately 5 mm (this is Day 0). FIG. 22 shows the starting tumour diameters for the mice used in this experiment. Two groups of mice were administered CMV-ntr plasmid by direct intratumoural injection at a dose of 0.2 mg DNA per injection. One of these groups was then administered with a single dose of 80 mg/kg of CB1954 on Day 2 by intra-peritoneal injection. The third group of mice had a single administration of CB1954 (80 mg/kg) by intra-peritoneal injection on Day 2 following intratumoural injection of saline control at Day 0. Animals were weighed daily (FIG. 23) and daily caliper measurements performed until the tumour sizes were in the region of 20 mm by 20 mm. Tumour volumes were estimated from these measurements (volume=d3×6) (FIG. 24). In addition any toxicity from these administered agents was determined. On the basis of these experiments the inventors determined that neither the CMV-ntr alone, CB1954 alone or the combination of both CMV-ntr and CB1954, has any anti-tumour activity as determined by tumour regression in this model system (FIG. 24).
  • Scheduling Experiment
  • Previous dose response experiments have shown that doses of less than 108 PFU virus per mouse do not appear to have any adverse effect of the animals health.
  • A dose of 107 PFU virus per mouse resulted in a great reduction in tumour growth, indeed after 100 days two out of three of the mice in the group had no visible tumour. This is very encouraging—the virus only at high doses may be enough to delay growth or cause tumour regression.
  • However to look at the effect of a combination of the virus and the prodrug CB 1954 a lower dose of the virus was studied—if the treatment of the virus alone results in growth delay for such a long period one would be unable to ascertain the addition or synergistic effects of the prodrug.
  • The inventors proceeded to investigate two doses of the virus in combination with CB1954. The doses selected were 105 PFU and 106 PFU. Both these doses caused some tumour growth delay in earlier experiments.
  • The prodrug is given as an 80 mg/kg intra-peritoneal injection, after dissolving the powdered form in 10% acetone and then making up the volume with peanut oil.
  • Another factor that determines how well the drug will work—hence how much tumour growth delay or regression is seen—is when the drug is actually given. As the prodrug will only be converted to an active substrate in the presence of NTR it was considered that the virus containing the NTR will have to been given first. It was also considered that if the virus is given time to replicate and produce more NTR then the prodrug may have a more pronounced effect.
  • To discover the optimal doses of both the virus and the drug and the optimal times of these treatments a scheduling experiment was set up.
  • Mice were randomized into treatment groups (treatment regimes shown in Table 2) of 3 animals when tumour diameters were approximately 5 mm (tumour volume 0.5-1.5 mm3). FIG. 25 shows the starting tumour volumes of each of the groups.
    TABLE 2
    Treatment groups
    1 105 HSV 1790 + drug (Day 2) + Drug (Day10)
    2 105 HSV 1790 + drug (Day 2) + vehicle (Day
    10)
    3 105 HSV 1790 + vehicle (Day 2) + drug (Day
    10)
    4 105 HSV 1790 + vehicle (Day 2) + vehicle
    (Day 10)
    5 No virus + drug (Day 2) + drug (Day 10)
    6 No virus + drug (Day 2) + vehicle (Day 10)
    7 No virus + vehicle (Day 2) + drug (Day 10)
    8 No virus + vehicle (Day 2) + vehicle (Day
    10)
    9 106 HSV 1790 + vehicle (Day 2) + vehicle
    (Day 10)
    10 106 HSV 1790 + drug (Day 2) + vehicle (Day
    10)
    11 106 HSV 1790 + drug (Day 2) + drug (Day 10)
    12 106 HSV 1790 + drug (Day 2) + drug (Day 10) + drug
    (Day 15)
    13 No virus + drug (Day 2) + drug (Day 10)
    14 No virus + vehicle (Day 2) + vehicle (Day
    10)
    15 105 HSV 1716 + drug (Day 2) + drug (Day 10)
    16 105 HSV 1716 + vehicle (Day 2) + vehicle
    (Day 10)
    17 105 HSV 1716 + drug (Day 2) + vehicle (Day
    10)
    18 105 HSV 1716 + vehicle (Day 2) + drug (Day
    10)
  • The treatment groups were administered with a single direct intratumoural injection of the virus and dose determined for that group. The virus was diluted PBS+10% serum. ‘No virus’ control groups received an intratumoural injection of 100 μl of PBS+10% serum. This day was designated as Experimental Day 0.
  • The intratumoural injections did not appear to have any adverse effects on the mice. Some tumours bleed slightly after injection but not to a great degree. The animals did not lose body weight (FIG. 26) and their behaviour did not appear to alter. In all the tumours that bleed slightly, the following day the healing process had begun and within 3-5 days there was little evidence of any puncture wound on any tumour.
  • Injections of CB1954 were given to the appropriate groups at days 2, 10 and 15. A dose of 80 mg/kg—the equivalent of approx. 2 mg per mouse—was given. The powdered form of the CB1954 drug (from Sigma) was dissolved in acetone to 10% of the final volume (10 μl per 2 mg). The volume was then made up to 2 mg CB1954 in 100 μl using peanut oil. A syringe was used to mix the drug as peanut oil is thick and viscous. The drug was made up fresh every time.
  • The appropriate groups were then injected intra-peritoneal with this solution. Control groups which were not receiving drug were injected intra-peritoneal with a 100 μl solution of 10% acetone in peanut oil.
  • No swelling or irritation at the site of injection was noted on any of the mice either at time of injection or at any later time point. The mice appeared slightly lethargic for a short period after the injection but did not lose any body weight (FIG. 26) or show signs of lethargy the following day.
  • S No Virus+CB1954 Prodrug
  • Groups 5, 6, 7, 8, 13 & 14 looked at the effect of prodrug alone on tumour growth. FIG. 27 shows that there is little effect on tumour growth when CB1954 is given alone.
  • 105 PFU Virus+/−CB1954 Prodrug
  • 105 PFU virus was given at Day 0 followed by either prodrug or vehicle at Days 2 and 10.
  • As can be seen from the graph in FIG. 28 tumours treated with either virus only or virus and prodrug did not grow as large as the untreated tumour. The tumour treated with the virus grew only to approximately half the size of the untreated control.
  • Treatment with virus and prodrug resulted in tumours which grew to only approx 2-3 mm3 in volume. This is significantly less than the untreated tumours which grew in size to approx 20 mm3.
  • 106 PFU Virus+/−CB1954 Prodrug
  • FIG. 29 shows the changes in tumour volume over time after treatment with a higher dose of virus, 106 PFU per injection, in combination with the prodrug, given as described in Table 2. As with the lower virus dose, treatment with either virus only, or in combination with CB1954, results in significantly smaller tumours compared to the untreated controls.
  • HSV 1716 Virus in Combination with CB1954 Prodrug
  • The parental strain of the virus, which has not been engineered to contain the CMV-ntr DNA was examined for its effects on tumour growth delay. This virus does have an oncolytic effect, however it doesn't contain the NTR gene needed to convert the inactive prodrug into its active metabolite. Therefore one would not expect any additional or synergistic effects when the prodrug is added in combination with the virus. FIG. 30 shows the results of this experiment.
  • The combination of the virus and the prodrug appeared to produce some reduction in tumour growth compared to the untreated control tumours.
  • The groups used in these results contained only 2 or 3 animals. The animals used were also older and their tumours had taken longer to grow than those used in previous experiments. Hence it is possible that repeating the experiment with a larger number, with younger mice or quicker forming tumours may result in a more marked growth delay after treatment with the HSV 1716 virus.
  • Comparison of HSV 1790 (at 105 and 106) and HSV 1716 in Combination with CB1954 Prodrug
  • FIG. 31 shows a comparison between the two doses of the HSV 1790 virus in combination with the prodrug and the HSV 1716 prodrug combination. The parental virus HSV 1716 shows some growth delay in comparison with the untreated control. We would assume that this growth delay is due to the oncolytic effect of the virus as the NTR gene is not present to alter the inactive prodrug into its active form.
  • Tumour growth is reduced further when the tumour is treated with the HSV 1790 virus containing the NTR gene. This appears to be dose dependent—the higher dose of the virus results in a greater growth delay than the lower dose.
  • In conclusion it would appear from these results that indeed the HSV 1790 virus used in combination with the prodrug CB1954 results in growth delay in the model system examined. Giving both virus and drug in combination has a greater effect than given either alone.
  • It appears that the timing at which the prodrug is given after virus treatment is important. When CB1954 was given soon after viral injection (Day 2 post viral injection) tumour growth was not delayed as much as if the drug was given at a later date (Day 10). It may be that given at Day 2 the drug killed the cells that were supporting viral growth and replication and actually reduced the oncolytic effect of the virus.
  • By day 10 the virus may have replicated and killed as many cells by oncolysis as possible. It is anticipated that due to heterogeneity of the cell type and growth state that all the cells within a tumour would not be susceptible to lysis by the virus. The drug then comes in and ‘mops up’ by killing any cells that are supporting viral growth (hence containing the NTR gene) but were not susceptible to oncolysis. As the active drug is diffusible and membrane permeable it may have a bystander effect—killing not only the cells infected with the virus but also its near neighbours.
    • Example 5 Construction of HSV1716 Variants Expressing siRNA
  • General Strategy
  • A plasmid that contains the siRNA construct designed to target expression of the SCCRO gene (SEQ ID No. 1) and designated 339i was provided by Dr Bhuv Singh, MSKCC, New York. A plasmid encoding a control siRNA (SEQ ID No 2), designated Coni, was also provided.
  • DNA sequences for the two constructs are as follows:
    339isiRNA (SEQ ID No.1):
    gatcCCCGTTCAGAGCAGCAACACAGTTCAAGAGACTGTGTTGCTGCTCT
    GAACTTTTTGGAAA
  • ConisiRNA (SEQ ID No.2):
    gatcCCCCGTCTACCTACACTCCCTCTTCAAGAGAGAGGGAGTGTAGGTA
    GACGTTTTTA
  • Both siRNA constructs were in the vector pSNRG and their expression is driven by the RNA polIII H1 promoter. RNA polIII only transcribes short RNA molecules and the H1 promoter would be insufficient to drive expression of IRES-gfp from the normal recombinant virus producing shuttle vector RL1-del.IRES.gfp so an alternative cloning strategy was adopted.
  • A cassette was constructed in the following manner. The 1.3 kbp blunt-ended EcoRI/AflII fragment that contains the PGK promoter/GFP gene was obtained by restriction digestion followed by Klenow treatment from the vector pSNRG and cloned into the RL1-del vector cut with the restriction enzyme NruI that generates blunt ends. Successful insertion of the PGK/GFP DNA was confirmed by BamHI digestion and the orientation of the inserted DNA identified using the unique XhoI site in RL1-del and the BsrGI site at the 3′ end of PGK/GFP. Plasmids with PGK/GFP in both forward and reverse orientation were obtained and the plasmids were designated RL1-dPGK/GFPfor and RL1-dPGK/GFPrev. Expression of GFP was confirmed in BHK cells transfected with the forward and reverse orientation plasmids.
  • Thus, sequences of interest along with their own promoters (in this arrangement it is preferred that a different promoter is used to drive transcription of the nucleotide sequence of interest and marker) can then be cloned into either RL1-dPGK/GFPfor or RL1-dPGK/GFPrev in either orientation using the remaining unique BglII, XhoI or HpaI unique restriction enzyme sites. The resulting plasmid can be used to derive recombinant HSV in which the marker GFP gene and the gene of interest are expressed independently from their own promoters
  • Materials and Methods
  • In the pSNRG plasmid and adjacent to the H1/siRNA coding sequence is a green fluorescent protein (gfp) expression cassette comprising the gfp gene with a Phosphoglycerokinase (PGK) promoter. Using the restriction enzymes HindIII and AflII sequentially, the 1.6 kbp DNA fragment that contains the H1/siRNA and PGK/EGFP expression cassettes were excised from their Coni and 339i plasmids. The 1.6 kbp DNA fragment was purified from a 1% agarose gel and blunt-ended by incubation with Klenow DNA polymerase for 30 minutes at 30° C. The blunt-ended fragment was ligated into the RL1-del shuttle vector which had been digested with the restriction enzyme Nru1 that produces a blunt-ended cut. Before ligation the Nru1-cut RL1-del was gel purified and phosphatase-treated using Calf Intestinal Alkaline Phosphatase. After an overnight ligation with either the blunt-ended 339i or Coni DNA fragments with the blunt-ended RL1-del plasmid, the reaction mix was used to transform DH5alpha cells and these were plated-out on LB amp plates. After overnight incubation at 37° C., individual clones from each of the LB amp plates were grown overnight in 3 ml of LB broth and plasmid DNA extracted.
  • To screen for recombinants, plasmids were initially digested with BamHI, as insertion of the H1/siRNA and PGK/gfp cassette increases the size of the RL1 BamHI fragment in the plasmid from 5.4 kbp to 7.0 kbp. For both Coni and 339i ligations 1/24 clones screened demonstrated a 7.0 kbp BamHI fragment and the presence of the H1/siRNA and PGK/EGFP cassette in these plasmids was confirmed by EcoR1, EcoR1/HindIII and EcoR1/SalI digests, the inserted H1/siRNA and PGK/EGFP cassette introduces a novel EcoR1 site into the RL1-del vector.
  • From a glycerol stock of the positive 339i and Coni clones, additional plasmid was prepared and used to transfect BHK cells. Fifty microlitres (50 μl) of plasmid was mixed with 6 μl lipofectamine 2000 in a final volume of 100 μl serum free medium and used to transfect BHK cells plated out on a 13 mm glass coverslip in a 24-well plate. After 48 hrs of transfection the cells were washed once in PBS, incubated for 2 hrs in 4% paraformaldehyde, washed once more in PBS and mounted on microscope slides using Vectashield. The presence of c5% gfp-positive cells following transfection with the RL1-del/339i and RL1-del/Coni plasmids confirmed the presence of the PGK/GFP cassette.
  • The RL1-del/339i and RL1-del/Coni plasmids were linearized using either of the restriction enzymes ScaI and XmnI and the linearized plasmid was used along with viral DNA to transfect BHK cells plated out to c80% confluency in 60 mm dishes. To 100 μl of linearized plasmid or undigested circular plasmid, 50 μl of HSV-1 strain 17+ DNA was added along with 20 μl lipofectamine 2000 in a final volume of 5001 serum free medium and the mix added to the BHK cells. After 4 hrs of transfection, the cells were shocked with 25% DMSO in HBSS for exactly 4 minutes, washed ×3 with medium and returned to 37° C. incubation in 5 ml of medium for 48 hrs. Viral cpe was evident after 48 hrs and the cells and medium were harvested together, sonicated and stored at −80° C. Undiluted medium/cells and 4×10-fold dilutions were plated out on BHK cells and, after 48 hrs, viral plaques were examined by fluorescent microscopy for gfp expression. On the undiluted plate from cells transfected with XmnI-linearized plasmid >100 gfp-positive plaques were observed for both Coni and 339i indicating a high degree of recombination. Interestingly, recombination, but at a lower frequency (c50 plaques/plate), was observed for the transfected circular plasmid but recombination with the ScaI-linearized plasmid was very low (<5 plaques/plate).
  • Using the highest dilution at which gfp-positive plaques were clearly visible (the PGK/GFP cassette gave a very strong fluorescent signal), two plaques each of Coni and 339i viruses were picked using a sterile pipette tip, placed in 1 ml medium, sonicated for 1 minute and stored at −80° C. Plaques were then subjected to 6 rounds of plaque purification, after, the 6th round no wild type, non-gfp expressing plaques were visible and 6 plaques each of Coni or 339i virus were picked for Southern blotting.
  • Each of the six plaques of Coni and 339i virus was used to infect a T175 flask of Vero cells, after 72 hrs of infection virus was harvested and titred. For 3 each of the Coni and 339i viruses that gave the highest titres 0.5 ml was used to infect a second T175 flask for 24 hrs. Viral DNA was then harvested from each of the 6 flasks. The BamHI-digested viral DNA was Southern blotted with the Alu/Rsa RL1 probe and the band pattern compared to wild type and HSV1716 DNA digested also with BamHI. A novel c6 kbp band, consistent with the insertion of the 1.6 kbp H1/siRNA and PGK/GFP cassette in the RL1 locus, was clearly visible in all six viral isolates and no wild type bands were detected. Stocks of the Coni and 339i viruses that gave the strongest signal on Southern blotting were produced.
    • REFERENCES
    • 1. B L Liu, M Robinson, Z-Q Han, R H Branston, C English, Preay, Y McGrath, S K Thomas, M Thornton, P Bullock, C A Love and R S Coffin; Gene Therapy (2003) 10, 292-303.
    • 2. WO 92/13943
    • 3. A Dolan, E Mckie, A R Maclean, D J McGeoch; Journal of General Virology (1992) 73 971-973.
    • 4. Aidan Dolan, Fiona E Jamieson, Charles Cunnigham, Barbara C Barnett Duncan J McGeoch; Journal of Virology March 1998 2010-2021.
    • 5. Joany Chou, Earl R Kern, Richard J Whitley, Bernard Roizman; Science (1990) 250 1262-1265.
    • 6. Coffin R S, MacLean A R, Latchman D S, Brown S M; gene therapy (1996) October 3(10) 886-91.
    • 7. McKie E A, Hope R G, Brown S M, Maclean A R; Journal of General Virology, (1994) April 75(Pt4) 733-41.
    • 8. McKay E M, McVey B, Marsden H S, Brown S M, MacLean A R; Journal of general Virology, (1993) November 74(Pt11) 2493-7.
    • 9. Joany Chou, Bernard Roizman; Journal of Virology; (1990) March 1014-1020.
    • 10. Green, N. K., Youngs, D. J, J. P. Neoptolemos, F. Friedlos, R. J. Knox, C. J. Springer, G. M. Anlezark, N. P. Michael, R. G. Melton, M. J. Ford, L. S. Young, D. J. Kerr, and P. F. Searle; Cancer Gene Therapy (1997) 4:229-238.
    • 11. Cherry L. Estilo, Pornchai O-charoenrat, Ivan Nagai, Snehal G. Patel, Pabbathi G. Reddy, Su Dao, Ashok R. Shaha, Dennis H. Kraus, Jay O. Boyle, Richard J. Wong, David G. Pfister, Joseph M. Huryn, Ian M. Zlotolow, Jatin P. Shah and Bhuvanesh Singh; Clinical Cancer Research (June 2003) Vol. 9 2300-2306.
    • 12. Brown S M, Harland J, MacLean A R et al. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP 34.5 negative herpes simplex virus. J Gen Virol 1994; 75: 2367-2377.
    • 13. McKie E A, MacLean A R, Lewis A D et al. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP 34.5 null mutants in primary human CNS tumours—evolution of a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-752.
    • 14. Rampling R, Cruickshank G, Papanastassiou V et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000; 7: 859-866.
    • 15. Papanastasssiou V, Rampling R, Fraser M et al. The potential for efficacy of the modified (ICP 34.5-) herpes simplex virus HSV 1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002; 9 : 525-526.

Claims (99)

1. A nucleic acid vector comprising:
first and second nucleotide sequences corresponding to nucleotide sequences flanking a predetermined insertion site in the RL1 locus of the genome of a selected herpes simplex virus (HSV); and
(I) a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding:
(a) one or a plurality of insertion sites; and
(b) a ribosome binding site or a regulatory nucleotide sequence; and
(c) a marker,
wherein the nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the ribosome binding site or the regulatory nucleotide sequence and the nucleic acid encoding the ribosome binding site or the regulatory nucleotide sequence is arranged upstream (5′) of the marker; or
(II) a nucleic acid cassette located between said first and second nucleotide sequences comprising:
(a) a third nucleotide sequence being of interest:
and nucleic acid encoding:
(b) a ribosome binding site or a regulatory nucleotide sequence; and
(c) a marker,
wherein the nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site or the regulatory nucleotide sequence and the ribosome binding site or the regulatory nucleotide sequence is arranged upstream (5′) of the marker.
2. (canceled)
3. The vector of claim 1 wherein the ribosome binding site comprises an internal ribosome entry site (IRES).
4-5. (canceled)
6. The vector of claim 1 wherein said regulatory nucleotide sequence is operably linked to said marker.
7. The vector of claim 1 wherein said regulatory nucleotide sequence comprises a constitutive or inducible promoter.
8. The vector of claim 1 wherein the nucleotide sequence of interest encodes an heterologous polypeptide.
9. The vector as claimed in claim 8 wherein the heterologous polypeptide is selected from the group consisting of: a bacterial polypeptide; a mammalian polypeptide; a human polypeptide.
10. The vector as claimed in claim 8 wherein the heterologous polypeptide is selected from the group consisting of: Sodium iodide symporter (NIS); Nitroreductase (NTR); E. coli NTR; Endothelial nitric oxide synthase (eNOS); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); a cytokine.
11. The vector of claim 1 wherein the nucleotide sequence of interest encodes a selected antisense nucleic acid or siRNA.
12. The vector of claim 1 wherein the cassette further comprises a regulatory nucleotide sequence located upstream (5′) of the nucleotide sequence of interest which has a role in regulating transcription of the nucleotide sequence of interest.
13. The vector of claim 1 wherein the cassette further comprises a regulatory nucleotide sequence located upstream (5′) of the insertion site(s).
14. The vector of claim 1 wherein the cassette comprises a plurality of said insertion sites.
15. The vector of claim 1 wherein each insertion site is formed by nucleic acid encoding a restriction endonuclease site.
16. The vector of claim 1 wherein the insertion sites comprise one or more of the ClaI, BglII, NruI and XhoI restriction endonuclease sites.
17. The vector of claim 1 wherein the first and second nucleotide sequences each comprise sequence corresponding to nucleotide sequences in the RL terminal or internal repeat region of the genome of the selected HSV.
18. The vector of claim 1 wherein said first and second nucleotide sequences correspond to nucleotide sequences flanking a predetermined insertion site formed in, or comprising all or a part of, the ICP34.5 protein coding sequence of the genome of a selected herpes simplex virus.
19. The vector of claim 1 wherein said first and second nucleotide sequences comprise contiguous portions of nucleotide sequence of the ICP34.5 gene of a herpes simplex virus.
20. The vector of claim 1 wherein said first and second nucleotide sequences comprise contiguous portions of nucleotide sequence encoding the ICP34.5 gene product of a herpes simplex virus.
21. The vector of claim 1 wherein the first and second nucleotide sequences have at least 60% sequence identity to their corresponding sequence in the viral genome.
22. The vector of claim 1 wherein said first and second nucleotide sequences hybridise to their corresponding nucleotide sequence in the HSV genome, or its complement, under high or very high stringency conditions.
23. The vector of claim 1 wherein the marker is a defined nucleotide sequence encoding a polypeptide.
24. The vector of claim 1 wherein the marker comprises the Green Fluorescent Protein (GFP) protein coding sequence or the enhanced Green Fluorescent Protein (EGFP) protein coding sequence.
25. The vector of claim 1 wherein the marker comprises a defined nucleotide sequence detectable by hybridisation under high stringency conditions with a corresponding labelled nucleic acid probe.
26. The vector of claim 1 wherein the cassette further comprises nucleic acid encoding a polyadenylation sequence located downstream (3′) of the nucleic acid encoding the marker.
27. The vector as claimed in claim 26 wherein the polyadenylation sequence comprises the Simian Virus 40 (SV40) polyadenylation sequence.
28. The vector of claim 1 wherein the vector further comprises nucleic acid encoding a second selectable marker.
29. The vector of claim 1 wherein the vector is a DNA vector, particularly a dsDNA vector.
30. Plasmid RL1.dIRES-GFP (ECACC accession number 03090303).
31. The vector of claim 1 wherein the vector is an expression vector.
32. A method of generating a herpes simplex virus which expresses a nucleotide sequence of interest, or polypeptide thereby encoded, comprising the step of culturing a selected herpes simplex virus with the vector of claim 1, thereby integrating components (a), (b) and (c) of said vector at said predetermined insertion site in the genome of the selected herpes simplex virus.
33. The method of claim 32 wherein said herpes simplex virus is an HSV-1 or HSV-2.
34. The method of claim 32 wherein the integrated components disrupt a protein coding sequence resulting in inactivation or lack of expression of the respective gene product in the generated virus.
35. The method of claim 32 wherein the generated herpes simplex virus:
is a gene specific null mutant;
is an ICP34.5 null mutant;
lacks only one expressible ICP34.5 gene;
is non-neurovirulent; or
a combination of two or more thereof.
36.-39. (canceled)
40. A medicament comprising the vector of claim 1.
41.-45. (canceled)
46. A medicament comprising a mutant herpes simplex virus generated using the vector of claim 1.
47. A kit of parts comprising a first container having a quantity of the vector of claim 1 and a second container comprising a quantity of herpes simplex virus genomic DNA.
48. An herpes simplex virus (HSV) wherein the herpes simplex virus comprises a nucleic acid cassette integrated in the RL1 locus of the HSV genome comprising nucleic acid encoding:
(I.)
(a) one or a plurality of insertion sites; and
(b) a ribosome binding site or a regulatory nucleotide sequence, and a
(c) marker,
wherein the nucleic acid encoding the one or plurality of insertion sites is/are arranged upstream (5′) of the ribosome binding site or the regulatory nucleotide sequence and the nucleic acid encoding the ribosome binding site or the regulatory nucleotide sequence is arranged upstream (5′) of the marker; or
(II.)
(a) a nucleotide sequence of interest; and nucleic acid encoding:
(b) a ribosome binding site or a regulatory nucleotide sequence; and
(c) a marker,
wherein the nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site or the regulatory nucleotide sequence and the ribosome binding site or the regulatory nucleotide sequence is arranged upstream (5′) of the marker.
49. (canceled)
50. The herpes simplex virus of claim 48 wherein the ribosome binding site comprises an internal ribosome entry site (IRES).
51. The herpes simplex virus of claim 48 wherein a transcription product of the cassette is a bi- or poly-cistronic transcript comprising a first cistron encoded by the nucleotide sequence of interest and a second cistron encoded by the marker nucleic acid wherein the ribosome binding site is located between said first and second cistrons.
52.-53. (canceled)
54. The herpes simplex virus of claim 48 wherein said regulatory nucleotide sequence is operably linked to said marker.
55. The herpes simplex virus of claim 48 wherein said regulatory nucleotide sequence comprises a constitutive or inducible promoter.
56. The herpes simplex virus of claim 48 wherein the nucleotide sequence of interest encodes an heterologous polypeptide.
57. The herpes simplex virus as claimed in claim 56 wherein the heterologous polypeptide is selected from the group consisting of: a bacterial polypeptide; a mammalian polypeptide; a human polypeptide.
58. The herpes simplex virus as claimed in claim 56 wherein the heterologous polypeptide is selected from the group consisting of: Sodium iodide symporter (NIS); Nitroreductase (NTR); E. coli NTR; Endothelial nitric oxide synthase (eNOS); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); a cytokine.
59. The herpes simplex virus of claim 48 wherein the nucleotide sequence of interest encodes a selected antisense nucleic acid or siRNA.
60. The herpes simplex virus of claim 48 wherein the cassette further comprises a regulatory nucleotide sequence located upstream (5′) of the nucleotide sequence of interest which has a role in regulating transcription of the nucleotide sequence of interest.
61. The herpes simplex virus of claim 48 wherein the cassette further comprises a regulatory nucleotide sequence located upstream (5′) of the insertion site(s).
62. The herpes simplex virus of claim 48 wherein the cassette comprises a plurality of said insertion sites.
63. The herpes simplex virus of claim 48 wherein each insertion site is formed by nucleic acid encoding a restriction endonuclease site.
64. The herpes simplex virus of claim 48 wherein the insertion sites comprise one or more of the ClaI, BglII, NruI and XhoI restriction endonuclease sites.
65. The herpes simplex virus of claim 48 wherein the nucleic acid cassette is integrated in the RL terminal or internal repeat region of the genome of the selected HSV.
66. The herpes simplex virus of claim 48 wherein the nucleic acid cassette is integrated at a site formed in, or comprising all or a part of, the ICP34.5 protein coding sequence of the genome of a selected herpes simplex virus.
67. The herpes simplex virus of claim 48 wherein the nucleic acid cassette is integrated in the genomic nucleotide sequence of the ICP34.5 gene of a herpes simplex virus.
68. The herpes simplex virus of claim 48 wherein the nucleic acid cassette is integrated in the genomic nucleotide sequence encoding the ICP34.5 gene product of a herpes simplex virus.
69. The herpes simplex virus of claim 48 wherein the marker is a defined nucleotide sequence encoding a polypeptide.
70. The herpes simplex virus of claim 48 wherein the marker comprises the Green Fluorescent Protein (GFP) protein coding sequence or the enhanced Green Fluorescent Protein (EGFP) protein coding sequence.
71. The herpes simplex virus of claim 48 wherein the marker comprises a defined nucleotide sequence detectable by hybridisation under high stringency conditions with a corresponding labelled nucleic acid probe.
72. The herpes simplex virus of claim 48 wherein the cassette further comprises nucleic acid encoding a polyadenylation sequence located downstream (3′) of the nucleic acid encoding the marker.
73. The herpes simplex virus as claimed in claim 72 wherein the polyadenylation sequence comprises the Simian Virus 40 (SV40) polyadenylation sequence.
74. The herpes simplex virus of claim 48 wherein the cassette disrupts a protein coding sequence in the HSV genome resulting in inactivation of the respective gene product.
75. The herpes simplex virus of claim 48 wherein the herpes simplex virus is a mutant of HSV-1 or HSV-2.
76. The herpes simplex virus of claim 48 wherein the herpes simplex virus is a mutant of one of HSV-1 strains 17 or F or HSV-2 strain HG52.
77. The herpes simplex virus of claim 48 which is a gene specific null mutant.
78. The herpes simplex virus of claim 48 which is an ICP34.5 null mutant.
79. The herpes simplex virus of claim 48 which lacks at least one expressible ICP34.5 gene.
80. The herpes simplex virus of claim 48 which lacks only one expressible ICP34.5 gene.
81. The herpes simplex virus of claim 48 which is non-neurovirulent
82. The herpes simplex virus of claim 48 for use in a method of medical treatment.
83. The herpes simplex virus of claim 48 for use in the treatment of cancer.
84. The herpes simplex virus of claim 48 for use in the oncolytic treatment of a tumour.
85. (canceled)
86. A method of lysing or killing tumour cells in vitro or in vivo comprising the step of administering to a patient in need of treatment a therapeutically effective amount of the herpes simplex virus of claim 48.
87. A medicament, pharmaceutical composition or vaccine comprising the herpes simplex virus of claim 48.
88. The medicament, pharmaceutical composition or vaccine as claimed in claim 87 further comprising a pharmaceutically acceptable carrier, adjuvant or diluent.
89. A method of generating a nucleic acid vector comprising the steps of:
i) providing a first nucleotide sequence comprising a predetermined second nucleotide sequence corresponding to a selected nucleotide sequence in the RL1 locus of the genome of a selected Herpes simplex virus; and
ii) inserting nucleotide sequence(s) in said second nucleotide sequence encoding:
a) one or a plurality of insertion sites and/or a nucleotide sequence of interest; and
b) a ribosome binding site or a regulatory nucleotide sequence; and
c) a marker,
wherein the insertion site(s)/nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site/regulatory nucleotide sequence and the ribosome binding site/regulatory nucleotide sequence is arranged upstream (5′) of the marker.
90. The method of claim 89 wherein the inserted nucleotide sequence(s) separates the second nucleotide sequence into two vector flanking sequences, the inserted nucleotide sequences forming a cassette therebetween.
91. The method as claimed in claim 89 wherein the second nucleotide sequence corresponds to a nucleotide sequence in the RL terminal or internal repeat region of the genome of the selected herpes simplex virus.
92. The method of claim 89 wherein the second nucleotide sequence corresponds to all or a part of the ICP34.5 protein coding sequence of the genome of the selected herpes simplex virus.
93. The method of claim 89 wherein said second nucleotide sequence comprises a contiguous portion of nucleotide sequence of the ICP34.5 gene of the selected herpes simplex virus.
94. The method of claim 91 wherein said second nucleotide sequence comprises a contiguous portion of nucleotide sequence encoding the ICP34.5 gene product of the selected herpes simplex virus.
95. The method of claim 89 wherein the second nucleotide sequence has at least 60% sequence identity to the corresponding sequence in the viral genome.
96. The method of claim 89 wherein said second nucleotide sequence hybridises to the corresponding nucleotide sequence in the viral genome, or its complement, under high or very high stringency conditions
97. A method of generating a mutant herpes simplex virus (HSV) comprising inserting a nucleic acid cassette comprising nucleotide sequence(s) encoding:
a) one or a plurality of insertion sites and/or a nucleotide sequence of interest; and
b) a ribosome binding site or a regulatory nucleotide sequence; and
c) a marker
into a predetermined insertion site in the RL1 locus of the genome of a selected HSV, wherein the insertion site(s)/nucleotide sequence of interest is arranged upstream (5′) of the ribosome binding site/regulatory nucleotide sequence and the ribosome binding site/regulatory nucleotide sequence is arranged upstream (5′) of the marker.
98. The method of claim 97 wherein said method comprises the steps of:
i) providing the vector of claim 1;
ii) where the vector is a plasmid, linearising the vector; and
iii) co-transfecting a cell culture with the linearised vector and genomic DNA from said selected HSV.
99. The method of claim 98 wherein said co-transfection is carried out under conditions effective for homologous recombination of said cassette into an insertion site in the viral genome.
100. The method of claim 97 wherein said method further comprises one or more of the steps of:
1) screening said co-transfected cell culture to detect mutant HSV expressing said marker; and/or
2) isolating said mutant HSV; and/or
3) screening said mutant HSV for expression of the nucleotide sequence of interest or the RNA or polypeptide thereby encoded; and/or
4) screening said mutant HSV for lack of an active gene product; and/or
5) testing the oncolytic ability of said mutant HSV to kill tumour cells in vitro.
101. The method of claim 97 wherein the nucleotide sequence of interest is heterologous to the selected herpes simplex virus.
102. The method of claim 97 wherein the nucleotide sequence of interest encodes an heterologous polypeptide.
103. The method as claimed in claim 102 wherein the heterologous polypeptide is selected from the group consisting of: a bacterial polypeptide; a mammalian polypeptide; a human polypeptide.
104. The method as claimed in claim 102 wherein the heterologous polypeptide is selected from the group consisting of: Sodium iodide symporter (NIS); Nitroreductase (NTR); E. coli NTR; Endothelial nitric oxide synthase (eNOS); Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF); a cytokine.
105. The method as claimed in claim 101 wherein the nucleotide sequence of interest encodes a selected antisense nucleic acid or siRNA.
106. An herpes simplex virus generated by the method of claim 97.
107. An herpes simplex virus gene specific null mutant generated by the method of claim 97.
108. An herpes simplex virus ICP34.5 null mutant generated by the method of claim 97.
US10/579,607 2003-11-17 2004-11-17 Vectors, mutant viruses and methods for generating mutant viruses Abandoned US20070110720A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0326798.6 2003-11-17
GBGB0326798.6A GB0326798D0 (en) 2003-11-17 2003-11-17 Methods for generating mutant virus
PCT/GB2004/004839 WO2005049844A2 (en) 2003-11-17 2004-11-17 Vectors, mutant viruses and methods for generating mutant viruses

Publications (1)

Publication Number Publication Date
US20070110720A1 true US20070110720A1 (en) 2007-05-17

Family

ID=29763982

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/579,606 Active US7498161B2 (en) 2003-11-17 2004-11-17 Mutant herpes simplex viruses comprising nucleic acid encoding a nitroreductase
US10/579,607 Abandoned US20070110720A1 (en) 2003-11-17 2004-11-17 Vectors, mutant viruses and methods for generating mutant viruses
US12/357,123 Abandoned US20090208460A1 (en) 2003-11-17 2009-01-21 Mutant Herpes Simplex Viruses Comprising Nucleic Acid Encoding A Nitroreductase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/579,606 Active US7498161B2 (en) 2003-11-17 2004-11-17 Mutant herpes simplex viruses comprising nucleic acid encoding a nitroreductase

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/357,123 Abandoned US20090208460A1 (en) 2003-11-17 2009-01-21 Mutant Herpes Simplex Viruses Comprising Nucleic Acid Encoding A Nitroreductase

Country Status (7)

Country Link
US (3) US7498161B2 (en)
EP (3) EP2281897A3 (en)
JP (1) JP2007511215A (en)
AT (2) ATE433493T1 (en)
DE (2) DE602004021496D1 (en)
GB (1) GB0326798D0 (en)
WO (2) WO2005049845A2 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
US20100272691A1 (en) * 2007-07-26 2010-10-28 Crusade Laboratories Limited Viruses
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2016061286A2 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018170021A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
WO2019236633A2 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020097269A1 (en) 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
WO2020107002A2 (en) 2018-11-21 2020-05-28 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2021216790A1 (en) 2020-04-22 2021-10-28 Indapta Therapeutics, Inc. Natural killer (nk) cell compositions and methods for generating same
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11920156B2 (en) 2017-02-09 2024-03-05 Indapta Therapeutics, Inc. Engineered natural killer (NK) cells and compositions and methods thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
WO2007026146A1 (en) * 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
WO2005049846A2 (en) 2003-11-17 2005-06-02 Crusade Laboratories Limited Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
GB0409596D0 (en) * 2004-04-29 2004-06-02 Crusade Lab Ltd Novel herpes simplex viruses and uses thereof
US20120301506A1 (en) * 2010-11-23 2012-11-29 Xiaoliu Zhang Oncolytic Virus as an Inducer for Innate Antitumor Immunity
WO2008099189A2 (en) * 2007-02-16 2008-08-21 Crusade Laboratories Limited Herpes simplex viruses and methods of viral replication
US8334097B2 (en) * 2009-05-01 2012-12-18 Vivebio, Llc Method of pooling and/or concentrating biological specimens for analysis
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
US10357577B2 (en) 2010-07-16 2019-07-23 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
EP2662117A1 (en) 2012-05-11 2013-11-13 Virttu Biologics Limited Herpes Simplex Virus for the treatment of liver cancer
EP3558377A1 (en) 2016-12-23 2019-10-30 Virttu Biologics Limited Treatment of cancer
CN110117577B (en) * 2018-02-05 2023-10-24 中国科学院武汉物理与数学研究所 Low-toxicity herpes simplex virus system and construction method and application thereof
TW202038947A (en) 2018-11-28 2020-11-01 德商創新分子有限責任公司 Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
LT7046B (en) 2022-04-15 2024-02-12 Vilniaus Universitetas Hydrolases and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6060273A (en) * 1992-08-27 2000-05-09 Beiersdorf Ag Multicistronic expression units and their use
US20030017600A1 (en) * 1999-12-20 2003-01-23 Philippe Gabant Double selection vector
US6573090B1 (en) * 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
US6602499B1 (en) * 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
DE68912441T2 (en) 1988-06-24 1994-05-11 British Tech Group Nonessential chickenpox virus regions.
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
EP0538496B1 (en) 1991-08-26 2003-10-29 Baxter Healthcare S.A. Recombinant fowlpox virus with intact FPV-tk-gene
JP4115514B2 (en) * 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Bacterial nitroreductase for reducing CB 1954 and its analogs to cytotoxic forms
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
AT403167B (en) * 1994-11-14 1997-11-25 Immuno Ag SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
EP0753581A1 (en) 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
ZA966287B (en) 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
CA2234877A1 (en) 1995-10-19 1997-04-24 St. Jude Children's Research Hospital Herpesvirus vectors and their uses
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
ES2233349T3 (en) 1999-08-31 2005-06-16 The General Hospital Corporation REORDERATION BY SPECIFIC PROMOTERS FOR A CELL AND / OR SPECIFIC FOR A TUMOR OF THE EXPRESSION OF THE GAMMA GENE 34.5 HERPETICO.
GB9930418D0 (en) 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
EP1252322B2 (en) * 2000-01-21 2009-03-04 BioVex Limited Herpes virus strains for gene therapy
WO2003008573A2 (en) * 2001-07-17 2003-01-30 Anne Josephine Milner Silencing of gene expression by sirna
NZ531413A (en) 2001-08-21 2006-01-27 Innovata Plc Improved nitroreductase enzymes
US7348418B2 (en) 2002-02-08 2008-03-25 Memorial Sloan-Kettering Cancer Center Carcinoma-related genes and polypeptides and methods of use thereof
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
CA2476724A1 (en) * 2002-03-01 2003-09-12 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060273A (en) * 1992-08-27 2000-05-09 Beiersdorf Ag Multicistronic expression units and their use
US5922576A (en) * 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
US6602499B1 (en) * 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
US6573090B1 (en) * 1998-12-09 2003-06-03 The General Hospital Corporation Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
US20030017600A1 (en) * 1999-12-20 2003-01-23 Philippe Gabant Double selection vector

Cited By (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081639A1 (en) * 2007-05-31 2009-03-26 Phil Hill Assay for sensitivity to chemotherapeutic agents
US20100272691A1 (en) * 2007-07-26 2010-10-28 Crusade Laboratories Limited Viruses
US8980282B2 (en) * 2007-07-26 2015-03-17 Virttu Biologics Limited Viruses
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013052915A2 (en) 2011-10-05 2013-04-11 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2016061286A2 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US9969998B2 (en) 2014-10-14 2018-05-15 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
US11584923B2 (en) 2014-10-14 2023-02-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
US11359022B2 (en) 2016-04-15 2022-06-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US10882914B2 (en) 2016-04-15 2021-01-05 Alpine Immune Sciences, Inc. ICOS ligand variant immunomodulatory proteins and uses thereof
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11479609B2 (en) 2016-04-15 2022-10-25 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11498967B2 (en) 2016-04-15 2022-11-15 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
WO2017181152A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
WO2018075978A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
US11920156B2 (en) 2017-02-09 2024-03-05 Indapta Therapeutics, Inc. Engineered natural killer (NK) cells and compositions and methods thereof
US11117950B2 (en) 2017-03-16 2021-09-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
EP4306537A2 (en) 2017-03-16 2024-01-17 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
US11096988B2 (en) 2017-03-16 2021-08-24 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
US11117949B2 (en) 2017-03-16 2021-09-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11117948B2 (en) 2017-03-16 2021-09-14 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11639375B2 (en) 2017-03-16 2023-05-02 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11230588B2 (en) 2017-03-16 2022-01-25 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
WO2018170021A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
WO2019079520A2 (en) 2017-10-18 2019-04-25 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
EP4371565A1 (en) 2018-06-04 2024-05-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019236633A2 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US11655455B2 (en) 2018-11-06 2023-05-23 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
WO2020097269A1 (en) 2018-11-06 2020-05-14 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy
WO2020107002A2 (en) 2018-11-21 2020-05-28 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2021216790A1 (en) 2020-04-22 2021-10-28 Indapta Therapeutics, Inc. Natural killer (nk) cell compositions and methods for generating same
WO2022147480A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma, Inc. Oncolytic virus encoding sialidase and multispecific immune cell engager
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen

Also Published As

Publication number Publication date
DE602004021496D1 (en) 2009-07-23
WO2005049845A2 (en) 2005-06-02
WO2005049844A2 (en) 2005-06-02
JP2007511215A (en) 2007-05-10
WO2005049845A9 (en) 2006-08-17
US20090208460A1 (en) 2009-08-20
US20070098689A1 (en) 2007-05-03
EP1685254A2 (en) 2006-08-02
GB0326798D0 (en) 2003-12-24
EP2281897A2 (en) 2011-02-09
ATE433493T1 (en) 2009-06-15
WO2005049845A3 (en) 2005-10-27
US7498161B2 (en) 2009-03-03
EP1692294A2 (en) 2006-08-23
ATE484596T1 (en) 2010-10-15
DE602004029608D1 (en) 2010-11-25
EP2281897A3 (en) 2011-11-30
EP1685254B1 (en) 2009-06-10
WO2005049844A3 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
US20070110720A1 (en) Vectors, mutant viruses and methods for generating mutant viruses
US8530437B2 (en) Methods for treating cancer using herpes simplex virus expressing antisense to the squamous cell carcinoma related oncogene
US6641817B1 (en) Herpes virus vectors for dendritic cells
AU2018230046B9 (en) Recombinant Herpes simplex virus and use thereof
JP2003520044A (en) Herpesvirus strains
WO2007132169A1 (en) Mutant hsv, materials and methods for generation of mutant hsv
WO2017085175A1 (en) Herpes simplex viruses
US20070196336A1 (en) Method For Constructing Recombinant Herpes Simplex Virus
WO2007049409A1 (en) Recombinant hsv useful for treatment of human glioma
US7063851B2 (en) Herpes viruses for immune modulation
JP2003508055A (en) Cell-specific and / or tumor-specific promoter retargeting of herpes γ34.5 gene expression
WO2020106566A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
WO2005005637A2 (en) Herpes simplex virus comprising a genetically modified glycoprotein d
EP3594328A1 (en) Recombinant herpes simplex virus and use thereof
US20040229362A1 (en) Method for producing non-pathogenic helper virus-free preparations of herpes virus amplicon vectors, the helper virus &amp; the cells used in this method, the corresponding genetic tools, as well as the applications of these non-pathogenic amplicon vectors
WO1998037905A1 (en) Arrestable therapeutic viral agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: CRUSADE LABORATORIES LIMITED,UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BROWN, SUSANNE MOIRA;REEL/FRAME:017898/0136

Effective date: 20050214

Owner name: CRUSADE LABORATORIES LIMITED,UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DUNN, PAUL;REEL/FRAME:017898/0140

Effective date: 20031219

Owner name: CRUSADE LABORATORIES LIMITED,UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONNER, JOE;REEL/FRAME:017898/0144

Effective date: 20050214

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION